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Abstract 
Antimicrobial resistance is one of the biggest threats to human health globally. Alarmingly, 
multidrug-resistant, extensively drug-resistant and even pan-drug resistant pathogens have 
emerged worldwide and constantly spread in healthcare centers. These bacteria are resistant to 
most, if not all currently available antibiotics. If no actions are taken to tackle the antimicrobial 
resistance issue there is a high risk to enter into a post-antibiotic era, where standard surgeries 
provide a high risk to the patient and people died from simple infections due to a lack of 
treatment options. In the last decades, many big pharmaceutical companies pulled away from 
antibiotic discovery due to a lower expectation of profits compared to other therapeutic areas, 
leading to empty pipelines and a lack of innovation in the antibiotic field.  To overcome this 
development gap, novel innovative therapeutic strategies may be needed. Adjuvant drug 
therapy to overcome antibiotic resistances is one of these innovative approaches. This therapy 
combines an antibiotic with an adjuvant drug, which specifically switches off the resistance 
mechanisms directed against the antibiotic. Such approach can potentially expand the life time 
of antibiotics by switching off an already developed resistance path or by delaying the onset of 
resistance. This work aimed to investigate the adjuvant therapy approach in Acinetobacter 
baumannii and Mycobacterium tuberculosis, which are two pathogens of great importance with 
constantly increasing drug resistance rates. 
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 Acinetobacter baumannii species 
 History 
Acinetobacter baumannii is an opportunistic pathogen that belongs to the Acinetobacter genus. 
The history of the genus started in 1911 when Beijerinck, a dutch microbiologist, described an 
organism isolated from soil, named Micrococcus calcoaceticus (Beijerinck, 1911). The 
taxonomy history of the genus is complex with similar organisms assigned to at least 15 
different genera and species (Peleg et al., 2008). The designation Acinetobacter was first 
proposed by Brisou and Prévot in 1954 and was definitely accepted in 1984 in the Bergey’s 
Manual (Bergogne-Bérézin, 2008; Brisou and Prevot, 1954). Acinetobacter spp. are strict 
aerobic, non-fermenting, Gram-negative coccobacilli. The Acinetobacter species 
differentiation was enabled by the work of Bouvet and Grimont on DNA-DNA hybridization 
studies in 1986 (Bouvet and Grimont, 1986). This work allowed to name different “genomic 
species” in the Acinetobacter genus with, among others, the assignment of A. baumannii 
species. Although few species of the Acinetobacter genus may cause infections, A. baumannii 
is the most relevant species causing different human infectious disease (Bergogne-Bérézin, 
2008).  
 Habitats 
Acinetobacter spp. have been isolated from diverse sources including environment, food, 
animal and are commonly present among the human skin flora (Al Atrouni et al., 2016).  
However, non-baumannii Acinetobacter spp. account for the major part of this human 
colonization whereas A. baumannii is rarely detected (Berlau et al., 1999a; Patil and Chopade, 
2001; Seifert et al., 1997). Similarly, A. baumannii have been recovered at low frequency in 
fecal samples of healthy volunteers indicating that the human intestine does not constitute an 
important community reservoir of this organism (Dijkshoorn et al., 2005). Importantly, 
A. baumannii have been reporter in food animal, meat, vegetables, milk and cheese, which 
could be vectors for subsequent human infections (Berlau et al., 1999b; Lupo et al., 2014; Rafei 
et al., 2015; Zhang et al., 2013).  
 Clinical manifestation and global epidemiology of A. baumannii 
Although the identification of A. baumannii as cause of infection emerged in the 1960s, it was 
considered a low virulence pathogen with minimal significance until the 1990s (Spellberg and 
Bonomo, 2014). Since then, the frequency and the severity of A. baumannii infections have 
increased progressively and this emergence is mainly due to its high ability to acquire resistance 
to multiple antibiotics (Dijkshoorn et al., 2007). Nowadays, A. baumannii belongs to the most 
relevant pathogens causing nosocomial infections and is member of the so-called ESKAPE 
pathogens group, which includes Enterobacter spp., Staphylococcus aureus/epidermidis, 
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterococcus faecalis/faecium (Pendleton et al., 2013). In 2013, the United States Centre for 
Disease Control and Prevention (CDC) classified multidrug resistant (MDR) A. baumannii as 
a “serious” threat (CDC, 2013). The same year, a study estimated that 45,000 and 1 million 
A. baumannii infections occurred in the United States and worldwide, respectively (Spellberg 
and Rex, 2013). In 2017, the World Health Organization (WHO) published its global priority 
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pathogens list where carbapenem resistant A. baumannii were assigned as top priority for the 
research and development of new and effective antibiotic treatments (WHO, 2017). Altogether, 
these reports highlight the importance of A. baumannii as a serious human pathogen.  
For convenience, most of the following data on clinical manifestation are described for 
Acinetobacter spp. infections since most of the surveillance reports do not specifically 
differentiate A. baumannii from others Acinetobacter species. However, it is important to note 
that non-baumannii Acinetobacter infections are rare and therefore most of these data can be 
attributed to A. baumannii infections (Dijkshoorn et al., 2007). 
 Healthcare-associated infections 
A. baumannii is mainly causing infections in critically ill patients hospitalized in intensive care 
units (ICUs). These infections emerged through the increase practise of modern intensive care 
medicine, such as mechanical ventilation, catheterisation and extensive antibiotic use. Foreign 
bodies enable pathogens to cross anatomical barriers, while antibiotic therapies alter the normal 
human microbiota allowing resistant A. baumannii to establish infection in hospitalized 
patients (Spellberg and Bonomo, 2014).  
The most common clinical manifestations of Acinetobacter spp. are ventilator-associated 
pneumonias (VAPs), central line-associated bloodstream infections (CLABSIs) and catheter-
associated urinary tract infections (CAUTIs) (Table 1 and Table 2). Acinetobacter spp. has a 
lower incidence in CAUTIs than in VAPs and CLABSIs. 
 Europe and United States 
In Europe, the surveillance of healthcare-associated infections (HAIs) is reported by the 
European CDC (ECDC). Data related to Acinetobacter spp. HAIs in three different ECDC 
reports are presented in the Table 1. The reports of 2007 and 2012 refer to ICU facilities data 
whereas the third report covers the period 2011-2012 with incidence in acute care hospitals. 
The Acinetobacter spp. CAUTI rates remained stable in the three studies while the CLABSI 
rates in ICUs increased from 2007 to 2012. In 2012, the Acinetobacter spp. VAP rates in acute 
care hospitals were approximatively twice higher than in ICU facilities. However, 
Acinetobacter spp. VAP cases reported in ICU facilities were approximatively 8 times greater 
than in acute care hospitals.  
In 2012, Acinetobacter spp were associated with 3.6 % of all HAIs in European acute care 
hospitals with a rate superior to 8 % in Bulgaria, Greece, Latvia and Romania (Figure 1). In 
ICU facilities in 2012, the country with the highest rates of Acinetobacter spp. HAIs were 
Estonia, Italy, Lithuania, Portugal, Romania and Slovakia with Acinetobacter spp. the major 
cause of VAP in Lithuania and Romania and the major cause of CLABSI in Romania 
(ECDC, 2015). Finally, the rate of carbapenem resistant Acinetobacter spp. isolates is very high 
in the three European reports (Table 1). This elevated carbapenem resistance rate is alarming 
considering that carbapenems are recognized as last resort antibiotics to treat MDR 
A. baumannii infections. 
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Table 1: Prevalence of Acinetobacter spp. hospital acquired infections in Europe and USA. 
 Infection types Carbapenem 
resistant 
Source 
VAP CLABSI CAUTI 
Europe 
ICU (2007) 
N * 9,749 4,911 5,117 
73.3 % (ECDC, 2012) 
rate ** 4.3 % 0.5 % 1.2 % 
ICU (2012) 
N * 13,672 6,313 3,174 
68.8 % (ECDC, 2015) 
rate ** 4.8 % 3.5 % 1.5 % 
non-ICU  
(2011-2012) 
N * 1,777 1,722 2,168 
81.2 % (ECDC, 2013) 
rate ** 8.7 % 4.1 % 1.5 % 
USA 
non-ICU  
(2011-14) 
N * 8,805 96,532 153,805 
46.6 – 69 % 
(Weiner et al., 
2016) rate ** 6.1 % 2.2 % 0.7 % 
* number of Acinetobacter spp. infection cases 
** rates of Acinetobacter spp infection as a percentage of all microorganisms reported 
CAUTI: catheter-associated urinary tract infection, CLABSI: central line-associated bloodstream infections, ICU: 
intensive care unit, VAP: ventilator-associated pneumonia. 
 
 
Figure 1: Relative frequency of Acinetobacter spp. causing HAIs as a percentage of all microorganisms 
(n=366 isolates) (ECDC, 2013). 
* Poor data representativeness in these countries. 
 
In the United States, the National Healthcare Safety Network reported the cases of HAIs from 
non-ICU facilities (acute care hospitals, long-term acute care hospitals and inpatient 
rehabilitation facilities) from 2011 to 2014 (Weiner et al., 2016). Acinetobacter spp. VAP, 
CLABSI and CAUTI cases are reported in Table 1. This report indicates that 46.6 to 69 % 
(depending on year and infection type) of Acinetobacter spp. VAPs, CLABIs and CAUTIs were 
caused by strains resistant to carbapenem, which is in accordance with the rates observed in 
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Europe. Similarly, 47.3 to 75.6 % of Acinetobacter spp. VAPs, CLABIs and CAUTIs were 
caused by MDR strains. These resistance rates are extremely high compared to those of other 
Gram-negative pathogens such as P. aeruginosa, K. pneumoniae and E. coli (Weiner et al., 
2016). The CDC estimated that MDR A. baumannii infections caused 500 deaths per year in 
United States (CDC, 2013). 
 Other regions 
Acinetobacter spp. pathogens are a global issue with infections reported worldwide. Since 2003, 
the International Nosocomial Infection Control Consortium (INICC) has published surveillance 
reports on device-associated HAIs in ICU facilities from individual countries (Rosenthal, 
2016). The rates of Acinetobacter spp. HAIs from these reports are summarized in the Table 2. 
Overall, Acinetobacter spp. are more isolated from VAPs and CLABSIs than from CAUTIs as 
seen in USA and in Europe. The rates of Acinetobacter spp. HAIs in Latin America countries 
are similar to those seen in USA and Europe. However, Acinetobacter spp. HAI rates in Asia, 
Middle East and Morocco (the only representative of Africa in these reports) are significantly 
higher than those reported for the USA and Europe. According to these reports, Acinetobacter 
spp. are the first pathogens causing HAIs in China, Philippines, Iran, Morocco and the second 
in Lebanon. 
Table 2: Prevalence of Acinetobacter spp hospital acquired infections expressed as a percentage of all 
microorganisms reported. 
Region Country HAIs (%) VAPs (%) CLABSI (%) CAUTI (%) Source 
Latin 
America 
Brazil 14.6 N.D. N.D. N.D. (Salomao et al., 2008) 
Mexico 2.8 2.9 3.3 1.6 (Ramirez Barba et al., 2006) 
Colombia 4.5 N.D. N.D. N.D. (Moreno et al., 2006) 
Cuba 10.3 15.4 33.3 0 (Guanche-Garcell et al., 2011) 
Peru 4.7 4.2 6.3 5 (Cuellar et al., 2008) 
El Salvador 4 N.D. N.D. N.D. (Dueñas et al., 2011) 
Asia 
China 19.1 25.4 12.3 3 (Tao et al., 2011) 
Philippines 21.1 25.5 18.2 11.1 (Navoa-Ng et al., 2011) 
India N.D. N.D. N.D. N.D. (Mehta et al., 2007) 
Middle 
East 
Lebanon 29.1 37.5 27.3 20 (Kanj et al., 2012) 
Iran 27.5 60 N.D. N.D. (Jahani-Sherafat et al., 2015) 
Turkey 22.6 29.2 23.2 7.5 (Leblebicioglu et al., 2007) 
Africa Morocco 31.9 45.8 14.3 18.8 (Madani et al., 2009) 
CAUTI: catheter-associated urinary tract infection, CLABSI: central line-associated bloodstream infections, HAI: 
hospital acquired infection, VAP: ventilator-associated pneumonia.  
 
 Other clinical manifestations 
Acinetobacter spp. can cause infection in other organ systems, including endocarditis, 
meningitis, intraabdominal abscess, osteomyelitis, soft tissue, and surgical site infections (Glew 
et al., 1977).  
Acinetobacter spp. have been reported as one of the major cause of osteomyelitis and wound 
infections during the military operations in the Middle East (Davis et al., 2005; Yun et al., 
2008). A. baumannii was the second most isolated Gram-negative pathogen from osteomyelitis 
infections from 2007 to 2009 in Sao Paulo, Brazil (Carvalho et al., 2012). The incidence of 
endocarditis caused by A. baumannii is rather low but the outcome can be dramatic with sudden 
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patient death (Laganà et al., 2015). A recent study indicates that, although S. aureus is the most 
common cause of meningitis following neurosurgical procedure, the rate of A. baumannii 
causing meningitis is increasing (Chen et al., 2016). Indeed, A. baumannii has been reported in 
31.8 % of the meningitis cases in a Taiwan hospital from 2008 to 2012, (Chen et al., 2016). 
Other studies further reported A. baumannii as the most common pathogen causing 
postneurosurgical meningitis in a private hospital of Tehran (Iran) from 2010 to 2012 and in 
Turkey from 2004 to 2013  (Sipahi et al., 2017; Yadegarynia et al., 2014). 
 Community-acquired infections 
Community-acquired A. baumannii infections typically occur in tropical regions during the wet 
season (Dexter et al., 2015). Community-acquired pneumonia caused by A. baumannii is rare 
but it is fulminant and generally extremely severe with a  mortality rate as high as 64 % (Anstey 
et al., 1992; Chen et al., 2001; Leung et al., 2006; Ong et al., 2009). This high mortality rate 
has been associated to non-appropriate treatment since an appropriate initial therapy reduced 
the mortality rate to 11 % (Davis et al., 2014).  It appears that hazardous alcohol consumption, 
smoking and chronic lung disease are important risk factors for community-acquired 
A. baumannii infections (Davis et al., 2014). 
 A. baumannii pathogenesis 
 Virulence and mortality rate 
A. baumannii is generally considered as a low virulence pathogen when compared to the other 
microorganisms of the ESKAPE group (Paterson and Harris, 2015). The mortality rate of 
A. baumannii infections is controversial due to the difficulty to attribute the cause of mortality 
to the infection per se or to underlying diseases. In 2003, a study concluded that A. baumannii 
bacteremia is not associated with increased mortality in ICU patients (Blot et al., 2003). The 
mortality rate of A. baumannii bacteremia was 42.2 % while the mortality rate of controls was 
34.4 % indicating an attributable mortality of 7.8 %. The same conclusions were drawn on 
A. baumannii pneumonia, which was not significantly associated with an attributable mortality 
rate (Garnacho et al., 2003). However, in 2006, a review of six matched case-control studies 
indicated that the attributable mortality rates of A. baumannii infection ranged from 7.8 % to 
23 % in hospital and from 10 % to 43 % in ICU facilities, indicating that A. baumannii infection 
might be associated with considerably increased mortality (Falagas et al., 2006).  
Hypervirulent A. baumannii causing outbreaks have been isolated, such as the LAC-4 strain 
that was isolated from nosocomial outbreaks in Los Angeles in 1997 (Valentine et al., 2008). 
This strain was considered as hypervirulent based on immunocompetent in vivo mouse model, 
but there are no clinical or epidemiologic data available for this strain (Harris et al., 2013). 
Recently, hypervirulent strains were isolated from fatal outbreaks in the northwest of United 
States (Jones et al., 2015). Interestingly, the most virulent strains in this study belong to the 
same clonal lineage than the LAC-4 strain. In contrast to the LAC-4 strain, clinical history is 
available for the strains reported by Jones and colleagues and they showed that patients had 
only minor underlying disease, suggesting that patient death was mainly caused by the 
A. baumannii infection. 
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Other data suggest A. baumannii isolates with enhanced virulence. A case of severe pneumonia 
was reported in a healthcare worker due to occupational transmission (Whitman et al., 2008). 
The strain recovered from the healthcare worker was most likely transmitted from a patient 
during endotracheal suctioning. Fulminant sepsis with patient death 6-days after transplantation 
have been reported (Patel et al., 2015). The autopsy revealed endocarditis, myocarditis, splenic 
and renal emboli, peritonitis, and pneumonia, highlighting the potential of A. baumannii to 
develop strong virulence. 
A. baumannii virulence has been assessed in different mouse models (de Breij et al., 2012; 
Bruhn et al., 2015; Eveillard et al., 2010). These studies demonstrated that virulence is highly 
strain dependant with some strains being hypervirulent and others being hypovirulent. Bruhn 
and colleagues tested different strains from the International Clonal Complex (ICC) 2, which is 
the most widespread clonal complex in hospital, in a bacteremia mouse model (Bruhn et al., 
2015). They showed that some strains inoculated at 2 x 107 colony forming units (CFUs) 
develop a lethal infection within seven days whereas other strains require an inoculum of 5 x 
107 CFUs to achieve the same outcome. These results suggest that factors independent of the 
clonal lineage are involved in A. baumannii virulence. 
 Persistence in hospital environment 
Long-term persistence in hospital environment most likely contributes to the success of 
A. baumannii. Clinical isolates can survive up to one month in simulated hospital conditions 
independently of the strain source (Jawad et al., 1998). A prospective cohort study examined 
the presence of A. baumannii in intensive care unit rooms with patient colonized or infected 
with this pathogen (Thom et al., 2011). Approximately half of the rooms sampled were positive 
for the bacteria and most of the strains were similar to the patient isolates. A recent study 
showed that 54 % of healthy health care worker were A. baumannii nasal carriers in long-term-
care facilities in Taiwan (Liou et al., 2017). Altogether, these data indicate that persistence in 
hospital environment and health care worker may play a major role in A. baumannii nosocomial 
infection. This persistence behaviour is associated with the ability of A. baumannii to resist 
desiccation and adhere to abiotic surfaces, which are both discussed below. 
 Resistance to desiccation 
A. baumannii is intrinsically more resistant to desiccation than other Gram-negatives pathogens, 
as demonstrated by a 2-log CFU reduction after 25 days compared to K. pneumoniae, 
P. aeruginosa and E. coli that showed a 5-log CFU reduction after 1 h, 2 h and 7 h, respectively 
(Hirai, 1991). Under dry conditions, A. baumannii undergoes morphological changes, including 
transition from rod to round shaped cells and significantly thickening of the cell wall, which 
most likely contribute to desiccation resistance (Houang et al., 1998). Interestingly, these 
morphological changes make A. baumannii phenotypically more resembling Gram-positive 
bacteria, which are more desiccation resistant than Gram-negative bacteria (Hirai, 1991).  
Boll and colleagues suggested that the hepta-acylated lipid A present in the outer membrane of 
A. baumannii renders the membrane less fluid than the hexa-acylated lipid A present in most 
Gram-negative (Boll et al., 2015).  Consequently, a decrease in membrane fluidity may reduce 
the leakage of essential growth factors therefore increasing long-term survival. They showed 
that a penta-acylated A. baumannii mutant strain could not survive desiccation conditions 
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compared to the hepta-acylated wild type strain, indicating that a specific outer membrane 
composition may explain the differences between A. baumannii and other Gram-negative 
bacteria in their ability to resist desiccation.  
Besides morphological changes, the RecA recombinase is required for A. baumannii 
desiccation resistance. It has been suggested that RecA, which is involved in several DNA 
repair mechanisms, allows to cope with DNA damages caused by desiccation stress (Aranda et 
al., 2011). However, this does not explain the differences in desiccation resistance between 
A. baumannii and other Gram-negative bacteria, because they all encode recA. 
 Adherence to abiotic surface 
A.  baumannii has the capacity to attach to glass or plastic surfaces and to form biofilms. The 
ability to adhere and survive on abiotic surfaces plays an important role in nosocomial 
infections due to A. baumannii colonization of medical devices, such as urinary catheters, 
central venous catheters and endotracheal tubes (Longo et al., 2014).  
Different mechanisms appear to be involved in this process. Tomaras and colleague have 
demonstrated that adherence to abiotic surfaces and subsequent biofilm formation is dependent 
on the expression of the csuE gene in A. baumannii ATCC-19606 strain (Tomaras et al., 2003). 
CsuE is part of the CsuA/BABCDE chaperone–usher pili assembly system, and pili formation 
promotes A. baumannii adherence to and biofilm formation on abiotic surfaces. Transposon 
mutagenesis on A. baumannii 307-0294 strain revealed that a protein homolog to the S. aureus 
biofilm-associated protein (Bap) is required for the stabilization of A. baumannii biofilms 
formed on glass (Loehfelm et al., 2008). Another transposon mutagenesis study on 
ATCC-19606 strain demonstrated that deletion of the outer membrane protein A gene (ompA) 
hampered biofilm formation on plastic surface (Gaddy et al., 2009). 
This section specifically discussed abiotic surfaces adherence and biofilm mechanisms. Other 
mechanisms are observed for adherence to biotic surfaces and some of them will be discussed 
in the next section on virulence determinants. 
 Virulence determinants 
The mechanisms involved in A. bamaunnii virulence and pathogenesis have been only partially 
elucidated (Gordon and Wareham, 2010; McConnell et al., 2013). This lack of knowledge can 
be attributed to the paucity of tools to genetically manipulate A. baumannii clinical isolates to 
study virulence factors (Wong et al., 2017). In addition, virulence studies were often performed 
on avirulent lab-adapted strains and/or non-relevant infections models (Wong et al., 2017). 
Therefore, virulence studies must be interpreted carefully keeping in mind the strains and 
models that were used and their potential limitations. Nevertheless, Wong and colleagues 
recently compiled all the studies related to A. baumannii virulence and separated the different 
virulence factors in function of the model used for their identification (Wong et al., 2017). This 
work highlights cell surface components, such as outer membrane proteins, pili, capsule and 
protein secretion systems, as important A. baumannii virulence factors. 
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 OmpA 
OmpA is the most abundant outer membrane protein in A. baumannii. This protein is involved 
in several virulence mechanisms, such as adherence and invasion of host epithelial cells, cell 
cytotoxicity and biofilm formation (McConnell et al., 2013). Adherence to host cells is an 
important bacterial virulence factor as it is the initial step of the colonization process. In 2006, 
light and scanning electron microscopy experiments showed the first evidence of A. baumannii 
attachment to human bronchial epithelial cells (Lee et al., 2006). Later, the work of Gaddy and 
colleagues revealed that OmpA is involved in epithelial cell attachment (Gaddy et al., 2009). 
A. baumannii ATCC-19606 OmpA-deficient mutant cells were drastically impaired in their 
ability to attach and invade A549 human alveolar epithelial cells compared to the parental 
strain. Same findings were obtained with the A. baumannii AB5075 clinical strain (Schweppe 
et al., 2015). Moreover, it has been shown that OmpA protein is able to translocate to the 
nucleus of host cells, to target mitochondria and to induces cell death (Choi et al., 2005, 2008). 
OmpA mediated cell death was also demonstrated in dendritic cells suggesting that this 
virulence mechanism allows A. baumannii to prevent the adaptive immune system 
response (Lee et al., 2010). Finally, the importance of OmpA for A. baumannii pathogenesis 
was demonstrated in vivo in lung infection mouse models (Schweppe et al., 2015; Wang et al., 
2014). 
 Pili 
Pilis are filamentous appendages at the surface of bacteria mediating interactions with their 
environment. The role of pili in A. baumannii virulence has not been completely 
decoded (Weber et al., 2015a).  
The most studied pili structure in A. baumannii is the chaperone/usher Csu pili. As previously 
mentioned, this system is involved in attachment and biofilm formation on abiotic 
surfaces (Tomaras et al., 2003). In addition, Csu pili subunits have been identified as major 
components in the matrix of the pellicle, which is the biofilm that A. baumannii forms at the 
air-liquid surface (Chabane et al., 2014; Marti et al., 2011). However, the Csu pili system is not 
required for attachment of A. baumannii ATCC-19606 to biotic surfaces, such as epithelial cells 
(de Breij et al., 2009). In addition, the A. baumannii clinical isolate ACICU harbours a non-
functional Csu system due to transposon insertion (Eijkelkamp et al., 2014). Therefore, it 
appears that the A. baumannii Csu pili system is important for biofilm formation but its role in 
virulence needs to be confirmed in vivo. 
 Capsule 
Bacterial capsules are composed by extracellular polysaccharides forming a protection layer 
around bacterial cells. Most A. baumannii clinical isolates produce a capsule without distinction 
between epidemic or sporadic strains (Koeleman et al., 2001). The biosynthesis pathway of 
capsules is encoded by a cluster of genes called the K locus. The K locus is organized with 
modules encoding genes for polysaccharide export or UDP-linked sugar precursors synthesis 
at each ends (Kenyon and Hall, 2013). Genes present in between these two modules code for 
sugar synthesis enzymes, glycosyltransferases, glycan modification enzymes, and repeat unit 
processing enzymes. Although the two modules flanking the K locus are relatively conserved, 
the genes present in between are highly variable leading to high diversity and complexity in 
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capsule sugar composition and capsule organization in A. baumannii strains (Hu et al., 2013; 
Kenyon and Hall, 2013). Nevertheless, glycoproteome analysis revealed that the capsule is 
composed by glycans with similar characteristics across all A. baumannii (Scott et al., 2014). 
In general, A. baumannii capsular polysaccharides are short (three to five residue), unbranched 
glycans and contain negatively charged amino-containing sugars that contribute to host 
immunity protection. Capsule production has been associated with A. baumannii defence 
against complement-mediated opsonisation and destruction, as well as phagocytic 
uptake (Geisinger and Isberg, 2015; Lees-Miller et al., 2013; Russo et al., 2010). Two different 
studies performed on a laboratory and a clinical strain indicated that capsule deficient 
A. baumannii mutants were negatively affected during in vitro serum survival and in in vivo 
mouse experiments (Lees-Miller et al., 2013; Russo et al., 2010). Sub-inhibitory concentration 
of antibiotics may trigger an increased production of capsule exopolysaccharides due to 
activation of the BfmRS two component system (TCS) (Geisinger and Isberg, 2015). Capsule 
hyperproduction confers increased virulence in bloodstream infection mouse model. Finally, 
hypervirulent strains with an unusual capsule harbouring legionamic acid residue have been 
reported (Hu et al., 2013; Jones et al., 2015; Ou et al., 2015). The similarity between legionamic 
acid and sialic acid, which is present on mammalian surface glycoproteins, suggests a role for 
legionamic acid containing capsules in immune system escape (Ou et al., 2015). 
 Secretion systems 
Protein secretion systems have been associated with virulence in Gram-negative bacteria. 
A. baumannii encodes two different types of secretion systems, the type II secretion system 
(T2SS) and the type VI secretion system (T6SS).  
The T2SS has been recently identified in A. baumannii and it was suggested to be commonly 
present in this species (Weber et al., 2015a). A. baumannii T2SS is involved in lipase secretion, 
which is required for growth on long-chain fatty acids as a sole carbon source (Johnson et al., 
2016). Exogenous lipid metabolism is broadly accepted as a virulence factor suggesting a role 
for T2SS in A. baumannii pathogenesis (Singh et al., 2010). A T2SS deficient A. baumannii 
mutant was outcompeted by its respective parental strain in a bacteremia mouse model 
confirming the role of T2SS in A. baumannii virulence (Johnson et al., 2016). 
T6SSs were first described as toxin secretion systems used to compete with and kill surrounding 
eukaryotic cells. T6SS deficient A. baumannii mutants are significantly attenuated in a Galleria 
mellonella killing assay indicating the role of T6SS in pathogenesis (Repizo et al., 2015). 
Additionally, it appears that T6SSs are important for infection establishment  by killing 
competing bacteria (Weber et al., 2015a). Indeed, T6SS expressing A. baumannii strains 
compete with and kill a wide range of bacteria in vitro, including other A. baumannii 
strains (Repizo et al., 2015; Weber et al., 2015b). T6SS expression is generally tightly regulated 
due to the considerable energy requirement of a functional system (Basler, 2015). In 
A. baumannii ATCC-17978 and Ab04 strains, T6SS expression is controlled by a 
transcriptional repressor present on a plasmid harbouring multiple resistance genes (Weber et 
al., 2015b). Weber and colleagues suggest that A. baumannii takes advantage of this regulation 
system to simultaneously associate infection establishment with antibiotic resistance. Indeed, 
spontaneous plasmid loss in a population subpart would enable T6SS expression and niche 
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establishment while the rest of the population harbouring the plasmid resists antibiotic 
treatment. 
 Iron acquisition 
Iron sequestration is used by the host to fight against bacterial infections (Mortensen and Skaar, 
2013). Successful pathogens including A. baumannii, have developed efficient iron acquisition 
systems to access iron from their hosts. A. baumannii iron acquisition mainly resides on two 
systems.  
The first system uses the uptake of bacterial or host proteins that bind iron with high affinity. 
Indeed, A. baumannii can secrete and take up several siderophores, which are proteins that 
scavenge iron, or directly ingest iron-bound hemes that are released during erythrocytes 
lysis (Mortensen and Skaar, 2013). In both cases, the uptake of iron-bound proteins is 
dependent on an energy-transducing system mediated by TonB dependent-receptors. The most 
studied A. baumannii siderophore is acinetobactin. Its biosynthesis pathway and uptake systems 
are required for A. baumannii virulence as demonstrated in G. mellonella and mouse infection 
models indicating that iron acquisition plays an important role in A. baumannii 
pathogenesis (Fiester et al., 2015; Gaddy et al., 2012; Penwell et al., 2012; Zimbler et al., 2013). 
The second A. baumannii iron acquisition mechanism resides in the direct uptake of reduced 
ferrous iron. The ferrous iron import system relies on FoeAB transporters, which are ubiquitous 
in A. baumannii clinical isolates (Antunes et al., 2011). Transposon sequencing experiment 
conducted in a bacteremia mouse model indicated that mutants in the FeoAB transport system 
have a fitness defect compared to wildtype strains (Subashchandrabose et al., 2016). Altogether, 
it appears that iron acquisition mechanisms are important for A. baumannii virulence. 
 Immune system response to A. baumannii infection 
Host defence mechanisms involved in the control of A. baumannii infections as well as factors 
involved in clinical outcome were recently elucidated (Wong et al., 2017). Virulence 
assessment of multiple strains in a bacteremia mouse model showed that bacterial growth 
inhibition and infection clearance require the concerted action of the three innate immunity 
components, which are the complement system, neutrophils and macrophages (Bruhn et al., 
2015). Indeed, only the combined depletion of the three innate immunity effectors significantly 
increases bacterial density in blood triggering lethal sepsis. Consequently, early host defence 
mechanisms are essential to control the bacterial load enabling subsequent A. baumannii 
infection clearance (Figure 2.A). However, A. baumannii virulent strains, such as capsule 
hyperproducers, may escape complement mediated killing and phagocytosis leading to 
increased bacterial density (Figure 2.B).  An increased bacterial load activates the second line 
of defence consisting in toll-like receptor 4 (TLR4) mediated macrophages recognition of 
bacterial lipopolysaccharide (LPS) that triggers an inflammation response (Knapp et al., 2006). 
In a non-lethal pneumonia model, bacterial burden was increased in TLR4 deficient mice 
leading to bacteremia. Therefore, the TLR4 mediated inflammatory response has been 
suggested as a key player in the elimination of A. baumannii infection. In contrast, in a lethal 
bloodstream mouse model TLR4 deficient mice survived A. baumannii infections while 
wildtype mice died from septic shock (Lin et al., 2012). Additionally, mice treated with LpxC 
inhibitors blocking the LPS production survived A. baumannii infections while non-treated 
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mice died from septic shock. These results suggest that TLR4 mediated LPS recognition, which 
triggers inflammatory response, negatively drives the clinical outcome of A. baumannii 
infection.  
 
Figure 2: Host response to A. baumannii infection can follow two scenarios (Wong et al., 2017). A) The innate 
immune effectors (1, complement; 2, neutrophils; 3, macrophages) are efficient in controlling and clearing the 
infection. B) The innate immune effectors fail to control infection, which induces LPS-TLR4 mediated 
inflammatory response leading to a macrophage induced cytokine storm and sepsis. 
 
Altogether, these data indicate that the host response to A. baumannii infections may follow 
two scenarios (Figure 2). In the first scenario, the innate immune effectors are efficient in 
controlling the infection by lowering the bacterial density and this prevents a strong deleterious 
inflammatory response and leads to final infection clearance. The second scenario happens in 
infections caused by highly virulent A. baumannii strains that escape the primary innate 
immune effectors killing triggering a damaging TLR4-LPS mediated inflammatory response. 
This finally leads to a cytokine storm, sepsis syndrome and death (Wong et al., 2017).   
 Antibiotic resistance 
A. baumannii is characterized by its high ability to acquire resistance to multiple antimicrobial 
agents. A case of A. baumannii nosocomial outbreak caused by a pan drug resistant (PDR) 
strain in a Spanish hospital illustrates the ability of this pathogen to resist all available 
antibiotics (Valencia et al., 2009). 
Until recently, criteria to classify A. baumannii strains as MDR, extensively drug resistant 
(XDR) and PDR were not standardized leading to a lack of consistence between different 
studies. Currently, the standard and broadly accepted definition of resistance types is based on 
nine clinically relevant antibacterial categories that include one to four antimicrobial agents 
(Table 3) (Magiorakos et al., 2012). MDR A. baumannii are defined as non-susceptible to at 
least one agent in three or more antimicrobial categories. XDR A. baumannii are non-
susceptible to at least 1 agent in all but two or fewer categories. Finally, PDR A. baumannii are 
non-susceptible to all 22 antimicrobial agents present in the list. This definition allows precise 
resistance classification that is consistent between different studies.  
 
 
A) B) 
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Table 3: Antimicrobial categories and agents used to define A. baumannii resistance types (Magiorakos et 
al., 2012). 
Antimicrobial categories Antimicrobial agents Mode of action 
Aminoglycosides Gentamicin, Tobramycin, Amikacin, Netilmicin Inhibition of protein synthesis  
Antipseudomonal 
carbapenems 
Imipenem, Meropenem, Doripenem  
Inhibition of cell wall 
synthesis 
Antipseudomonal 
fluoroquinolones 
Ciprofloxacin, Levofloxacin Inhibition of DNA synthesis 
Antipseudomonal penicilins 
+ β-lactamase inhibitors 
Piperacillin-tazobactam, Ticarcillin-clavulanic acid 
Inhibition of cell wall 
synthesis 
Extended-spectrum 
cephalosporins 
Cefotaxime, Ceftriaxone, Ceftazidime, Cefepime 
Inhibition of cell wall 
synthesis 
Folate pathway inhibitors Trimethoprim-sulfamethoxazole Inhibition of folate synthesis 
Penicillins 
+ β-lactamase inhibitors 
Ampicillin-sulbactam 
Inhibition of cell wall 
synthesis 
Polymyxins Colistin, Polymyxin B Cell membrane disruption 
Tetracyclines Tetracycline, Doxycycline, Minocycline Inhibition of protein synthesis 
A. baumannii infections are predominantly caused by a few successful lineages worldwide, 
which belong to the international clonal cluster (ICC) ICC1, ICC2 and ICC3 lineages (Higgins 
et al., 2010). Multilocus sequence typing (MLST), a PCR based method that relies on the 
sequence variation of internal portion of seven housekeeping genes, is the gold standard method 
for A. baumannii typing. The first MLST scheme to be developed for A. baumannii, named 
Oxford MLST, was published in 2005 and it relies on the sequence of the gltA, gyrB, gdhB, 
recA, cpn60, gpi, and rpoD genes (Bartual et al., 2005). Five years later, Diancourt and 
colleagues used a modified MLST scheme, named Pasteur MLST, to evaluate the phylogenetic 
relatedness of 154 A. baumannii clinical strains isolated in Europe (Diancourt et al., 2010). The 
Pasteur scheme introduced four new genes, namely fusA, pyrG, rpoB and rplB, and conserved 
the cpn60, gltA and recA genes of the Oxford scheme. Both schemes are now hosted in the same 
database (https://pubmlst.org/abaumannii/) but the Pasteur MLST represents the standard 
scheme to type A. baumannii clonal lineage (Zarrilli et al., 2013). 
A. baumannii successful clonal lineages are more likely to resist multiple antibiotics including 
carbapenems, which are last resort antibiotics for the treatment of MDR A. baumannii 
infections (Diancourt et al., 2010; Higgins et al., 2010; Zarrilli et al., 2013). Among the three 
international clonal complexes, the ICC2 is the most successful pathogenic lineage. A recent 
study evaluating biofilm formation in 114 A. baumannii clinical isolates demonstrated that 
95.7 % of the MDR isolate belonged to the ICC2 lineage and that ICC2 isolates produced less 
biofilm than other isolates (Hu et al., 2016). Consequently, the ability to resist antibiotic 
treatment might be a determinant for the A. baumannii epidemic spread. 
A recent global surveillance study indicated that A. baumannii has the highest rate of MDR 
among the major Gram-negative pathogens (Giammanco et al., 2017). The study described a 
dramatic increase in A. baumannii MDR rates from 23% (309/1,323) in 2004 to 63% (447/712) 
in 2014. This trend was confirmed by the 2015 ECDC report on antimicrobial resistance in 
Europe with several countries having a MDR rate above 50 % (Figure 3). These data are 
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alarming considering that A. baumannii MDR infections are associated with increased hospital 
stay and higher mortality rate than infections with drug susceptible A. baumannii (Lee et al., 
2007; Sunenshine et al., 2007). 
 
Figure 3: Percentage of MDR Acinetobacter spp. per country in 2015 (ECDC, 2017). 
 Mechanisms of antibiotic resistance 
Bacteria exploit several diverse mechanisms to resist antibiotic, including 
modification/inactivation of antibiotics, protection/modification/bypass of drug targets and 
increasing the cellular efflux or decreasing the influx to lower the intracellular antibiotic 
concentration (Figure 4) (Blair et al., 2015). Each of these mechanisms is represented in the 
A. baumannii arsenal of innate and acquired resistance determinants used to overcome 
antibiotic action. Genomic plasticity together with the high DNA acquisition capacity account 
for the broad-spectrum resistance of A. baumannii.   
Despite the predominance of few successful clonal lineages, the genome of A. baumannii 
strains causing infections is rather diverse (Imperi et al., 2011; Liu et al., 2014; Snitkin et al., 
2011). The high degree of genome plasticity is based on the presence of genomic islands and 
transposons that can move and re-organize across the genome by homologous recombination. 
Several genomic islands containing resistance determinants (AbaR resistance islands) have 
been identified in MDR isolates (Adams et al., 2008; Fournier et al., 2006; Iacono et al., 2008; 
Kim et al., 2013; Lean et al., 2015; Li et al., 2015; Ou et al., 2015; Post et al., 2010). AbaR-
type resistance island are in general integrated in the comM gene coding for an ATPase and the 
resistance genes were most probably acquired from other Gram-negative species. The plasticity 
and transfer capacity of AbaR-type resistance islands is highlighted by the presence of multiple 
mobile elements inside and around these gene clusters, such as insertion sequence (IS) 
elements. In addition to their role in genome plasticity, IS elements play an important role in 
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A. baumannii antibiotic resistance. Indeed, IS elements encode a strong promoter at the edge of 
their sequence that may drive the expression of surrounding antibiotic resistance genes, such as 
efflux pumps and β-lactamases (Lopes and Amyes, 2012; Mugnier et al., 2009; Sun et al., 
2012). 
 
Figure 4: Overview of Gram-negative antimicrobial resistance mechanisms (Zowawi et al., 2015).  
The main antibiotic resistance mechanisms are represented. These mechanisms include modification/inactivation 
of antibiotics, protection/modification/bypass of drug targets and increase efflux or decrease influx to lower 
intracellular antibiotic concentration. 
 
 β-Lactams 
The most significant mechanism of β-lactam resistance consists in antibiotic degradation due 
to the expression of β-lactamases encoding genes (bla) (Figure 4). A. baumannii naturally 
encodes two β-lactamases, the AmpC cephalosporinase and the OXA-51 class D oxacillinase. 
In addition, A. baumannii may acquire a multitude of other chromosomally or plasmid encoded 
β-lactamases.  
A. baumannii chromosomally encoded ampC (blaADC) is expressed at low level and its 
expression is not inducible in contrast to other AmpC producing pathogens (Bou and Martínez-
Beltrán, 2000). The insertion of an IS element upstream blaADC is required to confer AmpC 
mediated β-lactam resistance in A. baumannii. Transposon driven AmpC expression confers 
resistance to 3rd and 4th generation of extended-spectrum-cephalosporins, such as cefotaxime, 
ceftazidime and cefepime (Héritier et al., 2006; Lopes and Amyes, 2012).  
In addition to blaADC, A. baumannii may acquire other extended-spectrum-β-lactamases 
(ESBLs) conferring resistance to cephalosporins. The most frequently found ESBLs correspond 
to the Amber class A β-lactamases of the PER and VEB types. Notably, VEB-1 producing 
A. baumannii were responsible for an outbreak in 53 French hospitals in 2003-2004 (Naas et 
al., 2006a). This ESBL has been also reported in cephalosporin resistant A. baumannii clinical 
isolates from Belgium and Argentina (Naas et al., 2006b; Pasterán et al., 2006). More recently, 
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39.5 % (39 / 108) of A. baumannii clinical strains isolated from two hospitals in Teheran 
harboured blaVEB-1, which was the second most identified ESBL after blaPER-1 identified in 78 % 
of the strains (Fallah et al., 2014). A. baumannii isolates producing PER types of ESBL have 
been reported worldwide: in Europe (Belgium, Bulgaria, Hungary, France and Romania), 
America (Argentina and USA), Asia (China, Russia, Korea and India) and Middle-East (Iran, 
Egypt, Turkey and Saudi Arabia) (Al-Agamy et al., 2014; Bonnin et al., 2011; Fallah et al., 
2014; Hujer et al., 2006; Jeong et al., 2005; Litake et al., 2009; Naas et al., 2006b, 2007a, 2007b; 
Pasterán et al., 2006; Strateva et al., 2008; Szabó et al., 2008; Vahaboglu et al., 1997; Yezli et 
al., 2015; Zhang et al., 2010). Other ESBLs commonly found in A. baumannii include, TEM, 
SHV and CTX-M types (Alyamani et al., 2015; Endimiani et al., 2007; Naas et al., 2007c; 
Potron et al., 2011). Noteworthy, GES type ESBLs have been identified in A. baumannii  and 
some of these GES-type enzymes possess additional carbapenemase activity (Bonnin et al., 
2013; Chihi et al., 2016; Moubareck et al., 2009). 
Carbapenems are the antibiotics of choice to treat A. baumannii infections (Maragakis and Perl, 
2008; Peleg and Hooper, 2010). However, there is an increase in A. baumannii infections 
caused by carbapenem resistant isolates as illustrated by the ECDC map representing the rate 
of carbapenem resistant A. baumannii in Europe in 2015 (Figure 5). The major cause of 
carbapenem resistance consists of OXA type carbapenemases expression. A. baumannii 
ubiquitously encodes an OXA-51 like carbapenemase in its chromosome. Indeed, blaOXA-51 was 
used as specific marker for A. baumannii species genotyping (Turton et al., 2006a). Similarly 
to AmpC, OXA-51 confers carbapenem resistance only when an IS element is present upstream 
blaOXA-51 to drive its expression (Figueiredo et al., 2009; Turton et al., 2006b). In addition to 
the intrinsic OXA-51 like carbapenemases, A. baumannii may acquire several others OXA 
subclasses that are found both chromosomally or on plasmids (Poirel et al., 2010). Among them, 
the OXA-23 like, OXA-24(40) like, OXA-58 like, OXA-143 like and OXA-235 like are the 
most represented subclasses with OXA-23 being widespread in worldwide successful ICC2 
isolates (Mugnier et al., 2009; Potron et al., 2015).  
Different non-oxacillinase carbapenemases may be also present in carbapenem resistant 
A. baumannii. The Klebsiella pneumoniae carbapenemases (KPCs), which are widespread in 
Enterobacteriaceae and confer resistance to all β-lactams, have been only rarely identified in 
A. baumannii (Potron et al., 2015). Indeed, A. baumannii ICC2 isolates carrying KPC 
carbapenemases have been reported to date only in Puerto Rico (Martinez et al., 2016; Robledo 
et al., 2010). Metallo-β-lactamases (MBLs) with carbapenemase activity have been reported in 
A. baumannii isolates. The most worrisome MBL is the NDM-1 β-lactamase that was rather 
recently identified but spread widely among Enterobacteriaceae. NDM-1 carbapenemase was 
identified in A. baumannii isolated from several countries in Europe (Potron et al., 2015). In 
2013, an outbreak due to NDM-1 producing A. baumannii was reported in France (Decousser 
et al., 2013). A. baumannii harbouring NDM-1 carbapenemase are increasingly reported 
worldwide with a majority of cases coming from Asia and Middle-East (Dortet et al., 2014). 
Others MBLs, such as IMP-like, VIM-like or SIM-1 have been reported with a lower rate than 
the previously mentioned carbapenemases (Poirel and Nordmann, 2006; Potron et al., 2015). 
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Figure 5: Percentage of carbapenem resistant Acinetobacter spp. per country in 2015 (ECDC, 2017) 
 
The presence of non-β-lactamase resistance mechanisms have been suggested in A. baumannii. 
Loss of porins through which β-lactams permeate to reach the periplasm is a common resistance 
mechanism (Figure 4). However, this mechanism only slightly increases A. baumannii 
resistance to β-lactams and its clinical relevance is still debated (Catel-Ferreira et al., 2012; 
Clark, 1996; Dupont et al., 2005; Fonseca et al., 2013; del Mar Tomás et al., 2005).  
 Aminoglycosides 
Aminoglycosides are an important class of antibiotics to treat infections caused by Gram-
negative pathogens, including A. baumannii (Maragakis and Perl, 2008; Peleg and Hooper, 
2010). A. baumannii has developed a wide range of diverse aminoglycoside resistance 
mechanisms consisting in antibiotic modification, target modification and antibiotic efflux 
mechanisms (Figure 4). This led to a rapid emergence of aminoglycoside resistant A. baumannii 
isolates with a rate exceeding 50 % in several European countries in 2015 (Figure 6).   
The most common aminoglycoside resistance mechanism resides in antibiotic inactivation due 
to aminoglycoside modifying enzymes (AMEs). AMEs were detected in 94 % (79 / 84) of 
aminoglycoside non-sensitive A. baumannii strains isolated in Iran in 2014 indicating the major 
role of AMEs in A. baumannii aminoglycoside resistance (Sheikhalizadeh et al., 2017). 
A. baumannii may acquire a wide array of genes encoding AMEs that catalyse different type of 
modifications with more or less activity in function of the aminoglycosidic agent (Nemec et al., 
2004; Ramirez and Tolmasky, 2010). The three types of AMEs, namely acetyltransferases 
(AACs), phosphotransferases (APHs) and nucleotidyltransferases (ANTs), have been identified 
in A. baumannii. There is no clear hierarchy in the prevalence of AACs, APHs and ANTs with 
different preponderance observed in different studies (Akers et al., 2010; Atasoy et al., 2015; 
Introduction-Part A: A. baumannii 
19 
Cho et al., 2009; Miller et al., 1995; Noppe-Leclercq et al., 1999; Sheikhalizadeh et al., 2017). 
Nevertheless, these enzymes are each specific to certain aminoglycosides and do not confer 
broad aminoglycoside resistance like 16S rRNA methyltransferases and efflux pumps. 
 
Figure 6: Percentage of aminoglycoside resistant Acinetobacter spp. per country in 2015 (ECDC, 2017) 
Aminoglycosides block bacterial protein production by binding to the conserved 16S rRNA in 
the ribosome. Therefore, modification of 16S rRNA conformation mediated by 
methyltransferases confers broad and high level aminoglycoside resistance (Doi and Arakawa, 
2007). The ArmA methyltransferase is the most identified in A. baumannii isolates 
worldwide (Potron et al., 2015). Studies from Iran, China and Vietnam have reported a strong 
prevalence of armA in highly aminoglycoside resistant A. baumannii strains (94.4 %, 98 % and 
87.1 %, respectively) (Nie et al., 2014; Sheikhalizadeh et al., 2017; Tada et al., 2013). 
Noteworthy, A. baumannii strains co-producing carbapenemases and ArmA are emerging 
worldwide (Bakour et al., 2014; Brigante et al., 2012; El-Sayed-Ahmed et al., 2015; Hong et 
al., 2013; Karah et al., 2011; Milan et al., 2016; Shen et al., 2016a; Strateva et al., 2012; Tada 
et al., 2014, 2015; Wang et al., 2016). 
The last aminoglycoside resistance mechanism identified in A. baumannii consists in active 
efflux. The AdeABC efflux pump is involved in aminoglycoside resistance in the MDR 
A. baumannii BM4454 strain isolated from a patient with urinary tract infection (Magnet et al., 
2001). Kanamycin and gentamycin, two aminoglycosides, were further identified as substrate 
of the A. baumannii AbeM efflux pump (Su et al., 2005). However, only few studies have 
looked at the relation between aminoglycoside resistance phenotype and AdeABC or AbeM 
expression in A. baumannii clinical isolates. A recent study indicates that AdeABC and AbeM 
efflux pumps play only a minor role in aminoglycoside resistance in clinically isolated 
A. baumannii strains (Sheikhalizadeh et al., 2017). 
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 Fluoroquinolones 
Fluoroquinolones, such as ciprofloxacin and levofloxacin, played a major role in the treatment 
of A. baumannii infections (Peleg and Hooper, 2010). However, fluoroquinolones are no longer 
a valid option to treat A. baumannii infections in many countries due to high rate of resistance 
as illustrated in Greece with 94.9 % of resistance among the 946 isolates tested in 2015 
(Figure 7).  
The primary fluoroquinolone resistance mechanism consists in antibiotic target modification 
(Figure 4). Mutations in the subunits of the gyrase (gyrA) and topoisomerase IV (parC) confer 
high fluoroquinolone resistance in A. baumannii due to decreased fluoroquinolone affinity to 
the enzyme-DNA complex (Adams-Haduch et al., 2008; Hamouda and Amyes, 2004; Higgins 
et al., 2004; Lee et al., 2005; Park et al., 2011a; Vila et al., 1995, 1997). More recently, 
mutations in the second gyrase subunit (gyrB) were associated with fluoroquinolone 
resistance (Park et al., 2011a). The authors described that triple mutations (gyrA, gyrB and 
parC) may confer even higher ciprofloxacin resistance than gyrA and parC mutations. 
 
 
Figure 7: Percentage of fluoroquinolone resistant Acinetobacter spp. per country in 2015 (ECDC, 2017) 
 
The second fluoroquinolone resistance mechanism consists in active efflux. Expression of 
AdeABC, AdeFGH, AbeM and AbeS efflux pumps have been associated with fluoroquinolones 
resistance in A. baumannii (Coyne et al., 2010; Magnet et al., 2001; Srinivasan et al., 2009; Su 
et al., 2005). In accordance to what is observed with aminoglycoside resistance, the expression 
of efflux pumps may play a secondary and minor role in A. baumannii fluoroquinolone 
resistance compared to antibiotic target mutations that represent the predominant resistance 
mechanism. 
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 Tetracyclines 
Tetracycline agents, such as minocycline and its glycylcycline derivative tigecycline, are potent 
antibiotics used to treat A. baumannii infections (Peleg and Hooper, 2010). Indeed, tigecycline 
has the lowest MIC90 (2 µg/ml) and minocycline the lowest resistance rate (12.6 %) among 11 
antimicrobial agents tested on 8,294 MDR A. baumannii collected globally between 2004 and 
2014 (Giammanco et al., 2017).  
Tetracycline antibiotics target the 30S ribosomal subunit and prevent the attachment of 
aminoacyl-tRNA to the ribosomal acceptor site leading to protein synthesis inhibition (Chopra 
and Roberts, 2001). The major tetracycline resistance mechanisms reside in active efflux and 
target protection (Figure 4). A. baumannii active efflux systems that confer tetracycline 
resistance are encoded by tet(A) and tet(B) (Guardabassi et al., 2000; Ribera et al., 2003). An 
old study carried out on 35 tetracycline resistant A. baumannii strains isolated from European 
hospitals from 1981 to 1998 showed a similar ratio between tet(A) and tet(B) harbouring 
strains, whereas more recent studies showed a predominance of strains encoding 
tet(B) (Guardabassi et al., 2000; Mak et al., 2009; Vilacoba et al., 2016). The emergence of 
tet(B) harbouring strains might be due to minocycline selection. Indeed, tet(B) confers 
resistance to both tetracycline and minocycline, whereas tet(A) confers resistance mainly to 
tetracycline (Chopra and Roberts, 2001). In contrast, the ribosome protection gene tet(M) has 
been only rarely identified in A. baumannii clinical isolates although it confers resistance to 
minocycline (Huys et al., 2005a, 2005b; Ribera et al., 2003). 
The recently approved antibiotic tigecycline escapes the tet(A)/(B) and tet(M) mediated efflux 
and protection resistance mechanism, respectively (Esterly et al., 2011). However, 
overexpression of the AdeABC efflux pumps have been associated with A. baumannii 
tigecycline resistance. This AdeABC mediated tigecycline resistance mechanism is the scope 
of the section 2.1.1. 
 Polymyxins 
Polymyxin antibiotics, which consists of polymyxin E (colistin) and polymyxin B, are old 
antibiotics that were put aside due to their high-level nephrotoxicity (Brown et al., 1970; Koch-
Weser et al., 1970; Ryan et al., 1969). However, with increasing Gram-negative antibiotic 
resistance rates, polymyxins were re-introduced and are now considered as last resort antibiotic 
to treat carbapenem resistant Gram-negative infections, such as the one caused by 
A. baumannii (Falagas and Kasiakou, 2005; Li et al., 2006; Maragakis and Perl, 2008; Peleg 
and Hooper, 2010; Zavascki et al., 2007).  
Polymyxins are cationic polypeptides that bind to the negatively charged LPS and disturb the 
bacterial cell membrane, thus increasing permeability and leakiness, leading to cell 
death (Falagas and Kasiakou, 2005). Polymyxin resistance is conferred by lipid A 
modifications that lower the outer membrane negative charge and decrease polymyxin affinity 
(Figure 4) (Olaitan et al., 2014). The A. baumannii polymyxin resistance mechanism is the 
scope of the section 2.1.2. 
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 History  
Tuberculosis is an airborne infectious disease caused by the bacterial pathogen Mycobacterium 
tuberculosis. Tuberculosis has been a plague for humanity from ancient times up to present 
days (Daniel, 2006). The Mycobacterium genus may have originated more than 150 million 
years ago, while M. tuberculosis origin was estimated at 3 million years ago based on mutation 
rate studies (Gutierrez et al., 2005; Hayman, 1984). There are evidences of the presence of 
M. tuberculosis in Egypt 5000 years ago. Egyptian mummies skeletal bones presented 
abnormalities that are characteristic of tuberculosis disease and M. tuberculosis DNA has been 
identified on these Egyptian mummies (Crubézy et al., 1998; Nerlich et al., 1997; Zimmerman, 
1979). Similarly, M. tuberculosis DNA has been identified in a 1000-years-old pre-Columbian 
Peruvian mummy indicating its presence in America before European colonization (Salo et al., 
1994). Tuberculosis became endemic in Europe and America in the 18th and 19th centuries were 
it caused enormous amount of death (Daniel, 2006; Holmberg, 1990). In the early 19th century, 
Theophile Laennec first described with precision tuberculosis pathogenesis (Daniel, 2004). In 
1865, Jean-Antoine Villemin demonstrated the transmissibility of tuberculosis indicating the 
infectious nature of the disease (Keshavjee and Farmer, 2012). A major step in tuberculosis 
understanding was enabled in 1882 by Robert Koch who discovered the tubercle bacillus as the 
etiologic agent of tuberculosis (Daniel, 2006; Keshavjee and Farmer, 2012). Despite advance 
in tuberculosis understanding, appropriate treatments were missing until 1944, when 
streptomycin as the first antibiotic agent active on M. tuberculosis was isolated (Group, 1948; 
Hinshaw et al., 1946; Jellinek, 1949; Schatz et al., 2005). In 1952, isoniazid was discovered 
followed by ethionamide in 1956 and rifampicin in 1957, which are still used to treat 
M. tuberculosis infections nowadays (Keshavjee and Farmer, 2012).   
 Epidemiology 
Two to three billion people, which represents one-third of the world’s population, are estimated 
to be latently infected with M. tuberculosis according to the latest annual report on tuberculosis 
by the WHO (WHO, 2016). However, it is estimated that only 5 to 15 % of people carrying 
M. tuberculosis will develop tuberculosis in their lifetime. In 2015, 10.4 million new 
tuberculosis cases were estimated and 1.8 million people died from tuberculosis making the 
disease one of the top 10 causes of death worldwide. Sixty percent of new tuberculosis cases in 
2015 originate from six countries: India, Indonesia, China, Nigeria, Pakistan and South Africa. 
Globally, low income countries in southern Africa, southern Asia and Oceania are the most 
affected (Figure 8). 
In 2015, 11 % of estimated incident tuberculosis patients were HIV positive making HIV 
infection the major risk factor for tuberculosis. The proportion of HIV positive tuberculosis 
cases exceeded 50 % in parts of southern Africa (Figure 9). Twenty two percent (0.4 million) 
of tuberculosis deaths occured in HIV-positive people in 2015 indicating that tuberculosis-HIV 
co-infection is a factor increasing mortality. 
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Figure 8: Estimated tuberculosis incidence rates in 2015 (WHO, 2016)  
 
 
Figure 9: Estimated HIV prevalence in tuberculosis cases in 2015 (WHO, 2016)  
In 2015, the incidence of MDR M. tuberculosis, which is defined as resistance to rifampicin 
and isoniazid, was estimated at 480 000 new cases and the incidence of rifampicin resistant 
(RR) M. tuberculosis, which are newly eligible for MDR treatment regiment (see 
section 1.2.3.), was estimated at 100 000 new cases. Globally, MDR and RR M. tuberculosis 
represented 5 % of new cases of tuberculosis. The highest rate of MDR and RR M. tuberculosis 
was observed in the Russian Federation with rates superior to 18 % (Figure 10).  
Although the overall rate of MDR and RR M. tuberculosis was low, India is by far the country 
with the highest incidence of MDR and RR M. tuberculosis followed by China and the Russian 
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Federation, which together accounted for 45 % of those cases (Figure 11). Deaths from MDR 
and RR M. tuberculosis were estimated at 250 000 in 2015, which corresponds to 43 % of MDR 
and RR M. tuberculosis cases. Global tuberculosis mortality rate was 17 % in 2015 indicating 
that MDR and RR M. tuberculosis trigger increased tuberculosis mortality. 
 
Figure 10: Percentage of new tuberculosis cases with MDR and RR M. tuberculosis in 2015 (WHO, 2016) 
 
 
Figure 11: Incidence of MDR and RR M. tuberculosis in 2015 (WHO, 2016) 
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 Antibiotic treatments and resistance mechanisms 
 Antibiotic treatments 
Most of the drugs available to treat tuberculosis were discovered more than 50 years 
ago (Nguyen, 2016) (Table 4). The most potent anti-tuberculosis drugs represent the first-line 
treatment and include isoniazid, rifampicin, pyrazinamide and ethambutol. If these drugs are 
inefficient due to MDR or RR, second line drugs are used to fight the infection. However, the 
second-line drugs are generally less potent against M. tuberculosis and may have more severe 
toxic side effects. Second-line tuberculosis-drugs include cycloserine, ethionamide, 
p-Aminosalicylic acid (PAS), streptomycin, amikacin, capreomycin and broad-spectrum 
fluoroquinolones.  
The standard treatment regimen recommended for tuberculosis is a 6-month therapy consisting 
in an intensive 2-month treatment with isoniazid, rifampicin, pyrazinamide and ethambutol 
followed by a 4-month treatment with isoniazid and rifampicin (Nahid et al., 2016). Treatment 
failure is defined as positive culture after 4 and 5 months of appropriate treatment in United 
States and Europe, respectively (Nahid et al., 2016). This regimen is very efficient in treating 
infections caused by drug-susceptible M. tuberculosis with a cure rate of 90 to 95 % (Nahid et 
al., 2016).  
However, the prevalence of MDR and RR M. tuberculosis in certain regions of the world 
impairs the efficacy of the standard treatment regimen (Figure 10 and Figure 11). Treatment of 
MDR tuberculosis is built empirically in function of the resistance profile of the M. tuberculosis 
strain when this information is available. For MDR treatment regiment, the WHO recommends 
to use ethionamide combined with an injectable second-line drug, namely capreomycin or 
amikacin, a fluoroquinolone, at least another second-line drug, and the first-line drugs that are 
still active (World Health Organization, 2014). In contrast to drug susceptible, MDR 
tuberculosis treatment lasts up to 24 months and the cure rate is drastically reduced with only 
50 % of MDR tuberculosis patients successfully treated in 2014. More worryingly, XDR 
M. tuberculosis, which is defined as MDR with additional resistance to fluoroquinolones and 
one of the injectable second-line drugs, and totally-drug resistant (TDR) M. tuberculosis are 
emerging (Dorman and Chaisson, 2007; Udwadia, 2012). Infections caused by XDR or TDR 
M. tuberculosis strains are essentially incurable by the current anti-tuberculosis drugs (Nguyen, 
2016). 
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Table 4: Anti-tuberculosis drugs mode of action and resistance mechanisms (Palomino and Martin, 2014; 
Zhang and Yew, 2015) 
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 Resistance mechanisms 
M. tuberculosis is generally more resistant to antibiotics than other bacteria. This high intrinsic 
resistance not only protects M. tuberculosis from most available antibiotics but also impairs the 
development of new drugs. Intrinsic resistance has largely been attributed to the presence of an 
impermeable mycolic-acid-rich cell envelope, which is specific for the Mycobacterium 
genus (Jarlier and Nikaido, 1994; Nguyen, 2016). In addition to low permeability, 
M. tuberculosis encodes a system involved in resistance to multiple antibiotics, which is 
dependent on the transcriptional activator WhiB7 (Morris et al., 2005). The whiB7 multidrug-
resistance system is ubiquitous in all species of the Actinomycetales order, including 
M. tuberculosis, which are known for their ability to produce antibiotics, such as 
Streptomyces (Eldholm and Balloux, 2016).  
Anti-tuberculosis drugs may be grouped according to their spectrum, with tuberculosis specific 
drugs such as isoniazid, pyrazinamide, ethambutol, ethionamide and PAS, and broad-spectrum 
drugs such as rifampicin, cycloserine, the aminoglycosides and the fluoroquinolones. 
Interestingly, except ethambutol, all the tuberculosis specific drugs are prodrugs that need to be 
converted into active compound by the host or by M. tuberculosis itself. The prodrug approach 
increases the bioavailability and the effectiveness of the drugs while reducing potential 
toxicity (Mori et al., 2017). Prodrugs are prevalent in tuberculosis therapy in contrast to other 
therapeutic areas, where it is estimated that 10 % of the marketed drugs are prodrugs (Zawilska 
et al., 2013). However, anti-tuberculosis prodrug approach was not aimed and the prodrug 
feature of these agents were discovered only in 1992, 1996, 2000 and 2006 for isoniazid, 
pyrazinamide, ethionamide and PAS, respectively (Baulard et al., 2000; Scorpio and Zhang, 
1996; Zhang et al., 1992; Zheng et al., 2013). The negative counterpart of prodrugs is the 
possibility for the pathogen to resist the action of the drug by disrupting the bioactivation 
pathway.  
Another M. tuberculosis exception resides in its low ability of horizontal gene transfer, low 
recombination and mutation rates and therefore low genome diversity (Eldholm and Balloux, 
2016). In theory, these features render M. tuberculosis unlikely to develop resistances compared 
to other successful pathogens that use horizontal gene transfer and genome plasticity to resist 
antibiotics. However, MDR, XDR and TDR M. tuberculosis are rapidly emerging indicating 
the ability of this pathogen to develop resistance mechanisms. M. tuberculosis resistance mostly 
arises through endogenous mechanisms that does not require acquisition of foreign DNA, such 
as mutations of the antibiotic target or inactivation of the bioactivation enzymes, which is a 
prevalent resistance mechanism in M. tuberculosis (Table 4). 
The mode of actions and antibiotic resistance mechanisms of first- and second-line anti-
tuberculosis drugs have recently been reviewed and are summarized in the Table 4 (Palomino 
and Martin, 2014; Zhang and Yew, 2015). 
 Ethionamide resistance 
Ethionamide is a second-line anti-tuberculosis drug analogue to the first-line drug isoniazid 
(Vilchèze and Jacobs, 2014). Both molecules are prodrugs, ethionamide is activated by the 
M. tuberculosis monooxygenase EthA whereas isoniazid is activated by the M. tuberculosis 
catalase-peroxidase KatG (Baulard et al., 2000; Fraaije et al., 2004; Lei et al., 2000; Zhang et 
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al., 1992). In both case, the resulting activated drugs inhibit the enoyl-ACP reductase InhA by 
forming NAD+ adducts that sit in the active site of the NADH dependent enzyme 
(Figure 12) (Banerjee et al., 1994; Rawat et al., 2003; Wang et al., 2007). InhA is part of the 
fatty acid synthase type II system and its inhibition stops mycolic acid biosynthesis, which is 
one of the major components of M. tuberculosis cell wall therefore resulting in mycobacteria 
cell death (Marrakchi et al., 2000; Takayama et al., 1972; Vilchèze et al., 2000; Winder et al., 
1971).  
 
Figure 12: Ethionamide and isoniazid mode of action (Vilchèze and Jacobs, 2014). 
Ethionamide (ETH) and isoniazid (INH) are activated by the monooxygenase EthA and the catalase peroxidase 
KatG, respectively, to form a reactive species that binds to NAD+. The resulting adducts, ETH-NAD or INH-NAD, 
inhibit the enoyl-ACP reductase InhA of the FASII system, resulting in mycolic acid biosynthesis inhibition. 
 
The predominant ethionamide resistance mechanism in M. tuberculosis is the direct mutation 
of the target InhA or mutation in the promoter region of inhA. Mutations in InhA result in a 
lower affinity for the ethionamide- and isoniazid-NAD+ adducts leading to increased drug 
resistance (Vilchèze et al., 2006). On the other hand, mutations in the promoter region of inhA 
result in InhA overexpression leading to increased ethionamide and isoniazid 
resistance (Vilchèze et al., 2006). In a panel of 38 ethionamide resistant M. tuberculosis strains 
isolated from United States, Russia and Brazil, 73 % of the strains harboured mutation in InhA 
and/or inhA promoter (Morlock et al., 2003). Mutations in inhA promoter were predominant 
(n = 26) over mutations in InhA (n = 9). Similarly, 62 % of 47 ethionamide resistant 
M. tuberculosis strains isolated from France harboured mutations in InhA and/or inhA 
promoter (Brossier et al., 2011). Again, mutations in inhA promoter were predominant (n = 26) 
over mutations in InhA (n = 6). Mutations in InhA are rare due to the essential role of this 
enzyme in M. tuberculosis mycolic acid biosynthesis pathway. Three different InhA mutations 
were reported in ethionamide resistant M. tuberculosis strains causing the amino acid 
substitutions I21T(or V), S94A and I95P (Morlock et al., 2003; Ristow et al., 1995). In contrast, 
mutation in inhA promoter leading to InhA overexpression are widespread. Three different inhA 
promoter mutations were reported in ethionamide resistant M. tuberculosis strains, namely the 
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t-8c, the c-15t and the g-17t, which are located 8 bp, 15 bp and 17 bp upstream the inhA start 
codon, respectively (Brossier et al., 2011; Morlock et al., 2003). Among them, the c-15t 
mutation is the most widespread and it leads to a 20-fold InhA overexpression and an 8-fold 
increase in ethionamide MIC (Vilchèze and Jacobs, 2014; Vilchèze et al., 2006).  
The second ethionamide resistance mechanism in M. tuberculosis resides in the disruption of 
the prodrug bioactivation pathway. Ethionamide is activated by the M. tuberculosis 
monooxygenase EthA and ethA expression is negatively regulated by the TetR-type 
transcriptional regulator EthR (Baulard et al., 2000; Fraaije et al., 2004). Therefore, EthA and 
EthR mutations have been associated with ethionamide resistance in M. tuberculosis clinical 
isolates (Vilchèze and Jacobs, 2014). Indeed, EthA mutations that impair ethionamide 
bioactivation activity result in increased resistance. Ethionamide resistant M. tuberculosis 
clinical isolates have been reported with missense mutations and nucleotide deletions or 
insertions all over the coding sequence of ethA without any mutation hotspot (Boonaiam et al., 
2010; Brossier et al., 2011; DeBarber et al., 2000; Leung et al., 2010; Morlock et al., 2003). 
EthA mutation was reported in 47 % of the 47 ethionamide resistant M. tuberculosis strains 
isolated in France and 39 % of the 38 ethionamide resistant M. tuberculosis strains isolated in 
United States, Russia and Brazil (Brossier et al., 2011; Morlock et al., 2003). In contrast, 
mutations in EthR were only rarely reported (Brossier et al., 2011). EthR mutations triggering 
an increased resistance would require protein modifications that tighten the binding of EthR to 
its operator site to increase promoter repression and consequently prevent ethA expression. The 
appearance of such EthR modifications is rather unlikely and may explain the low prevalence 
of EthR mutations. 
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The goal of this thesis was to study the potential of adjuvant drug therapy to overcome antibiotic 
resistances in multidrug resistant pathogens. For this we followed two main projects that were 
focused on the A. baumannii and M. tuberculosis pathogens. 
 
The overall goal of the first project is the identification of suitable therapeutic targets to 
overcome antibiotic resistance in A. baumannii. 
To achieve this goal, I have followed several specific aims: 
- generate a genome-editing method that can be applied to laboratory and clinical 
A. baumannii strains, independently of their resistance profile 
- apply the genome editing method to characterize potential drug targets in 
A. baumannii clinical strains. 
 
The overall goal of the second project is the development of an adjuvant drug to boost the 
ethionamide bioactivation pathway in M. tuberculosis. This project is part of a collaboration in 
between BioVersys and researchers from the University of Lille (France). During the project, 
we discovered an alternative ethionamide bioactivation pathway called EthA2-EthR2, which is 
analogue to the previously known EthA-EthR bioactivation pathway. My contribution in this 
project was to assist the development of EthR2 inhibitor compounds that are active on the novel 
bioactivation pathway to boost ethionamide efficacy against M. tuberculosis. 
To achieve this goal, I have followed several specific aims: 
- generate a synthetic mammalian gene circuit to sense EthR2-DNA interactions 
- characterize the synthetic gene circuit 
- apply this bioassay to evaluate the ability of compounds to inhibit EthR2-DNA 
interactions. 
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Infections with the Gram-negative coccobacillus Acinetobacter baumannii are a major threat in hospital settings. The progress-
ing emergence of multidrug-resistant clinical strains significantly reduces the treatment options for clinicians to fight A. bau-
mannii infections. The current lack of robust methods to genetically manipulate drug-resistant A. baumannii isolates impedes
research on resistance and virulence mechanisms in clinically relevant strains. In this study, we developed a highly efficient and
versatile genome-editing platform enabling the markerless modification of the genome of A. baumannii clinical and laboratory
strains, regardless of their resistance profiles. We applied this method for the deletion of AdeR, a transcription factor that regu-
lates the expression of the AdeABC efflux pump in tigecycline-resistant A. baumannii, to evaluate its function as a putative drug
target. Loss of adeR reduced theMIC90 of tigecycline from 25g/ml in the parental strains to 3.1g/ml in theadeRmutants,
indicating its importance in the drug resistance phenotype. However, 60% of the clinical isolates remained nonsusceptible to
tigecycline after adeR deletion. Evolution of artificial tigecycline resistance in two strains followed by whole-genome sequencing
revealed loss-of-functionmutations in trm, suggesting its role in an alternative AdeABC-independent tigecycline resistance
mechanism. This finding was strengthened by the confirmation of trm disruption in the majority of the tigecycline-resistant clin-
ical isolates. This study highlights the development and application of a powerful genome-editing platform for A. baumannii
enabling future research on drug resistance and virulence pathways in clinically relevant strains.
One of the greatest global health problems results from thelimited treatment options to fight bacterial infections caused
by multidrug-resistant (MDR) organisms. The group of ESKAPE
organisms that is comprised of Enterobacter spp., Staphylococcus
aureus/epidermidis, Klebsiella pneumonia, Acinetobacter bauman-
nii, Pseudomonas aeruginosa, and Enterococcus faecalis/faecium is
considered to cause the vast majority of, often untreatable, noso-
comial infections (1). Among these ESKAPE pathogens A. bau-
mannii is most difficult to treat due to its multiple intrinsic and
acquired resistance mechanisms that resulted in the development
of MDR, extensively drug resistant (XDR), or even pan-drug-re-
sistant (PDR) phenotypes (2–5).
Bacteria have evolved multiple ways to evade antibiotic-medi-
ated cell death, such as (i) enzymatic modification/cleavage of
the antibiotic (e.g., beta-lactams), (ii) modification/protection
of the antibiotic target (e.g., fluoroquinolones), or (iii) reduction
of the intracellular concentration by antibiotic efflux or reduced
influx (e.g., tetracyclines) (6). The expression of such defense
mechanisms may require an extensive metabolic investment, of-
ten leading to a reduced fitness of these resistant bacteria in the
absence of the external selection pressure (7). To overcome these
ecological drawbacks, bacteria have developed diverse transcrip-
tional regulation mechanisms that ensure specific expression of
the resistance genes only in the presence of poisoning antibiotics
(8). The need for precise regulation of resistance gene cluster ex-
pression makes transcriptional regulators promising drug targets
as part of a strategy to overcome antibiotic resistances. Small mol-
ecules that specifically interfere with the transcriptional regulator
function may switch off the resistance mechanism. The combina-
tion of such inhibitors with a potent antibiotic as an adjuvant drug
may provide a new tool to fight infections caused by MDR, XDR,
or even PDR pathogens by restoring the efficacy of an approved
antibiotic (9, 10).
In clinical settings the use of different and/or combinations of
antibiotics to treat hazardous infections caused by the Gram-neg-
ative pathogenA. baumannii leads to a tremendous selection pres-
sure toward the development of multidrug-resistant strains. Un-
fortunately, we currently have only limited understanding of the
innate and acquired antibiotic resistance mechanisms of A. bau-
mannii clinical isolates. This lack of knowledge is mainly based on
the unavailability of robustmethods that allow the geneticmanip-
ulation of MDR, XDR, and PDR patient-derived strains (11). In
most studies investigating antibiotic resistance mechanisms in A.
baumannii, laboratory strains were used, such as ATCC-19606
and ATCC-17978, which do not represent the problematic clonal
lineages that are currently present in hospitals (12, 13).
In this study, we developed a novel method allowing the short-
term construction of markerless gene knockouts in A. baumannii
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clinical isolates, regardless of their resistance profiles. We applied
this powerful tool in 10 diverse A. baumannii strains that were
resistant to multiple antibiotics to evaluate the transcriptional
regulator AdeR as a potential drug target to rejuvenate the ac-
tivity of tigecycline, a drug of last resort for treatment of XDR A.
baumannii infections (14). We demonstrated that AdeR-regu-
lated AdeABC-mediated drug efflux is not the exclusive tigecy-
cline resistance mechanism in XDR A. baumannii clinical strains,
disqualifying AdeR as a direct drug target.
MATERIALS AND METHODS
Bacterial strains, MICs, MLST, and oligonucleotides. Ten XDR A. bau-
mannii clinical isolates from the BioVersys proprietary strain collection
were used in this study. As a control the tigecycline-susceptible A. bau-
mannii ATCC-17978 strain from the American Type Culture Collection
(ATCC) was used. Multilocus sequence type (MLST) analysis was per-
formed according to the Pasteur scheme by using specific primers (source:
http://pubmlst.org/abaumannii/) (12). MICs were determined by themi-
crodilution method in cation-adjusted Mueller-Hinton broth (CA-
MHB) according to CLSI guidelines (15). Bacteria were grown using
Luria-Bertani (LB) broth or agar at 37°C unless otherwise stated. All oli-
gonucleotides used in this study are listed in Table S1 in the supplemental
material and were synthesized at Microsynth AG (Balgach, Switzerland).
Cloning of the gene knockout vector backbone pVT77 suitable for
genetic manipulation of drug-resistant A. baumannii strains. The vec-
tor pSEVA238 (Standard European Vector Assembly platform [http:
//seva.cnb.csic.es/]) was used as the starting backbone for cloning of the
pVT77 knockout plasmid (16). First, the pUC19 origin of replication
(ColE1) was PCR amplified from the pUC19 plasmid using the primers
oVT01/oVT02 and cloned into the AscI and FseI restriction sites of
pSEVA238, creating plasmid pVT52. A synthetic cassette containing the
thiopurine S-methyltransferase (tpm) gene of Acinetobacter baylyi (locus
tag ACIAD2922) driven by the Burkholderia cenocepacia rpsL PCS12
promoter was cloned with EcoRI and PacI into pVT52 to allow anti-
biotic-independent selection for genomic plasmid integration by so-
dium tellurite (pVT59). For counterselection with 3=-azido-3=-deoxythy-
midine (AZT), the thymidine kinase (tdk) gene was PCR amplified from
Escherichia coli DH5 genomic DNA using primers oVT113/oVT114
flanked with an upstream ribosome binding site (RBS) and cloned into
pSEVA234, creating plasmid pVT66. On this plasmid tdk is placed under
the repression of LacI. The lacI-tdk cassette was excised from pVT66 with
PacI and AscI restriction enzymes and subsequently cloned into pVT59,
resulting in plasmid pVT67. Further modifications were done to maxi-
mize the cloning possibilities in the multiple cloning site (MCS). The
EcoRI restriction site present in the lacI-tdk cassette was removed by PCR
mutagenesis using primers oVT141/oVT142. The present MCS was also
replaced with a more complete MCS, including StuI, XhoI, EcoRI, SacI,
KpnI, SmaI, BamHI, XbaI, PstI, and HindIII restriction sites, by cloning
annealed oligonucleotides oVT149 and oVT150 into EcoRI and HindIII
restriction sites of pVT67. The resulting plasmid was named pVT77, and
it was used as a backbone for the cloning of flanking regions to knock out
any specific targets in A. baumannii clinical isolates (Fig. 1A).
Construction of adeR and trm gene deletions in A. baumannii iso-
lates. Scarless deletions of the adeR and trm genes were done in A. bau-
mannii using a two-step allelic exchange method adapted from Amin and
colleagues (Fig. 1B) (17). DNA fragments corresponding to 700-bp up-
and downstream genomic regions of the genes to be deleted were ampli-
fied by PCR using primers oVT154/oVT106 and oVT107/oVT155 for
adeR and oVT412/oVT413 and oVT414/oVT415 for trm, respectively.
The up- and downstream fragments of each gene were ligated and intro-
duced into pVT77 previously digested with XhoI/XbaI and EcoRI/XbaI
for adeR and trm, respectively, using Gibson assembly. The resulting
knockout plasmids were transformed in the E. coli conjugative strain
MFDpir, which is auxotrophic for diaminopimelic acid (DAP) (18). The
transfer of the plasmid in A. baumannii isolates was achieved by conjuga-
tion, as previously described (17). Briefly, 0.2-ml overnight cultures from
the donor (MFDpir cells containing the knockout plasmid) and receiver
(A. baumannii isolate) strains were mixed and washed twice with 1 ml of
LB broth to remove residual antibiotics. The cells were resuspended in 50
l of medium and transferred onto a 0.45-m-pore-size nitrocellulose
filter placed on LB agar containing 300MDAP. After overnight incuba-
tion at 37°C for conjugative plasmid transfer, the cells were scraped off the
filter and resuspended in 0.4 ml of 0.85% (wt/vol) NaCl, and 0.1-ml ali-
quots were plated on LB agar plates containing 100 g/ml sodium tellu-
rite. After overnight selection at 37°C, clones were screened for genomic
plasmid integration by PCR using primers oVT93/oVT08 and oVT423/
oVT8 for adeR and trm, respectively. Clones containing up- and down-
stream plasmid integrations were used to inoculate 2 ml of fresh LB broth
containing 1 mM isopropyl--D-1-thiogalactopyranoside (IPTG) and
cultured for 3 h at 37°C to express the heterologous thymidine kinase.
Culture aliquots (0.1ml) of a 1:10 dilution series (100 to 102) were plated
on LB agar plates containing 200 g/ml AZT and incubated overnight at
37°C for plasmid removal from the genome. Clones were screened for
gene deletion and plasmid removal by PCR using primers oVT93/oVT94
and oVT423/oVT424 for adeR and trm, respectively. The genomic gene
deletions were finally confirmed by DNA sequencing (Microsynth AG,
Balgach, Switzerland).
Restoration of a functional trm gene by chromosomal single nucle-
otide knock-in in A. baumannii isolates. For allelic replacement of the
mutated trm, a 1.4-kbDNA fragment including thewild-type trm (lacking
the A240 deletion) was PCR amplified from isolate BV186 using primers
oVT416/oVT417. This fragment was cloned into pVT77 previously di-
gested with KpnI/XbaI using Gibson assembly. The two-step allelic ex-
changemethod described abovewas used to restorewild-type trm, and the
successful gene replacement was confirmed by sequencing using primers
oVT312/oVT161.
qRT-PCR. The expression of the efflux pump operon adeABC was
evaluated by quantifying adeB expression using adeB-qRT-F/adeB-
qRT-R primers. A. baumannii isolates were grown in LB broth at 37°C to
mid-log phase (optical density at 600 nm [OD600] of 0.5), and total RNA
was extracted using a PureLink RNA minikit (Ambion) according to the
manufacturer’s recommendations. Residual DNA contaminations were
removed using a Turbo DNA-free kit (Ambion). Quantitative reverse
transcription-PCR (qRT-PCR) was performed using a GoTaq 1-Step
RT-qPCR System kit (Promega) on a StepOne Real-Time PCR Light-
Cycler (Applied Biosystems). Extracted RNA (25 ng) was mixed with
10 l of GoTaq MasterMix, 3 l of 8 M primers, 0.4 l of GoScript
RT mix, and 0.3 l of carboxy-X-rhodamine (CXR) standard dye in a
total volume of 20 l. As a housekeeping gene, the RNA polymerase
sigma factor D (rpoD) was quantified with primers rpoD-qRT-F/
rpoD-qRT-R, and adeB expression was normalized to that of rpoD
using the comparative CT (where CT is threshold cycle) method. A
detailed description of the DNA probes used for RNA detection is
given in Table S1 in the supplemental material.
Genotyping of adeR, adeS, and trm in clinical isolates. A genomic
sequence including adeR and adeS was PCR amplified from all A. bau-
mannii isolates using primers oVT05 and oVT134 (except for ATCC-
17978, for which the oVT151 primer was used instead of oVT134). A
genomic sequence including trm was PCR amplified from all A. bauman-
nii isolates using primers oVT160 and oVT161. The PCR products were
subsequently sent for sequencing (Microsynth AG, Balgach, Switzerland).
In vitro evolution of tigecycline resistance. A. baumannii ATCC-
17978 and its adeRmutant (ATCC-17978adeR) were subjected to serial
passages to develop tigecycline resistance in vitro (see Fig. S1 in the sup-
plementalmaterial). In brief, LB broth liquid cultures were passaged every
48 h starting with a tigecycline concentration of 0.2 g/ml and incubated
at 37°C. For passaging, the cultures were diluted 1/100 and exposed to
double the tigecycline concentration of the preceding culture until a con-
centration of 6.4 g/ml tigecycline was reached. The artificially evolved
tigecycline-resistant strains derived from strain A. baumannii ATCC-
Trebosc et al.
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17978 and its adeR mutant were designated ATCC-17978(TGC) and
ATCC-17978adeR(TGC), respectively.
Whole-genome sequencing. Genomic DNA (gDNA) of ATCC-
17978(TGC), ATCC-17978adeR(TGC), and their parental strains was ex-
tracted using a GeneJET genomic DNA purification kit (Thermo Scien-
tific) according to the manufacturer’s recommendations. The four gDNA
samples were multiplex sequenced using a Illumina MiSeq system (Illu-
mina, Inc.) using a paired-end 250-bp protocol at the Quantitative
Genomics Facility (Department of Biosystems Science and Engineering,
ETH Zurich, Basel, Switzerland). Four to eight million high-quality reads
per sample were generated and mapped against the reference genome of
A. baumannii ATCC-17978 (GenBank accession number CP000521.1)
using Bowtie2, achieving an average coverage above100 (19). Small nucle-
otide variations were spotted using SAMtools (20). Recombination events
were screened with a series of in-house perl scripts based on (i) coverage
fluctuations, (ii) the distribution of start/end positions ofmapped reads, and
(iii) reads that significantly mapped to at least two noncontiguous regions of
the reference chromosome (i.e., regions including the newly formed recom-
bination boundaries). In addition, de novo assembly of reads with poormap-
ping scorevalueswasperformedwithSOAPdenovo2and identified insertion
sequences (IS) were aligned with the ISFinder insertion sequence database
(https://www-is.biotoul.fr/) (21, 22).
Accession number(s). The sequence of the pVT77 cloning vector has
been deposited in the GenBank under accession number KX397287. Se-
quences of the adeR and adeS genes for the following isolates were deposited
in GenBank under the indicated accession numbers: BV26 (KX819204),
FIG1 Schematic representation of the knockout platformdeveloped for targeted gene deletion in XDRA. baumannii. (A) Representation of themodular pVT77
cloning vector. Important features of the vector platform are shown: (i) a thiopurine S-methyltransferase (tpm) for antibiotic-free selection of clones after
plasmid integration and a kanamycin resistance cassette (neo) for selection in E. coli (in red); (ii) a functional counterselection cassette (lacIq-Ptrc-lacO-tdk;
shown in blue) for genomic plasmid removal in the presence of IPTG and AZT; (iii) an origin of transfer (oriT; in green) for conjugative plasmid transfer from E.
coli to A. baumannii; (iv) ColE1 ori for efficient plasmid replication in E. coli (please note that this origin of replication is not active in A. baumannii, resulting in a
suicide vector for this pathogen) and the transcriptional terminator T0 (in gray); and (v) a multiple cloning site (MCS; black) allowing the integration of the up- and
downstream regions of the target gene. The plasmidmapwas generated with CLCMainWorkbench, version 6.9.1. (B) Representation of the two-step allelic exchange
method for targetedgenedeletionusingderivatives of theknockoutplasmidpVT77.Theknockoutplasmid is site-specifically integratednext to a target geneby an initial
homologous recombination event, and clones are selected with potassium tellurite. Afterwards, a second recombination event for the subsequent plasmid removal is
producedby the inductionof the counterselection cassette,which triggers cytotoxicity in thepresenceofAZT, leading to 50%knockoutmutants orwild-type revertants.
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BV94 (KX819205), BV173 (KX819206), BV175 (KX819207), BV185
(KX819208), BV186 (KX819209), BV187 (KX819210), BV189 (KX819211),
BV190 (KX819212), and BV191 (KX819213). Sequences of the trm gene
were deposited inGenBank under the indicated accession numbers: BV26
(KX819214), BV94 (KX819215), BV173 (KX819216), BV175 (KX8192
17), BV185 (KX819218), BV186 (KX819219), BV187 (KX819220), BV189
(KX819221), BV190 (KX819222), and BV191 (KX819223). The reads of
the whole-genome sequencing have been deposited in the GenBank
Sequence Read Archive (SRA) as follows: ATCC-17978 (GenBank acces-
sion number SRR4176247), ATCC-17978adeR (SRR4176248), ATCC-
17978(TGC) (SRR4176249), and ATCC-17978adeR(TGC) (SRR4176250).
RESULTS
Knockout technology for genetic manipulation of A. bauman-
nii clinical isolates regardless of their antibiotic resistance pro-
files.A. baumannii is among the ESKAPEpathogensmost difficult
to treat because it often combines a multitude of intrinsic and
acquired drug resistance mechanisms (2). In order to investigate
the function of putative drug targets in clinically problematic
drug-resistant isolates of A. baumannii, we had to develop a novel
technology platform enabling the genome modification of these
MDR isolates because traditional methods using antibiotic selec-
tion cassettes cannot be applied in these pathogens.We screened a
collection of clinically relevantA. baumannii isolates for their sus-
ceptibilities to various chemical agents and demonstrated that all
strains were sensitive to sodium tellurite (MIC 8g/ml) (Table
1). Our results suggested that a tellurite resistance cassette might
be a powerful tool to select for genetic manipulation of MDR,
XDR, and PDR A. baumannii isolates independently of their an-
tibiotic resistance profiles. A two-step homologous recombina-
tion approach was developed to target clinical isolates (Fig. 1B).
Traditional antibiotic selection cassettes were replaced by the
Acinetobacter baylyi-derived tellurite resistance marker gene tpm,
encoding a thiopurine S-methyltransferase, to allow selection for
chromosomal plasmid integration with sodium tellurite (23). In
bacteria, expression of Tpm enzymatically detoxifies tellurite by a
reduction and methylation of tellurite to produce volatile di-
methyl telluride (24). The sacB gene, widely used as a counterse-
lection cassette to initiate a second recombination event in differ-
ent bacteria, was shown not to be capable of efficiently removing
the integrated plasmid from the genome of A. baumannii and E.
coli (17, 25). During our design process we also noticed that SacB
expression is slightly toxic even in the absence of sucrose, leading
to the selection of inactivating mutations in the sacB gene. As an
alternative, we PCR amplified the E. coli-derived thymidine kinase
gene (tdk) and cloned it under the control of an isopropyl--D-
thiogalactopyranoside (IPTG)-inducible promoter. The expres-
sion of thymidine kinase in the presence of the reverse transcrip-
tase small-molecule inhibitor 3=-azido-3=-deoxythymidine (AZT)
results in the incorporation of a chain-terminating thymidine an-
alogue duringDNA replication, which finally leads to cell death or
removal of the tdk-expressing plasmid from the genome (26). This
powerful setup selected for the second recombination event with
an efficiency of 95% in A. baumannii clinical isolates. The ap-
plication of our gene knockout platform enabled us to efficiently
delete different target genes in A. baumannii strains of diverse
origins that were antibiotic susceptible or that accumulated mul-
tiple antibiotic resistance mechanisms.
Deletion of genomic adeR reveals an AdeABC-independent
tigecycline resistancemechanism.Tigecycline is considered to be
a last-resort treatment regimen for infections with MDR/XDR A.
baumannii (14). Resistance to tigecycline is mediated by the
AdeABC efflux pump,which is controlled by theAdeRS two-com-
ponent system (TCS) (27–31). This TCS was recently suggested as
a putative drug target for small-molecule intervention to interfere
with different antibiotic resistance pathways inA. baumannii (10).
In order to evaluate the importance of the transcriptional regula-
torAdeR inmediating tigecycline resistance in clinicalA. bauman-
nii isolates, we customized our gene knockout platform (Fig. 1A)
to produce genomic adeR deletions.We selected a diverse panel of
10 tigecycline-resistant clinical A. baumannii isolates using the
following parameters: (i) their recent isolation from diverse geo-
graphic locations, (ii) their antibiotic resistance profile to first-,
second-, and last-line drugs (carbapenems, colistin, and tigecy-
cline, respectively), and (iii) their clonal lineage as determined by
usingMLST according to the Pasteur scheme (12). All strains were
isolated between 2011 and 2013 (except for BV26, which was iso-
lated in 1979) and classified as XDR according to the definition
TABLE 1 Characterization of the A. baumannii clinical isolate panel used in this study
Strain
designation
Strain isolation
MLST
MIC (g/ml)a
Location Date GEN MEM CIP TIM* CTX SXT* SAM* CST TET TEL
ATCC-17978 France 1951 77 2 0.5 1 16/2 16 >8/152 4/2 0.5 2 4
BV26 Switzerland 1979 1 >128 1 4 >256/2 16 >8/152 64/32 0.5 128 4
BV94 USA 2011 2 >128 32 256 >256/2 >256 >8/152 16/8 64 32 8
BV173 Greece 2012 2 >128 >64 128 >256/2 >256 >8/152 128/64 32 >256 1
BV175 Turkey 2012 2 128 32 256 >256/2 256 >8/152 32/16 >256 256 0.5
BV185 Mexico 2013 2 >128 >64 128 >256/2 >256 >8/152 64/32 >256 256 1
BV186 USA 2013 2 16 64 256 >256/2 >256 >8/152 32/16 16 8 4
BV187 USA 2013 2 32 64 256 >256/2 >256 >8/152 16/8 16 8 4
BV189 Spain 2013 2 128 32 128 >256/2 256 >8/152 32/16 64 16 8
BV190 Greece 2012 1 >128 64 64 >256/2 >256 >8/152 64/32 256 256 4
BV191 China 2013 2 >128 >64 256 >256/2 >256 >8/152 128/64 >256 >256 2
ATCC-25922b 1 	0.06 	0.25 8/2 	0.25 0.125/2.34 4/2 1 2 4
a MLST, multilocus sequence type; CIP, ciprofloxacin; CST, colistin; CTX, cefotaxime; GEN, gentamicin; MEM, meropenem; SAM, ampicillin-sulbactam; SXT,
trimethoprim-sulfamethoxazole; TIM, ticarcillin-clavulanate; TEL, tellurite (nonantibiotic compound); TET, tetracycline. Classification of antibiotic resistance was done according
to breakpoints published by the Clinical and Laboratory Standards Institute and is indicated as follows: susceptible, underlining; intermediate, italics; resistant, boldface (46). *,
values for the components are separated by a slash.
b Quality control.
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given by Magiorakos and colleagues (32). MLST analysis revealed
that eight of the clinical isolates belonged to clonal cluster 2 (CC2),
and two belonged to clonal cluster 1 (CC1), clusters that represent
the most prominent worldwide epidemic clonal lineages (12, 13)
(Table 1). Conjugation from E. coli was used to introduce the
knockout plasmid into A. baumannii isolates. The plasmid conju-
gation/integration efficiency was measured as the number of
transconjugants per receiver cell and was similar among different
clinical isolates (1.8  107 
 0.2  107 transconjugants/cell;
n  3) and one order of magnitude lower than for the reference
strain ATCC-17978 (3.2  106 transconjugants/cell). We suc-
cessfully created scarless adeR knockout (adeR)mutants of these
10 XDR A. baumannii strains and also deleted adeR in the refer-
ence strain ATCC-17978. We characterized the tigecycline resis-
tance profile of theadeRmutants and their parental strains using
the microdilution method. Deletion of adeR in 10 XDR A. bau-
mannii strains reduced the MIC90 of tigecycline from 25 g/ml to
3.1 g/ml, demonstrating a significant shift of adeR mutants
toward tigecycline susceptibility (Table 2). Our data indicate that
AdeR is important for A. baumannii to develop tigecycline resis-
tance. However, in clinical practice the tigecycline susceptibility
breakpoint for A. baumannii infections is 1 g/ml (33). Our
results demonstrated that 60% of the tested clinical isolates re-
mained tigecycline nonsusceptible after adeR deletion and suggest
that AdeR-regulated AdeABC-mediated tigecycline resistance is
not the exclusive resistance mechanism rendering tigecycline in-
active in these strains. We propose the existence of at least one
AdeR-unrelated resistance mechanism that may be developed in
A. baumannii clinical isolates to render tigecycline ineffective.
AdeR was previously shown to activate the expression of the
RND (resistance-nodulation-cell division)-type AdeABC efflux
pump and most likely controls the extrusion of tigecycline from
the cells (31). However, the presence of an alternative activating
mechanism for AdeABCmediated by the TCS BaeSR was recently
suggested (34). In order to determine if overexpression of Ad-
eABC was mediating tigecycline resistance despite the deletion of
adeR, we quantified the expression level of adeB, which is themain
component of the RND efflux pump. By using quantitative real-
time PCR, we demonstrated general overexpression of adeB in all
tested tigecycline-resistant clinical isolates (Fig. 2). The overex-
pression of the adeABC efflux pump correlated with elevated tige-
cycline MICs, as demonstrated by 990-fold and 160-fold overex-
pression levels of adeB in strains BV94 and BV191with the highest
tigecycline resistance levels, respectively. In contrast, all adeR
mutants lost the ability to express adeB, suggesting that AdeR is
the main transcriptional activator of the AdeABC efflux pump.
These data further indicate that an AdeR-unrelated tigecycline
resistancemechanism inA. baumannii clinical isolates is not based
on deregulated expression of the AdeABC efflux pump.
To evaluate if the AdeABC efflux pump overexpression in tige-
cycline-resistant clinical isolates was triggered bymutations in the
AdeRS TCS as previously described, we analyzed the genomic se-
quences of adeR and adeS (35). To distinguish between mutations
involved in adeABC overexpression and those coming from clonal
lineage evolution,weused as reference sequences the tigecycline-sen-
sitive A. baumannii strains AYE and ACICU, which are representa-
tives of clonal clusters CC1 and CC2, respectively (12). The only
strain that containedmutations in the transcriptional regulatorAdeR
was BV173 (Table 2). One of the identified amino acid substitutions
(D21V) in this strain was previously described to mediate adeABC
overexpression (36).Mutations in the sensor kinaseAdeSweremuch
more abundant, and different amino acid substitutions were identi-
fied in four clinical isolates (Table 2). Interestingly, five tigecycline-
resistant clinical isolates hadwild-typeAdeRS sequenceswithout any
amino acid substitutions. For these strains, we further analyzed the
sequence of the intergenic regulatory region between adeRS and ad-
eABC that encodes the AdeR DNA-binding site. However, we could
not identify any mutations that could explain the overexpression of
adeABC. These strains, with the exception of BV175, were not resen-
sitized to tigecycline by the deletion of adeR (Table 2).
Taken together, these results indicate that the loss of adeR in
XDRA. baumannii clinical isolates abolished the expressionof adeB,
leading to increased tigecycline sensitivity in 8 out of 10 adeRmu-
tants.However, 60%of the clinical isolates remained tigecyclinenon-
susceptible, with anMIC above the clinical susceptibility breakpoint
of1 g/ml (33, 37). The requirement for AdeR to express the Ad-
eABC efflux pump and the absence of mutation in four strains that
were not resensitized to tigecycline indicate the presence of an alter-
nativeAdeR-AdeABC-independent tigecycline resistance pathway in
these strains and disqualify AdeR as an adjuvant drug target.
Insights into alternative tigecycline resistance mechanisms.
To investigate putative AdeRS-AdeABC-unrelated tigecycline re-
sistancemechanisms inA. baumannii, we developed artificial tige-
TABLE 2 Tigecycline resistance profile and list of identified mutations
in the clinical A. baumannii isolate panel and the corresponding adeR
strains
Strain
designation
Tigecycline MIC (g/ml)
AdeRS amino acid
substitution(s)
Deletion in
trmWild type adeR strain
ATCC-17978 0.4 0.4 Reference
BV26 6.3 0.4 AdeS E201K E237K
BV94 25 3.1 AdeS F170S G1065
BV173 6.3 0.8 AdeR D21V D26N A240
BV175 3.1 0.8 A240
BV185 6.3 3.1 A240
BV186 3.1 3.1 G1065
BV187 3.1 3.1 G1065
BV189 6.3 3.1 A240
BV190 6.3 0.8 AdeS Q339K T1050
BV191 25 1.6 AdeS G79S A240
FIG 2 Quantification of adeB expression levels in tigecycline-resistantA. bau-
mannii clinical isolates and theiradeRmutants. The adeB expression levels of
the individual strains were determined by quantitative real-time PCR and
normalized to the adeB expression of the reference strain ATCC-17978.
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cycline-resistant strains by subjecting A. baumannii ATCC-17978
and itsadeRmutant (ATCC-17978adeR) to liquid serial passage
in the presence of increasing tigecycline concentrations (see Fig.
S1 in the supplemental material). After 12 days (6 passages) we
obtained wild-type and adeR-derived strains able to grow at
6.4 g/ml tigecycline and designated them ATCC-17978(TGC)
and ATCC-17978adeR(TGC), respectively. We analyzed the
susceptibilities of these artificially evolved strains to various
antibiotic classes. As expected, both strains were resistant to
high tigecycline concentrations (see Table S2 in the supplemen-
tal material). In parallel with the tigecycline resistance, MICs of
tetracycline increased to 32 g/ml and 64 g/ml, and MICs of
ciprofloxacin increased to 2 g/ml and 4 g/ml for ATCC-
17978(TGC) and ATCC-17978adeR(TGC), respectively. In con-
trast, MICs to meropenem remained unchanged in both evolved
strains. Both strains also showed a slight shift toward gentamicin
susceptibility. To investigate if an alternative regulatory mecha-
nism induced the adeABC expression, we analyzed the expression
of adeB but could not detect an altered adeB expression pattern in
the parental and evolved strains. This result was consistent with
the presence of wild-type adeS and adeRS sequences in the evolved
knockout and parental strains, respectively. In summary, our re-
sults suggest the presence of an AdeRS-unrelated tigecycline resis-
tance mechanism leading to an increased resistance pattern to
diverse antibiotics.
To unravel this new resistance mechanism, we sequenced the
genome of the artificially evolved tigecycline-resistant strains
ATCC-17978(TGC) and ATCC-17978adeR(TGC) and compared
the sequences with those of the parental strains. We identified the
trm gene (A1S_2858) coding for a methyltransferase with un-
known function as the only gene that was disrupted in both inde-
pendently evolved strains (see Table S3 in the supplemental
material). In ATCC-17978(TGC), we identified an insertion se-
quence (IS) of approximately 1 kb integrated into the trm gene at
nucleotide position 747 (total trm length, 1,212 nucleotides [nt]).
The IS shared 97% sequence identity with ISAba12, a transposon
that is present in two copies in the genome of ATCC-17978 (22).
In ATCC-17978adeR(TGC), an adenine deletion at trm nucleo-
tide 311 caused a frameshift leading to a premature stop codon. In
conclusion, both strains expressed a truncated Trm variant that is
most likely nonfunctional. We also identified several other mu-
tated genes in the two independently evolved strains. However,
these genes were mutated in one or the other strain and therefore
cannot represent a general alternative tigecycline resistancemech-
anism (see Table S3). To evaluate the relevance of trm disruption
in clinical strains, we sequenced the trm gene in our tigecycline-
resistant A. baumannii strain panel. Except for BV26, all clinical
isolates carried a nucleotide deletion in trm leading to an early stop
codon and therefore a nonfunctional methyltransferase (Table 2).
These data suggest that loss of Trmmay potentially confer tigecy-
cline resistance by using a pathway independent of the efflux
pump AdeABC. To our surprise, three adeR mutant strains
(BV173, BV175, and BV190) contained a disrupted Trm variant
but remained susceptible to tigecycline.
To characterize the role of trm disruption in tigecycline resis-
tance we (i) deleted trm from the genome of the reference strain
ATCC-17978, and (ii) we restored the functionality of chromo-
somal trm by reintroducing the deleted nucleotide A240 in clinical
isolates. Loss of Trm in ATCC-17978marginally increased tigecy-
cline resistance whereas trm restoration in clinical isolates slightly
decreased tigecycline resistance (see Table S4 in the supplemental
material). Although these MIC shifts are considered in the stan-
dard deviation of themethod, the consistency of the results among
the strains suggests that loss of Trm plays a general role in tigecy-
cline resistance in A. baumannii.
DISCUSSION
In contrast to the use of conventional antibiotics that target
conserved essential mechanisms, the adjuvant approach aims
to modulate nonessential mechanisms, which may vary signif-
icantly within the same species. Consequently, the identification
of new drug targets for adjuvant therapy requires extensive vali-
dation in diverse clinical strains to ensure target relevance. Unfor-
tunately, methods to manipulate these drug-resistant strains are
lacking, rendering drug target validation difficult. Recently, a
method based on the recombineering technology has been devel-
oped to produce gene deletionmutants inA. baumannii (11). This
method requires the plasmid-encoded expression of a recombi-
nase to enhance the efficiency of homologous recombination and
electroporation to incorporate foreign DNA into the cells (11).
Unfortunately, clone selection is performed with two different
antibiotic resistance cassettes, and electroporation may be very
inefficient in clinical isolates, which prevents an adaptation of this
method for the manipulation of drug-resistant strains. Moreover,
the recombinase expression vector has to be cured from the cells to
allow the subsequent introduction of another vector that ex-
presses the FLP recombinase, which once again has to be cured to
finally produce markerless mutants (11). Overall, this recom-
bineering-based method is a time-consuming procedure and is
incompatible with multidrug-resistant isolates.
Amin and colleagues previously developed a two-step method
to construct scarless knockout mutants in MDR A. baumannii by
implementation of a tellurite resistance operon into their knock-
out plasmids that allowed targeting A. baumannii isolates regard-
less of their antibiotic resistance profiles (17). The applied operon
used as selection marker consisted of three consecutive genes
(kilA, telA, and telB) carried by a 3-kb DNA sequence. Its expres-
sion requires an enormous metabolic investment and confers re-
sistance to 30g/ml tellurite (17). A sacB cassette was further used
to select for the second recombination event and plasmid removal
from the genome. Several sucrose passages were required for suc-
cessful plasmid removal, indicating the inefficiency of this coun-
terselection cassette (17). SacB is also prone to accumulate inacti-
vation mutations due to its slight cytotoxicity even in the absence
of sucrose, making the use of this counterselection marker disad-
vantageous in A. baumannii (25).
Here, we report the design of a highly efficient knockout plat-
form for A. baumannii isolates, regardless of their antibiotic resis-
tance profiles. The knockout platform takes advantage of an effi-
cient thiopurine S-methyltransferase encoded by a single tpm gene
of Acinetobacter baylyi (Fig. 1A). This resistance marker confers
resistance to 100 g/ml tellurite and requires a low fitness in-
vestment from the cells. We combined this selection marker with
an inducible variant of an E. coli-derived thymidine kinase (tdk) to
select for the second recombination event, allowing plasmid re-
moval with an efficiency of 95% in A. baumannii isolates in a
one-step counterselection passage on AZT. The developed knock-
out technology enables us to performmarkerless gene deletions in
A. baumannii clinical and laboratory strains in only 3 days, with
the capability for repetitive application of the process to delete
Trebosc et al.
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multiple genes from the same genome. The platform is suitable for
a multitude of genome engineering techniques in drug-resistant
bacteria. Besides producing targeted gene knockouts, we used this
technology platform to do gene disruptions and targeted chromo-
somal insertions (knock-ins) of single nucleotides (point muta-
tion) as well as longer DNA sequences to produce conditional
knockoutmutants inA. baumannii. Moreover, this platform has a
modular architecture and allows the exchange of the individual
genetic building blocks (e.g., origin of replication, selection
marker, or counterselection cassette) by digestion/ligation reac-
tions, enabling the potential for customization to target other
pathogens (Fig. 1A).We successfully employed amodified version
of the knockout platform to produce markerless gene deletions in
MDRP. aeruginosa, highlighting the potential for expansion of the
platform to other pathogenic species (data will be published else-
where).
In a case study we demonstrated the efficient deletion of adeR
from the genome of diverse XDR A. baumannii clinical isolates.
We characterized these isolates with an antibiotic panel that was
chosen to discriminate between non-MDR, MDR, and XDR
strains and found that most of the strains were resistant to all
tested antibiotics (Table 1) (32). Our data suggest that some of the
strains may be even classified as PDR; however, further analyses
are required to finalize this classification.
The analysis of AdeR as a potential adjuvant drug target con-
firmed the importance of AdeR inmediating tigecycline resistance
in A. baumannii. Our data further suggest that there is at least one
AdeR-unrelated mechanism that confers moderate resistance to
tigecycline in A. baumannii clinical isolates (Table 2). The U.S.
Food and Drug Administration (FDA) and the European Com-
mittee on Antimicrobial Susceptibility Testing (EUCAST) do not
provide breakpoints for A. baumannii treatment with tigecycline.
However, in clinical practice the susceptibility breakpoint of 1
g/ml is commonly accepted (33, 37).
Because in the absence of AdeR the expression of adeB was
abolished, this alternative resistance pathway is unrelated to
AdeABC-mediated drug efflux (Fig. 2). It was recently shown that
the TCS BaeSRmay trigger the activation of adeABC expression in
A. baumannii ATCC-17978 (34). Our results indicate that the
BaeSR regulation of adeABC expressionmay occur through AdeR
because the loss of adeR completely abolished adeABC expression
under the tested conditions. This observation suggests a cross talk
between both TCSs by either BaeS-mediated phosphorylation of
AdeR or specific activation of adeR expression by BaeR. Further
experiments are required to clarify a putative dynamic interaction
between AdeRS and BaeSR.
Sequencing of adeRS in our strain panel revealed that five A.
baumannii isolates contained mutations in AdeRS (Table 2). We
found one strain with mutated AdeR, but four strains with alter-
ations in the sequence of AdeS, suggesting that the sensor kinase is
more prone to mutations, leading to an overexpression of
AdeABC. With the exception of the D21V substitution mutation
in AdeR of strain BV173, the identified mutations have not been
previously described (27, 31, 35, 36, 38, 39). To our surprise, the
tested XDR strain panel contained four tigecycline-resistant iso-
lates with wild-type AdeRS that were not resensitized for tigecy-
cline by deletion of adeR (Table 2). This finding highlights the
presence of an alternative AdeABC-independent resistancemech-
anism mediating tigecycline protection in A. baumannii. The
hypothesis of an alternative resistance pathway was further sup-
ported by the successful in vitro development of tigecycline resis-
tance in ATCC-17978adeR.
Whole-genome sequencing of artificially in vitro-evolved
tigecycline-resistant strains identified the trm gene, coding for a
methyltransferase, as the only gene that was disrupted in both
independently evolved strains (see Table S3 in the supplemental
material). Chen and colleagues recently developed artificial tige-
cycline resistance in A. baumannii ATCC-19606 and also found a
mutated trm gene, suggesting an important role of this methyl-
transferase in conferring moderate tigecycline resistance (40).
Methyltransferases are able to catalyze the methylation of ribo-
somal RNAs (rRNAs). The conformational modification of the
rRNAs, which are the molecular targets of tigecycline, may result
in an alteration of the antibiotic target interaction, suggesting that
trm disruption could be a valid tigecycline resistance mechanism
(41).We also sequenced the trm gene of our XDR strain panel and
found in 9 out of 10 clinical isolates a disrupted trm gene (Table 2).
Interestingly, the isolate that harbors a wild-type trm (BV26) was
isolated in 1979, almost 25 years before tigecycline was approved
by the FDA. Our finding suggests that in contrast to AdeABC
efflux pumpoverexpression, which can be selected under pressure
of different antibiotic classes, trm disruption may be a specific
result of tigecycline selection pressure in clinical settings. We
demonstrated that the disruption of trm plays only a moderate
role in tigecycline resistance in clinical isolates, suggesting that loss
of Trm may not be the only trigger for an alternative AdeABC-
independent tigecycline resistance pathway.
Besides trm, we found other genes that were mutated in one of
the two independently evolved strains (see Table S3 in the supple-
mental material) and that were previously linked to tigecycline
resistance in A. baumannii, such as rpsJ (S10) or adeN (42–45).
However, to our knowledge the identifiedmutations in the RNase
E 23S rRNA pseudouridylate synthase and in the promoter of the
MATE family efflux pumpAbeM (see Table S3) were never linked
to tigecycline resistance, and further studies are required to verify
their impact on tigecycline resistance.
Since the development of our gene knockout platform enables
efficient and quick genetic manipulation of A. baumannii clinical
isolates regardless of their resistance profiles, this technology is a
powerful tool to investigate the molecular nature of different
pathways that allow A. baumannii to escape antibiotic-mediated
killing. By using AdeR as an example, our study revealed the ge-
netic variability of different tigecycline-resistant isolates, which
may be a cause of the different selection pressures applied during
patient treatment in clinical units, clearly demonstrating that the
study of one model strain is not sufficient to obtain a global pic-
ture of species-related pathogenesis and antibacterial resistance.
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concentrations. The cells were passaged every 48h into fresh medium containing a duplication in the tigecycline 
concentration. The artificially evolved tigecycline resistant strains derived from strain A. baumannii ATCC-17978 
and its ∆adeR mutant were designated ATCC-17978(TGC) and ATCC-17978ΔadeR(TGC), respectively. The figure 
was produced, in part, by using Servier Medical Art. 
Table S1: Oligonuclotides used in this study. 
Oligo name Sequence (5’-3’) 
oVT01 GGCGCGCCCTGTCAGACCAAGTTTACTC 
oVT02 GGCCGGCCTATCAGCTCACTCAAAGG 
oVT05 ACTGACTTTAGCCGGTGGTG 
oVT08 GTTTTCCCAGTCACGACGC 
oVT93 GCAGCTTGTAGGCGTTCATAC 
oVT94 AACTTGCTCAATACGACGGC 
oVT106 TTTTAATATTATCCCGGGAGAAAATCTGGCTATAGAAAGTG 
oVT107 GCCAGATTTTCTCCCGGGATAATATTAAAAAATAGCTAGGGAATATTTTATG 
oVT113 CCGCTCGAGCCTAGGGAATTCAAAGAGGAGAAAATGGCACAGCTATATTTCTACTATTCCGC 
oVT114 AACTGCAGAAGCTTGGCGCGCCAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTG
TTAATCGTGGCGATGCCTTTC 
oVT134 TTTTTGCGGCCATTGGTGAG 
oVT141 CATTTTCTCCTCTTTGTATTCGCGCGGCCGCG 
oVT142 CGCGGCCGCGCGAATACAAAGAGGAGAAAATG 
oVT149 AATTGAGGCCTCTCGAGGAATTCGAGCTCGGTACCCGGGGATCCTCTAGAGCCTGCAGGAAGC
TTCG 
oVT150 GGCCCGAAGCTTCCTGCAGGCTCTAGAGGATCCCCGGGTACCGAGCTCGAATTCCTCGAGAGG
CCTC 
oVT151 AAAAGAGAGTGAGGGGGCAC 
oVT154 GGAGAATTGAGGCCTCTCGAGTGCACCTTCAGTGACAAAAG 
oVT155 AGCTTCCTGCAGGCTCTAGATTTAAGAACTTTTTCAACTACCG 
oVT160 ACTGCCATAACCACACCAGC 
oVT161 CCCATTCATCTTCGGGCTCA 
oVT312 AAGGAGAGTTGACACAGCTG 
oVT412 AGAATTGAGGCCTCTCGAGGAATTCGCACCTGCACCTAAAAGC 
oVT413 CTGGTCTTGCCCGGGGGAGAAAACCGACACTGATATAC 
oVT414 GGTTTTCTCCCCCGGGCAAGACCAGTTGCCGATC 
oVT415 CCGCAAGCTTCCTGCAGGCTCTAGACGCTGTGCCCGTTATAATG 
oVT416 GAGGAATTCGAGCTCGGTACCTTACAAAAACGGCAAGCC 
oVT417 CCGCAAGCTTCCTGCAGGCTCTAGAAGCAATCATCACGTCCAG 
oVT423 GGCTACTACAGGAGCAGCAG 
oVT424 CTACTTTGATGGCGGCGTTG 
adeB-qRT-F GGATTATGGCGACAGAAGGA 
adeB-qRT-R AATACTGCCGCCAATACCAG 
rpoD-qRT-F GAGTCTAATGGCGGTGGTTC 
rpoD-qRT-R ATTGCTTCATCTGCTGGTTG 
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Table S2: Antibiotic resistance profile of the in vitro evolved tigecycline resistant strains and their parental 
strains. 
MIC (µg/ml) Tigecycline Tetracycline Meropenem Ciprofloxacin Gentamycin 
ATCC-17978 0.4 2 0.5 0.5 2 
ATCC-17978(TGC) 25 32 0.5 2 0.5 
ATCC-17978ΔadeR 0.4 2 0.25 0.25 1 
ATCC-17978ΔadeR(TGC) 6.3 64 0.5 4 0.5 
Table S3: Important mutations identified by whole genome sequencing of in vitro evolved tigecycline resistant 
strains.  
Mutated gene or 
region 
Mutations 
Protein function References ATCC-17978(TGC) ATCC-17978ΔadeR(TGC) 
trm (A1S_2858) IS-17 like transposon 
inserted in the coding 
sequence 
Adenine in position 311 
of trm deleted leading to 
early stop codon 
Methyltransferase 
potentially involved in 
rRNAs methylation 
(1) 
RNase E (A1S_0403) 58 bp deletion in the 
coding sequence 
- Ribonuclease involved in 
rRNAs processing and 
RNA decay 
(2) 
Intergenic region 
between RNase E 
(A1S_0403) and 23S 
rRNA 
pseudouridylate 
synthase (A1S_0404) 
ISAba11 element 
inserted at position 
439,336 in the 
intergenic region 
- RNase E see above. 
23S rRNA pseudouridylate 
synthase involved in 
modification of 23S rRNA 
(3) 
adeN (A1S_1979) - ISAba11 transposon 
inserted in the coding 
sequence 
Transcriptional repressor 
of the adeIJK efflux pump 
(4) 
abeM (A1S_0395) - Cytosine to thymidine 
mutation (position 
429,259) in the promoter 
region of abeM 
MATE family efflux pump (5) 
rpsJ (A1S_3081) - S12F substitution in the 
coding sequence 
30S ribosomal protein S10 
part of tigecycline binding 
site in the ribosome 
(6, 7) 
Table S4: Tigecycline resistance profile of the trm knockout and trm restored strains. 
Tigecycline 
MIC 
(µg/ml) 
trm knockout trm wildtype recovery 
ATCC-17978 BV185 BV186 BV191 
WT ∆trm WT trm+ WT trm+ WT trm+ 
0.4 0.8 3.1 1.6 3.1 1.6 12.5 6.3 
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Abstract of the paper 
Nosocomial infections with Acinetobacter baumannii are a global problem in intensive care 
units causing severe infections with high mortality rates. The rapid emergence of strains 
resistant to the first and second line antibiotics have forced the use of colistin as last resort 
treatment. However, increasing development of colistin resistance in A. baumannii has been 
reported and strategies to recover colistin efficacy are needed. In this study, we evaluated the 
transcriptional regulator PmrA as potential drug target to restore colistin efficacy in 
A. baumannii. Deletion of pmrA in a panel of extensively drug resistant A. baumannii clinical
isolates reduced the MIC80 of colistin from 32 µg/mL in the parental strains to 1 µg/mL in the
ΔpmrA strains, indicating its importance in the drug resistance phenotype. However, 17% of
the clinical isolates remained highly resistant to colistin, indicating that PmrA-mediated
overexpression of the phosphoethanolamine (PetN) transferase PmrC is not the exclusive
colistin resistance mechanism in A. baumannii. A detailed genetic characterization revealed that
colistin resistance in 2 clinical isolates was mediated by genetic integration of the transposon
ISAbaI upstream of the PmrC homolog EptA leading to its overexpression. We found that eptA
was ubiquitously present in clinical strains belonging to the international clone 2, but absent in
the international clone 1, and that ISAbaI integration upstream of eptA was required to mediate
the colistin resistant phenotype. To our surprise, we found three distinct genome-encoded eptA
isoforms in one clinical isolate. Our data highlight the importance of PetN-transferase mediated
colistin resistance in clinical strains and disprove PmrA as a direct drug target for adjuvant
therapies. However, we suggest that direct targeting of the highly homologous PetN-
transferases PmrC/EptA with small molecule inhibitors may have the potential to overcome
colistin resistance in A. baumannii.
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Abstract 
Nosocomial infections with Acinetobacter baumannii are a global problem in intensive care 
units causing severe infections with high mortality rates. The rapid emergence of strains 
resistant to the first and second line antibiotics have forced the use of colistin as last resort 
treatment. However, increasing development of colistin resistance in A. baumannii has been 
reported and strategies to recover colistin efficacy are needed. In this study, we evaluated the 
transcriptional regulator PmrA as potential drug target to restore colistin efficacy in 
A. baumannii. Deletion of pmrA in a panel of extensively drug resistant A. baumannii clinical
isolates reduced the MIC80 of colistin from 32 µg/mL in the parental strains to 1 µg/mL in the
ΔpmrA strains, indicating its importance in the drug resistance phenotype. However, 17% of
the clinical isolates remained highly resistant to colistin, indicating that PmrA-mediated
overexpression of the phosphoethanolamine (PetN) transferase PmrC is not the exclusive
colistin resistance mechanism in A. baumannii. A detailed genetic characterization revealed that
colistin resistance in 2 clinical isolates was mediated by genetic integration of the transposon
ISAbaI upstream of the PmrC homolog EptA leading to its overexpression. We found that eptA
was ubiquitously present in clinical strains belonging to the international clone 2, but absent in
the international clone 1, and that ISAbaI integration upstream of eptA was required to mediate
the colistin resistant phenotype. To our surprise, we found three distinct genome-encoded eptA
isoforms in one clinical isolate. Our data highlight the importance of PetN-transferase mediated
colistin resistance in clinical strains and disprove PmrA as a direct drug target for adjuvant
therapies. However, we suggest that direct targeting of the highly homologous PetN-
transferases PmrC/EptA with small molecule inhibitors may have the potential to overcome
colistin resistance in A. baumannii.
Author summary 
Antibiotic resistance is a major and global threat for our health care system. The discovery of 
antibiotics revolutionized modern medicine and enabled to cure previously deadly bacterial 
infectious diseases. The risk to re-enter a pre-antibiotic era has been mentioned due to the 
emergence of the so-called “superbugs” that do not respond to most of antibiotics available. 
Colistin represents one of our last resort antibiotic that is still active against most of bacterial 
Results-Part A: A. baumannii 
51 
pathogens. However, colistin resistance is increasingly reported worldwide, in particular due to 
the protein MCR-1 present in superbugs, such as E. coli and K. pneumonieae. In this study, we 
showed that colistin resistance in A. baumannii, a top priority superbug causing deadly 
nosocomial infections, is mediated through different avenues that all lead to the same end, 
which resides in the activity of a specific enzyme called PetN transferase. Considering that 
MCR-1 is also a PetN transferase, our findings indicate that PetN transferases might be the 
Achilles’ heel of superbugs to restore colistin efficacy and like this preserve our most potent 
weapon against bacterial infections.  
Introduction 
Antimicrobial resistance is a serious threat to global health systems resulting in the loss of 
treatment options to fight a growing number of bacterial infections (1). Considering the paucity 
of newly developed antibiotics in the last decade, old antibiotics such as polymyxins have been 
re-introduced to treat infections caused by multidrug resistant (MDR) Gram-negative pathogens 
(2–4). Nowadays, the polymyxin antibiotics polymyxin E (colistin) and polymyxin B represent 
the last resort for the treatment of MDR Gram-negative infections, such as infections caused by 
carbapenem resistant Enterobacterieaceae, MDR Pseudomonas aeruginosa and MDR 
Acinetobacter baumannii (5,6). Unfortunately, the increasing use of polymyxins to treat serious 
infections caused by MDR pathogens leads to a spread of resistance to these last line drugs (7). 
There is a high unmet medical need for new drugs effective against Gram-negative bacteria to 
treat infections caused by these pathogens and to reserve colistin to fight MDR pathogens (8). 
Besides this, an alternative strategy resides in the recovery of colistin efficacy by blocking 
bacterial colistin resistance mechanisms. Antibiotic adjuvants therapies consist in the 
combination of a potent antibiotic with a non-antibiotic agent interfering with specific antibiotic 
resistance or virulence mechanisms. This strategy may provide a new tool to fight infections 
caused by drug resistant pathogens by restoring or boosting the efficacy of an approved 
antibiotic (9). 
Colistin resistance is conferred by lipopolysaccharide (LPS) modifications at the outer cell 
envelope. Reduction of the negative charge on LPS results in a reduced affinity of colistin to 
LPS (10). The two main LPS modifications conferring colistin resistance are the addition of 
4-amino-4-deoxy-L-arabinose (AraN) and phosphoethanolamine (PetN) to the lipid A (11). The
expression of LPS modifying enzymes is regulated by the concerted action of several two-
component systems (TCSs). In Enterobacteriaceae PhoPQ and PmrAB TCSs regulate the
expression of colistin resistance mechanisms, whereas in P. aeruginosa the PhoPQ, PmrAB,
ParRS, ColRS and CprRS TCSs seem to be involved (11). Plasmid mediated colistin resistance
has been recently reported in Enterobacteriaceae due to the PetN transferase MCR-1. The
presence of MCR-1 on a plasmid leads to its rapid geographical and interspecies spread (12,13).
In A. baumannii, colistin resistance is mediated by PetN addition to the lipid A and this
resistance mechanism is regulated by the PmrAB TCS. In contrast to other pathogens, AraN
lipid A modification pathway is not present in A. baumannii (11), rendering A. baumannii  a
suitable pathogen to develop an adjuvant therapy approach to rejuvenate colistin efficacy by
blocking the PmrAB TCS.
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Colistin resistance in A. baumannii clinical isolates is associated with alterations in the pmrCAB 
operon. pmrC gene codes for a PetN transferase and pmrA and pmrB code for the TCS (14). It 
has been shown that mutations in the PmrAB TCS induce the overexpression of pmrC leading 
to the modification of lipid A with PetN and colistin resistance (14–18). Because PmrA is the 
transcriptional regulator that triggers PmrC overexpression, inhibition of PmrA with a small 
molecule may potentially block PmrC overexpression and therefore switch-off colistin 
resistance in A. baumannii (19). This study was designed to evaluate the relevance of PmrA as 
a drug target to restore colistin efficacy in A. baumannii clinical isolates. We demonstrate that 
in absence of PmrA-mediated expression of PmrC, transposition of an insertion sequence (IS) 
element can lead to overexpression of the alternative highly similar PetN transferase EptA that 
also confers colistin resistance. Our results show that in all studied clinical isolates 
overexpression of at least one PetN transferase (PmrC or various EptA variants) was 
responsible for colistin resistance indicating that PetN transferases may be a suitable drug target 
to overcome colistin resistance in A. baumannii. 
Results 
PmrA is not always essential for colistin resistance in A. baumannii clinical isolates. 
We deleted pmrA from the genome of a panel of 12 colistin resistant A. baumannii strains to 
evaluate the transcriptional regulator PmrA as a potential drug target to rejuvenate colistin 
efficacy in A. baumannii. The strains in the panel consisted of recently isolated colistin resistant 
clinical strains collected at diverse geographical origins. They belong to three distinct and 
highly successful clonal lineages, the international clone 1 (ST1), international clone 2 (ST2) 
and ST25 clonal lineages (Table 1) (20–22). All strains were classified as extensively drug 
resistant according to criteria of Magiorakos and colleagues (23). These data underscore the 
clinical relevance and the diversity of the strain panel.  The colistin susceptible A. baumannii 
ATCC-17978 strain was included as a reference strain. In all strains pmrA was deleted by 
applying a previously described method that allows efficient scarless genome engineering even 
in extensively resistant A. baumannii clinical isolates (24). 
The colistin sensitivity of the parental clinical isolates and their corresponding pmrA knockout 
mutants (∆pmrA) was determined by microdilution method. pmrA deletion reduced MICs 64- to 
1024-fold in 10 out of 12 initially colistin resistant clinical isolates (83%) thus restoring 
susceptibility to colistin (MIC ≤ 2 µg/ml) (Table 2). To our surprise, however, two strains 
(BV94 and BV189) retained colistin resistance even in absence of pmrA.  
We investigated the differences between strains that became susceptible after pmrA deletion 
and those that remained resistant by analysing the sequence variations of the PmrAB TCS in 
the strain panel. The PmrA and PmrB sequences of the A. baumannii AYE, ACICU and NIPH 
146 strains were used as reference for ST1, ST2 and ST25 clonal lineages, respectively. Non-
synonymous mutations were found only in the PmrB sensor kinase (Table 2). Interestingly, the 
two strains with an unaltered PmrB sequence were those that remained colistin resistant after 
pmrA deletion (BV94 and BV189). Our data suggest that colistin resistance in these two strains 
is not conferred by a PmrA-mediated PmrC overexpression. We confirmed this hypothesis by 
quantifying the expression of pmrC using quantitative reverse-transcription PCR (qRT-PCR) 
(Fig 1.A). The control strain ATCC-17978, and the two refractory strains BV94 and BV189 
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showed only marginal levels of pmrC expression. In contrast, the 10 other strains showed pmrC 
overexpression and this overexpression was abolished in the ∆pmrA mutant. 
Table 1: Characterization of the A. baumannii clinical isolate panel used in this study. 
Abbreviations: CIP: ciprofloxacin, CTX: cefotaxime, GENT: gentamycin, MERO: meropenem, MLST: 
Multilocus sequence type, SAM: ampicillin-sulbactam, SXT: trimethoprim-sulfamethoxazole, TET: tetracycline, 
TZP: piperacillin-tazobactam. Classification of antibiotic resistance was done according to breakpoints published 
by the Clinical and Laboratory Standards Institute: susceptible (green), Intermediate (yellow), resistant (red) (25). 
Table 2: Effect of loss of PmrA on colistin susceptibility and PmrB mutations in the strain panel. 
Strain 
designation 
Colistin MIC (µg/ml) * PmrB mutations 
(amino acid 
substitutions) 
wildtype ΔpmrA 
ATCC-17978 0.25 0.25 reference 
BV94 64 32 wildtype 
BV95 32 0.5 L274W 
BV172 256 1 Q43L and L267F 
BV173 128 1 A138T and A226V 
BV174 64 1 Q277R 
BV175 256 0.5 L267W 
BV185 256 0.25 P233S 
BV186 16 0.25 Q277R 
BV187 16 0.25 Q277R 
BV189 64 64 wildtype 
BV190 256 0.5 A138T and A226V 
BV191 256 0.25 A138T and P233S 
Red background indicates the strains that did not recover colistin susceptibility after pmrA deletion. 
*susceptibility breakpoint ≤ 2 µg/ml.
Taken together, colistin resistance in A. baumannii is predominantly conferred by mutations in 
the PmrB TCS sensor kinase that lead to overexpression of PmrC, as shown in 10 out of 12 
strains. However, some isolates (2 out of 12 strains in our panel) may use an alternative colistin 
resistance mechanism independent of PmrA mediated PmrC overexpression to resist the 
antibacterial activity of colistin. 
Strain 
designation 
Strain isolation 
MLST 
MICs (µg/ml) 
location date GENT MERO CIP TZP CTX SXT SAM TET 
ATCC-17978 France 1951 77 2 0.5 1 8/4 16 > 8/152 4/2 2 
BV94 USA 2011 2 > 128 32 256 > 256/4 > 256 > 8/152 16/8 32 
BV95 Colombia 2010 25 1 64 128 256/4 32 > 8/152 16/8 > 256
BV172 Israel 2012 2 > 128 64 32 256/4 > 256 > 8/152 64/32 > 256
BV173 Greece 2012 2 > 128 > 64 128 > 256/4 > 256 > 8/152 128/64 > 256
BV174 USA 2012 2 8 64 256 256/4 256 > 8/152 32/16 32 
BV175 Turkey 2012 2 128 32 256 > 256/4 256 > 8/152 32/16 256 
BV185 Mexico 2013 2 > 128 > 64 128 > 256/4 > 256 > 8/152 64/32 256 
BV186 USA 2013 2 16 64 256 > 256/4 > 256 > 8/152 32/16 8 
BV187 USA 2013 2 32 64 256 > 256/4 > 256 > 8/152 16/8 8 
BV189 Spain 2013 2 128 32 128 > 256/4 256 > 8/152 32/16 16 
BV190 Greece 2012 1 > 128 64 64 > 256/4 > 256 > 8/152 64/32 256 
BV191 China 2013 2 > 128 > 64 256 > 256/4 > 256 > 8/152 128/64 > 256
ATCC-25922 (Quality control) 1 < 0.06 < 0.25 4/4 < 0.25 0.125/2.34 4/2 2 
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Fig 1: Discrimination and quantification of pmrC and eptA. 
Expression levels of (A) pmrC and (B) eptA were quantified by qRT-PCR in colistin resistant A. baumannii isolates 
(white bars) and their ∆pmrA mutants (black bars). The expression levels were normalized to the pmrC expression 
in the ATCC-17978 reference strain. (C) Schematic representation of differences in the pmrC, eptA-1 and eptA-2 
coding sequence. Black (oVT162/oVT163) and red primers (oVT164/oVT165) were used to detect pmrC and eptA 
in qRT-PCR experiments, respectively. The green primers (oVT152/oVT153) were used to genotype the eptA 
isoforms. Blue (oVT198/oVT199) and orange primers (oVT201/oVT202) were used to discriminate eptA-1 and 
eptA-2, respectively. (D) Representation of ISAbaI-eptA-1, ISAbaI-eptA-2 and the probably duplicated 
ISAbaI-eptA-3 genomic sequence of clinical isolate BV94. The junction between ABK1_3144 and ISAbaI-eptA3 
has been sequenced while the sequence downstream ABK1_2603 could not be resolved. The ABK1 gene 
annotation is shown according to the genomic sequence of A. baumannii strain 1652-2 (Genbank accession number 
NC_017162). 
EptA, a PmrC homolog, is present in the A. baumannii strains of international clone 2. 
Lesho and colleagues described the presence of the alternative PetN transferase EptA in 
A. baumannii (17). EptA and PmrC are homologous proteins with 93% amino acid identity
suggesting similar enzymatic activities. However, the role of EptA in A. baumannii colistin
resistance is still unclear (17). To investigate the prevalence of eptA in A. baumannii, we took
advantage of sequence differences between pmrC and eptA at the N- and C-terminal ends of the
open reading frames and designed oligonucleotides (oVT152/oVT153) that can discriminate
eptA from pmrC (Fig 1.C and Table S1). Using these eptA specific primers we detected eptA in
all our international clone 2 strains, but not in international clone 1 strains. This finding was
further confirmed by screening 12 additional isolates from the BioVersys strain collection (data
not shown).
The integrated transposon ISAbaI causes eptA overexpression in BV94 and BV189. 
Two isoforms of eptA, eptA-1 and eptA-2 (Genbank accession number KC700024 and 
KC700023, respectively), were previously described to be present at different locations in the 
genome of various A. baumannii strains (17). Taking advantage of the different flanking 
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regions, we designed primers able to discriminate eptA-1 and eptA-2 (oVT198/oVT199 and 
oVT201/oVT202, respectively) (Fig 1.C and Table S1). By genotyping the strain panel, we 
demonstrated that all strains that belong to the international clone 2 contained eptA-1 and four 
of them contained an additional copy of eptA-2 (Fig S1). Interestingly, the PCR products 
obtained for eptA-2 in BV94 and eptA-1 in BV189 were approximately 1 kilobase larger than 
the expected fragment size. Sequencing of the PCR products identified an insertion of 
transposon ISAbaI upstream of eptA-2 and eptA-1 in BV94 and BV189, respectively. The 
ISAbaI orientation enabled its strong promoter (Pout) to drive eptA overexpression as previously 
described for other antibiotic resistance determinants (Fig 1.D) (26,27).  
Using probes specific for eptA and pmrC we quantified their expression levels in our strains. 
eptA was 550- and 25-fold higher expressed in BV94 and BV189, respectively, than the 
homologous isoform pmrC in the control strain ATCC-17978 (which does not encode eptA) 
(Fig 1.B). This eptA overexpression was not altered in the ∆pmrA mutant strains suggesting that 
eptA expression in both strains is regulated independently of the PmrAB TCS. These data 
suggest that an ISAbaI-driven eptA overexpression may represent an alternative and PmrAB-
independent colistin resistance mechanism in BV94 and BV189. 
ISAbaI driven eptA overexpression confers colistin resistance in A. baumannii clinical 
isolates. 
To validate this hypothesis, we deleted eptA-1 in the clinical isolates BV189 and BV94 and 
determined MIC values. Indeed, BV189 (which carries ISAbaI upstream of eptA-1) became 
colistin susceptible upon eptA-1 deletion, indicating an essential role of ISAbaI-eptA-1 in 
conferring colistin resistance in this strain (Table 3). In contrast, BV94, encoding both eptA-1 
and eptA-2 isoforms, but carrying an ISAbaI insertion upstream of eptA-2, remained colistin 
resistant after deletion of eptA-1 suggesting the key role of the position of ISAbaI insertion for 
colistin resistance in A. baumannii. To further confirm the importance of ISAbaI, we 
constructed the double mutant BV94∆eptA-1/∆eptA-2 and evaluated its colistin susceptibility. A 
4-fold MIC reduction was observed in BV94∆eptA-1/∆eptA-2 mutant compared to BV94 and
BV94∆eptA-1 parental and single mutant, respectively, indicating that eptA-2 with an upstream
ISAbaI affects colistin resistance of BV94 (Table 3). However, we were surprised to see that
BV94∆eptA-1/∆eptA-2 remained resistant to colistin with a MIC of 16 µg/ml indicating that there
must be yet another colistin resistance mechanism present in this isolate.
Table 3: Recovery of colistin susceptibility after deletion of different eptA isoforms. 
Colistin MIC (µg/ml) 
Strains wildtype ∆eptA-1 ∆eptA-1/∆eptA-2 ∆eptA-1/∆eptA-2 /∆eptA-3 
BV189 128 0.5 - - 
BV94 64 64 16 1 
Three different eptA variants can confer colistin resistance in A. baumannii. 
We genotyped the BV94∆eptA-1/∆eptA-2 double mutant and confirmed the successful deletion of 
eptA1 and eptA2. However, we detected the presence of at least one additional eptA copy 
(eptA-3) in the double mutant (Fig S2). We performed a fusion primer and nested integrated 
PCR experiment (FPNI-PCR) to amplify genomic flanking regions of the additional eptA-3 
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variant (28). Sequencing revealed an upstream ISAbaI and downstream gene ABK1_2603 
showing an identical context of eptA-3 as for eptA-2 in strain 1652-2 (Genbank accession 
number NC_017162). However, further upstream there were marked differences. 
ISAbaI-eptA-3 was adjacent to ABK1_3144 while ISAbaI-eptA-2 had ABK1_2605 (Fig 1.D). 
We could not determine the downstream flanking region of ISAbaI-eptA3 ABK1_2603 in 
multiple attempts. Our results suggest that eptA-3 in BV94 might be a result of an 
ISAbaI-eptA-2 cassette gene duplication.  
We finally deleted the DNA fragment between ABK1_3144 and ABK1_3143 containing 
eptA-3 to confirm that ISAbaI-eptA-3 was responsible for the high residual colistin resistance 
in BV94∆eptA-1/∆eptA-2. In addition, we performed PCR-based eptA genotyping on the resulting 
triple mutant BV94∆eptA-1/∆eptA-2/∆eptA-3 to exclude the presence of yet another eptA copy (Fig S2). 
The loss of all 3 eptA isoforms in BV94∆eptA-1/∆eptA-2/∆eptA-3 rendered this triple mutant susceptible 
to colistin, indicating that colistin resistance in BV94 was entirely conferred by the 
overexpression of EptA-isoforms (Table 3). 
Targeting PetN transferases may overcome colistin resistance in A. baumannii. 
In this study we have shown that colistin resistance was mediated in 10 out of 12 analysed 
clinical strains by PmrA mediated overexpression of PmrC.  In the remaining two strains ISAbaI 
driven EptA expression conferred colistin resistance. Taken together, in all tested clinical 
isolates colistin resistance was mediated by the overexpression of PetN transferases, suggesting 
that inhibition of these homologous enzymes with small molecules may have the potential to 
overcome colistin resistance in A. baumannii (Fig 2). Chin and colleagues recently suggested 
that the acetyl-galactosamine (GalNAc) deacetylase NaxD plays a role in colistin resistance in 
A. baumannii (29). In this report, the expression of NaxD was regulated by the PmrAB TCS
and NaxD mediated galactosamine (GalN) addition to lipid A finally conferred the colistin
resistance phenotype. We performed additional experiments to exclude the possibility that the
observed colistin re-sensitisation after deletion of PmrA was based on a modulation of naxD
and not pmrC. We first confirmed the PmrAB controlled naxD expression based on qRT-PCR
data for BV191 and BV191∆pmrA (Fig S3). BV191 has a PmrB mutation that likely triggers
PmrA-mediated pmrC overexpression. Similarly, naxD expression was 15-fold higher in the
colistin resistant strain BV191 compared to the susceptible strain ATCC-17978. In BV191∆pmrA,
lacking the response regulator PmrA, pmrC and naxD overexpression was abolished confirming
that both genes were regulated by the PmrAB TCS. Notably, pmrC overexpression was 20-fold
higher compared to naxD overexpression. To confirm the major role of PmrC in PmrA-
mediated colistin resistance and to exclude that another PmrA-regulated gene is involved in
colistin resistance, we directly deleted the effector pmrC from the genome of BV191. The loss
of PmrC rendered BV191 susceptible to colistin (MIC of 0.5 µg/ml) and resulted in a similar
phenotype as in BV191∆pmrA (Table 2). By contrast, naxD was still 15-fold overexpressed in
BV191∆pmrC (Fig S3). This result suggests that overexpression of naxD is not sufficient to confer
colistin resistance in BV191 and indicates that PmrC is the main effector of PmrA-mediated
colistin resistant A. baumannii strains, such as BV191.
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Fig 2: Schematic representation of A. baumannii colistin resistance mechanisms.  
The two pathways leading to phosphoethanolamine (PetN) transferase overexpression and colistin resistance are 
represented. The major A. baumannii PetN transferase overexpression pathway results from pmrC expression, 
which is activated by the transcriptional regulator PmrA previously phosphorylated (activated) by a mutated 
variant of the sensor kinase PmrB (PmrB*). Alternatively, A. baumannii PetN transferase overexpression can 
result from the integration of ISAbaI transposon upstream of an eptA isoform. PetN transferase enzymes decorate 
the outer membrane lipid A with PetN thereby lowering the negative charge and preventing colistin binding. PmrA 
inhibitor would only block the pmrC pathway (dark blue cross), while PetN transferase inhibitor would block 
lipid A modification (red cross) and restore colistin efficacy against A. baumannii. 
Discussion 
Bacteria have evolved multiple ways to escape the hazardous action of antibiotics. In 
nosocomial infections, the individual strain history of antibiotic exposures during patient 
treatment may result in the development and accumulation of different resistance mechanisms 
in strains of the same species. Therefore, it is important to study resistance mechanism on 
multiple strains. Moreover, it is crucial to study these mechanisms on strains that developed 
resistance during patient treatment due to the discrepancy that may be observed between in vitro 
and in vivo developed mechanisms. For instance, A. baumannii polymyxin resistance is 
commonly mediated by LPS loss when A. baumannii is exposed to the drug in vitro but this 
mechanism is not viable in vivo due to the strong fitness cost it engenders (16,30). 
In this study, we dissected the mechanisms conferring colistin resistance in 12 clinically 
relevant A. baumannii strains. To our knowledge, this is the first time that colistin resistance is 
genetically characterized in a panel of A. baumannii clinical strains that developed resistance 
during patient treatment. This gap in knowledge originates from the difficulties to manipulate 
the genome of A. baumannii colistin resistant clinical strains. Indeed, as exemplified in our 
strain panel, such strains are generally resistant to all other antibiotics because colistin is used 
as last option in the treatment of A. baumannii infections, only when other antibiotics failed. To 
break the barrier of antibiotic resistance in these strains, we applied a genome editing method 
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based on non-antibiotic resistance marker, which is efficient regardless of the resistance profile 
of the strain (24).   
We demonstrated two different ways to overexpress PetN transferases that cause colistin 
resistance in A. baumannii clinical isolates (Fig 2). The predominant colistin resistance 
mechanism found in 83% of the studied clinical isolates was mediated by pmrC overexpression. 
The overexpression of pmrC in these strains was entirely caused by mutations in the sensor 
kinase PmrB, although previous studies also found mutations in the response regulator 
PmrA (14,15,17). We found 7 different PmrB variants among the 10 PmrC-mediated colistin 
resistant strains indicating the diversity of mutations that lead to PmrC overexpression. Except 
the A226V and P233S mutations, the identified PmrB mutations were not yet reported in 
A. baumannii (11,15,16).
Interestingly, we found two clinical isolates in which colistin resistance was conferred by a 
genomic insertion of the transposon ISAbaI resulting in a strong overexpression of the pmrC 
homolog eptA. eptA-1 and eptA-2 genes have been previously identified in A. baumannii, 
however, their distribution, expression regulation, and role in colistin resistance was not 
assessed (17). Our study revealed that A. baumannii strains of the international clone 2, which 
represent the most problematic strains in hospital, carry at least one eptA variant. In contrast, 
international clone 1 strains did not encode eptA.  Our data further show that eptA expression 
is not regulated by the PmrAB TCS but, instead, integration of ISAbaI upstream of any eptA 
isoform is required to confer the resistance phenotype, presumably by ISAbaI-driven eptA 
overexpression. Consequently, detection of an eptA gene alone is not sufficient to classify 
A. baumannii strains as colistin resistant.
The analysis of PmrA as a potential drug target confirmed the importance of this protein in
mediating colistin resistance in A. baumannii. However, the high prevalence of eptA and the
ability of ISAbaI to integrate upstream of eptA and drive its expression independently of the
PmrAB TCS disproved PmrA as a direct drug target for re-sensitisation of A. baumannii to
colistin (Fig 2). An adjuvant therapy consisting of a PmrA inhibitor in combination with colistin
would most likely select for ISAbaI driven EptA overexpressing colistin resistant strains. As
demonstrated by the two clinical isolates BV94 and BV189, such strains are already present in
the hospitals. One of the strains also contained a duplicated ISAbaI-eptA cassette suggesting
that this functional cassette mediating colistin resistance was present on a mobile element. The
presence of a mobile colistin resistance-mediating cassette increases the probability of intra-
and interspecies transfer of the resistance pathways by the integration into plasmids. This
phenomenon was recently illustrated with plasmid encoded PetN transferase mcr-1, which was
initially found in China but rapidly spreads globally and in different species (12,13).
One of the major colistin resistance pathways in Enterobacteriaceae and P. aeruginosa is the
addition of AraN to lipid A (11). Although we describe here two different ways to overexpress
PetN transferases, our results suggest that colistin resistance in clinical A. baumannii isolates is
exclusively conferred by PetN addition to lipid A. A recent study suggested that a GalN-based
modification of lipid A may be involved in colistin resistance in A. baumannii (29). In contrast,
our results suggest that alteration of the lipid A structure by addition of PetN plays the major
role in colistin resistance in A. baumannii. It has been also described that loss of LPS may
confers colistin resistance in A. baumannii (31). However, most of the LPS deficient colistin
resistant mutants were obtained in vitro after colistin evolution and it has been shown that these
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mutants are hypersusceptible to other antibiotic classes and are avirulent (16,30). Emergence 
of LPS-deficient colistin resistant mutants in patients is therefore unlikely. 
In conclusion, the overexpression of homologous PetN transferases caused colistin resistance 
in all studied clinical isolates, but in some cases this occurred independently of PmrAB. Our 
data suggests that a direct inhibitor of homologous PetN transferases PmrC and EptA may have 
the potential to overcome colistin resistance in A. baumannii clinical strains (Fig 2). 
Materials and methods 
Bacterial strains, MIC, MLST and oligonucleotides. The A. baumannii reference strain 
ATCC-17978 and twelve extensively drug resistant A. baumannii clinical isolates from the 
BioVersys proprietary strain collection were used in this study. The microdilution method was 
used to determine MICs according to the CLSI guidelines (32). Multiple locus sequence type 
(MLST) was determined according to the Pasteur scheme using specific primers (source: 
http://pubmlst.org/abaumannii/) (20). Oligonucleotides used in this study are listed in Table S1. 
Genomic deletions of pmrA, eptA-1, eptA-2, eptA-3 and pmrC in A. baumannii clinical 
isolates. Scarless deletions of pmrA, pmrC and the eptA isoforms were performed using a two-
step recombination method previously described (24).  
DNA fragments corresponding to 700-bp up- and downstream genomic regions of the genes to 
be deleted were amplified by PCR and cloned in the multiple cloning site of the knockout 
platform pVT77. Oligonucleotides oVT49/oVT50 and oVT51/oVT52 were used to amplify the 
up- and downstream regions, respectively, of pmrA. The resulting DNA fragments were ligated 
and introduced into pVT77 previously digested by EcoRI and BamHI. Similarly, 
oligonucleotides oVT235/oVT236 and oVT237/oVT238 were used to amplify the flanking 
regions of eptA-1 and oligonucleotides oVT305/oVT306 and oVT307/oVT242 were used to 
amplify the flanking regions of eptA-2. The resulting DNA fragments for eptA-1 and eptA-2 
were introduced into pVT77 previously digested by XhoI and XbaI using NEBuilder HiFi DNA 
assembly (New England Biolabs). For eptA-3 deletion, the genomic regions flanking the 
duplicated cassette were amplified using oVT390/oVT391 and oVT392/oVT393. The resulting 
DNA fragments were cloned into pVT77 previously digested with EcoRI and XbaI using 
NEBuilder HiFi DNA assembly. Lastly, the flanking regions of pmrC were amplified using 
oVT324/oVT325 and oVT326/oVT327 and the resulting DNA fragments were cloned into 
pVT77 previously digested with KpnI and PstI using NEBuilder HiFi DNA assembly.  
The cloned knockout plasmids were transformed in E. coli conjugative strain MFDpir to 
proceed with the construction of markerless deletion in A. baumannii, as previously described 
(24). Briefly, after conjugation, genomic plasmid integration was selected on LB agar plates 
containing 100 µg/ml sodium tellurite. Clones were screened for up- or downstream integration 
by PCR using primers oVT8 that anneals on the plasmid and oVT91, oVT243, oVT311 or 
oVT328 that anneal upstream of pmrA, eptA-1, eptA-2 and pmrC, respectively. For eptA-3, 
clones were screened using primers oVT8/oVT396 and oVT174/oVT397 for up- and 
downstream integration, respectively. Clones containing up- and downstream plasmid 
integrations were transferred on LB agar plates containing 1 mM isopropyl-β-D-1-
thiogalactopyranoside and 200 µg/ml 3’-azido-3’-deoxythymidine to select for plasmid 
removal from the genome. Clones were screened for gene deletion and plasmid removal by 
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PCR using primers oVT91/oVT92, oVT243/oVT244, oVT246/oVT311, oVT396/oVT397 and 
oVT328/oVT14 for pmrA, eptA-1, eptA-2, eptA-3 and pmrC, respectively. The genomic gene 
deletions were finally confirmed by DNA sequencing (Microsynth AG, Balgach, Switzerland). 
Genotyping of pmrA, pmrB and eptA. A genomic DNA sequence including pmrA and pmrB 
was PCR amplified from all the strains of the panel using oVT91 and oCK292 and the PCR 
products were sent to sequencing (Microsynth AG, Balgach, Switzerland). The genotyping of 
eptA isoforms was performed by PCR using eptA specific primers oVT152 and oVT153 that 
anneal on all eptA isoforms but not on pmrC (Fig 1.C). PCR using primers oVT198/oVT199 
and oVT201/oVT202 that anneal on the flanking sides of eptA-1 and eptA-2, respectively, were 
used to discriminate between eptA isoforms (Fig 1.C). 
qRT-PCR. Quantitative reverse transcription-PCR was performed as previously 
described (24). The specific expression of the PetN transferases pmrC and eptA was evaluated 
using oVT162/oVT163 and oVT164/oVT165 primers, respectively (Fig 1.C). The expression 
of naxD was evaluated using oVT314/oVT315 primers. Expressions were normalized to that 
of the housekeeping gene rpoD using the comparative ∆∆CT method. The expression of rpoD 
was evaluated using rpoD-qRT-F/rpoD-qRT-R primers. 
FPNI-PCR. Fusion primer and nested integrated PCR was performed as previously described 
(28). This method relies on a three-step PCR using arbitrary degenerated oligonucleotides fused 
to known adaptors and three sequence specific oligonucleotides, which consist in our case of 
eptA specific oligonucleotides. FPNI-PCR experiments was performed on the BV94∆eptA-1/∆eptA-2 
mutant with two sets of three eptA specific oligonucleotides oVT343, oVT344, oVT345 and 
oVT340, oVT341, oVT342 to identify the sequence up- and downstream of the new eptA copy, 
respectively. The degenerated primers and the known adaptor primers were directly taken from 
the previously described method (28). Briefly, the first round of PCRs was performed using the 
degenerated primers and oVT343 for upstream identification and oVT340 for downstream 
identification. The second round of PCRs were performed with the first adaptor primer FSP1 
and oVT344 for upstream identification and oVT341 for downstream identification. The last 
round of PCRs was performed with the second adaptor primer FSP2 and oVT345 for upstream 
identification and oVT342 for downstream identification. The brightest and most isolated PCR 
products obtained were sent to sequencing (Microsynth AG, Balgach, Switzerland). 
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Supporting information 
Fig S1: Agarose gel of eptA-1 and eptA-2 genotyping in the strain panel. 
The genotyping of eptA-1 (upper gel) and eptA-2 (lower gel) was performed by PCR using primers 
oVT198/oVT199 and oVT201/oVT202, respectively. Lane 1: 2-log ladder (New England Biolabs), lane 2: ATCC-
17978, lane 3: BV94, lane 4: BV95, lane 5: BV172, lane 6: BV173, lane 7: BV174, lane 8: BV175, lane 9: BV185, 
lane 10: BV186, lane 11: BV187, lane 12: BV189, lane 13: BV190, lane 14: BV191 and lane 15: 2-log ladder. 
Compared to the expected size of 1,862-bp and 1,827-bp, the PCR products for BV94 eptA-2 and BV189 eptA-1 
genotyping are approximately 1 kilobase larger corresponding to the presence of ISAbaI.  
Fig S2: Gel agarose of eptA genotyping in the clinical isolate BV94 and its eptA knockout mutants.  
The genotyping of eptA isoforms was performed by PCR using primers oVT152/oVT153. Lane 1: 2-log ladder 
(New England Biolabs), lane 2: BV94, lane 3: BV94∆eptA-1, lane 4: BV94∆eptA-1/∆eptA-2, lane 5: 
BV94∆eptA-1/∆eptA-2/∆eptA-3. The triple mutant BV94∆eptA-1/∆eptA-2/∆eptA-3 did not encode any other eptA isoform. 
Fig S3: Quantification of pmrC and naxD expression levels in A. baumannii BV191 and its ∆pmrA mutants. 
The expression of pmrC (white bars) and naxD (black bars) was quantified by qRT-PCR and normalized to the 
gene expression level in the reference strain ATCC-17978.   
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Table S1: Oligonucleotides used in this study 
Oligo name Sequence (5’-3’) 
oVT8 GTTTTCCCAGTCACGACGC 
oVT14 TGAGGTGCCCCAAATCAGTC 
oVT49 GGAATTCCGGTTACCAAGTGACTTGG 
oVT50 CGAAATTTTAAATCCCCCGGGGGAGTTCTAGGCTCGCTTTAGTTTAC 
oVT51 CTCCCCCGGGGGATTTAAAATTTCGGGACTTC 
oVT52 CGGATCCGTCGTAATTCATGAGCAGC 
oVT91 CGGGTATGCCACGTGTAGAT 
oVT92 CAAATGCTGAATACGCGCCA 
oVT152 AGTTCTTTTCTTAGGGGCGACA 
oVT153 ACATTGGCTCAACATATCAAGTTTGT 
oVT162 CCATTTGGCTAGGTGCAATTT 
oVT163 ACCGCATAATAGGTAGCAACA 
oVT164 TGCTTTTATCTATCTGGCTAGGTT 
oVT165 TGTCGCCCCTAAGAAAAGAACT 
oVT174 ACCCAGCATGATATTCCGGA 
oVT198 CTCAAGGAGCCATCGTCATAT 
oVT199 GGGTTACGACTGCCCTCTTA 
oVT201 AGTTTTACTAGCTAAGATTTCGAG 
oVT202 TGATGCATAGCTGACGAAG 
oVT235 GGAGAATTGAGGCCTCTCGAGCATTCAGGTGTTGCTGTG 
oVT236 CCCTCTTACCCGGGATATGACGATGGCTCCTTG 
oVT237 TCGTCATATCCCGGGTAAGAGGGCAGTCGTAACC 
oVT238 AGCTTCCTGCAGGCTCTAGAAATGGGGGCTTCTGG 
oVT242 AGCTTCCTGCAGGCTCTAGACGCCCTTTGGTCTCCTAAC 
oVT243 TATGGCACAAGAAGAAGGCG 
oVT244 ACAGCTTGGCCATAGGAAGC 
oVT246 GCTTTTGTGAAGTTGGGGCC 
oVT305 GGAGAATTGAGGCCTCTCGAGACGATTGCGAGCATCAGG 
oVT306 ACGAAGGTCCCGGGCGAAACATCGGTCTGCAC 
oVT307 GATGTTTCGCCCGGGACCTTCGTCAGCTATGCATC 
oVT311 ATGTAAACCACTGCTCACCG 
oVT314 TGGCAAAGGTGTGCTATTGC 
oVT315 ATTTGGCAGCAGCAGTTTCC 
oVT324 AATTCGAGCTCGGTACCAGAGGTTCTGCTTCAGCTC 
oVT325 CTCGCTTTACCCGGGAAACAGGGAAATCTGTTTATTTC 
oVT326 CCCTGTTTCCCGGGTAAAGCGAGCCTAGAACATG 
oVT327 CGCAAGCTTCCTGCAGATTGAGGTGCCCCAAATC 
oVT328 TCGACAAACATTGGTGGTGG 
oVT340 AGCGGTTTCTGTGCCATGTA 
oVT341 CCGCGTTTGATTGTTCTGCA 
oVT342 TACAGGGCTGTTCGCAAACT 
oVT343 GCAGGTCCATGACTACCCAC 
oVT344 TGCAGAACAATCAAACGCGG 
oVT345 CCGACCACTGCAAATGAAGC 
oVT390 AGAATTGAGGCCTCTCGAGGAATTCATATGTGTTGTGGTCTGGG 
oVT391 TGGGATTTTTCCCGGGGACCCACAAAATCTCTTTTC 
oVT392 TTTGTGGGTCCCCGGGAAAAATCCCACCGAAGTG 
oVT393 CCGCAAGCTTCCTGCAGGCTCTAGAAAACGTGCTCAAACTGC 
oVT396 TAAATCCTGGCACTTGGTGG 
oVT397 CCGGTGGTATGGAGTCGATG 
oCK292 GGACAGGCTGGGTCGTTTG 
rpoD-qRT-F GAGTCTAATGGCGGTGGTTC 
rpoD-qRT-R ATTGCTTCATCTGCTGGTTG 
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Antibiotic resistance is one of the biggest threats to human health globally. Alarmingly,
multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis have
now spread worldwide. Some key antituberculosis antibiotics are prodrugs, for which
resistance mechanisms are mainly driven by mutations in the bacterial enzymatic
pathway required for their bioactivation. We have developed drug-like molecules that
activate a cryptic alternative bioactivation pathway of ethionamide in M. tuberculosis,
circumventing the classic activation pathway in which resistance mutations have now
been observed. The first-of-its-kind molecule, named SMARt-420 (Small Molecule
Aborting Resistance), not only fully reverses ethionamide-acquired resistance and
clears ethionamide-resistant infection in mice, it also increases the basal sensitivity of
bacteria to ethionamide.
A
ntibiotic resistance is a rapidly growing
health concern and is observed for many
antibacterial agents, both in hospital and in
community settings (1, 2). The development
of drug resistance—especially rifampicin
resistance (RR), multidrug resistance (MDR)
and extensive drug resistance (XDR)—is parti-
cularly worrisome for tuberculosis (TB) (3). Ap-
proximately 580,000 MDR/RR-TB cases have
occurred in 2015, resulting in about 250,000 deaths.
This situation seriously undermines efforts to
control the global epidemic of TB and may soon
counteract the slow but continuous annual de-
cline of ~1.5% observed during the past 14 years (4).
Discovering new anti-TB therapeutics is dif-
ficult (5), and few new drugs have emerged during
the past 30 years. Moreover, because current TB
treatment requires poly-therapeutic approaches,
losing key antibiotics because of the emergence
of drug resistance may impair the efficacy of the
whole combination.
Drug resistance in bacteria can occur through
mutations in the antibiotic’s target; the acquisi-
tion of enzymes that modify or degrade the drug,
such as aminoglycoside-modifying enzymes or
b-lactamases; their active expulsion from the
bacteria; or alterations of the cell permeability (6).
Sometimes, antibiotic resistance can be reversed—
for example, through restoration of the antimi-
crobial activity of b-lactams by clavulanic acid,
which inhibits enzymes responsible for their
degradation (7). Unfortunately, there are so far
no other examples of this 40-year-old paradigm.
Some of the most effective anti-TB antibotics
require bioactivation byMycobacterium tuberculosis
enzymes to acquire their antibacterial effect. These
pro-antibiotics not only include the 40-year-old
compounds isoniazid (INH), pyrazinamide (PZA),
p-aminosalicylic acid (PAS) and ethionamide (ETH),
but also the recently approved drug delamanid
(OPC-67683) and the under-clinical-evaluation com-
pound pretomanid (PA824). However, bioactiva-
tion of pro-antibiotics is vulnerable to mutational
inactivation or attenuation of the corresponding
bioactivating enzymes, as observed for INH-, PZA-,
and ETH-resistant clinical isolates with mutations
in katG (8), pncA (9), and ethA (10, 11), respec-
tively. Similarly, experimentally generated and
clinical resistance to delamanid and to pretomanid
pointed to enzymes and coenzymes involved
in their bioactivation (12–14). Resistance to PAS
also involves mutations in enzymes, such as di-
hydrofolate synthase, which is implicated in its
bioactivation (15).
We have discovered a spiroisoxazoline family
of Small Molecules Aborting Resistance (SMARt)
that induces expression of an alternative bioac-
tivation pathway of ETH, reverting acquired re-
sistance of M. tuberculosis to this antibiotic.
The bioactivation of ETH in M. tuberculosis
is normally catalyzed by the Baeyer-Villiger mono-
oxygenase EthA (10, 11, 16). Transformation of
ETH by EthA into highly reactive intermedi-
ates leads to the formation of a stable covalent
adduct of ETH and nicotinamide adenine di-
nucleotide (NAD) (10, 17). This adduct binds to
and inhibits the enoyl reductase InhA involved
in mycolic acid biosynthesis, one of the essential
components in the mycobacterial cell wall (18, 19).
The production of EthA is regulated by the TetR-
type transcriptional repressor EthR (20). Previous-
ly, we have shown that small-molecule inhibitors
of EthR stimulate the transcription of the ethA
gene (21–24), which improves the bioactivation of
ETH and consequently boosts its antibiotic ac-
tivity, both in vitro and in vivo (25). These booster
molecules, such as BDM41906, reduce or reset
the innate resistance of M. tuberculosis to ETH;
however, as expected, they were unable to boost
the bioactivation of ETH in strains harboring mu-
tations in ethA (Table 1, panel B).
During optimization of first-generation EthR
inhibitors, most derivatives revealed a good cor-
relation between binding to EthR and ETH-
boosting activity against the bacteria (21–24).
However, unexpectedly, the replacement of the
oxadiazole-piperidine motif by a more constrained,
structurally divergent, spiroisoxazoline scaffold
completely abolished the ability of the compounds
to bind to EthR in vitro, whereas they remained
highly effective in boosting ETH activity against
M. tuberculosis (Fig. 1A).
Because these compounds had no antibacte-
rial activity in the absence of ETH but boosted
ETH activity independently of EthR, we hypoth-
esized that they may trigger an alternative bio-
activation pathway for ETH.
To identify this pathway, we studied the impact
of SMARt-420, a representative member of the
spiroisoxazoline family, on the transcriptome of
Mycobacterium bovis Bacillus Calmette-Guérin
(BCG) and compared it with the impact of the
bona fide EthR-inhibitor BDM41906 (23).
When the mycobacteria were treated with
BDM41906, overexpression of both ethA and
ethR was observed (Fig. 1B), which is in agree-
ment with previous reports showing that EthR
represses both ethA and its own expression (20).
No other major modification of the transcriptome
was observed, suggesting that the inhibitory activ-
ity of BDM41906 is restricted to EthR. In contrast
to BDM41906, SMARt-420 only weakly induced
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the expression of ethA and ethR. However,
SMARt-420 strongly activated the expression of
the distantly located group of genes bcg_0107c–
bcg_0108c, corresponding to rv0076c–rv0077c (Fig.
1C) in M. tuberculosis. According to protein ho-
mology, Bcg_0108c is predicted to be a member
of the large family of oxidoreductases (http://
enzyme.expasy.org/EC/1.-.-.-), which also includes
EthA. In silico analyses revealed that bcg_0108c
is neighboring the tetR type transcriptional re-
gulator gene bcg_0109 (http://pfam.xfam.org/
family/PF00440), indicating analogies between
the rv0076c-rv0078 and the ethR-ethA loci
(rv3854c-rv3855). The genetic organization of
the two loci is also similar: rv0077c and rv0078,
like ethA and ethR, are divergent open reading
frames, both separated by small intergenic re-
gions [76 base pairs (bp) and 62 bp for ethR-ethA
and rv0077c-rv0078, respectively] (Fig. 1C). By
analogy with the transcriptional organization
of the ethA-ethR regulon (20), these observa-
tions indicate that Rv0078 might regulate the
expression of rv0077c by binding within the
intergenic region. This hypothesis was confirmed
with surface plasmon resonance experiments
(SPR, Biacore), demonstrating the specific bind-
ing of Rv0078 to the intergenic region of rv0077c-
rv0078 (Fig. 2A). In contrast, no binding of EthR
to the intergenic region of rv0077c–rv0078 was
observed, even at high concentrations of protein,
thus excluding EthR for controlling the expres-
sion of the rv0076c–rv0078 locus (Fig. 2B). Con-
versely, no interaction was detected between
Rv0078 and the ethA–ethR intergenic region, indi-
cating the absence of cross-talk between the two
regulons (Fig. 2B). We assigned the names EthR2
and EthA2 to Rv0078 and Rv0077c, respectively.
The direct binding of SMARt-420 to EthR2 was
analyzed in vitro by means of thermal shift as-
say. The dose-dependent thermal stabilization of
EthR2 through binding to SMARt-420 is illus-
trated in Fig. 2C, whereas no interaction be-
tween BDM41906 and EthR2 was observed at
equivalent concentrations, which is in agree-
ment with the lack of effect of BDM41906 on
the transcription of ethA2.
A detailed understanding of the interaction
of SMARt-420 with EthR2 was obtained from the
x-ray structure of the complex, which shows that
EthR2 forms a homodimer in which one mol-
ecule of SMARt-420 is embedded in each mono-
mer (Fig. 2D). The structure also confirmed EthR2
as a typical TetR-type regulator harboring two
twistable helix-turn-helix (HTH) motifs that are
typically involved in the binding of the homodimer
to its DNA target (26). In this family of repressors,
binding of ligands to the distant specific pockets
located in the regulatory core of the homodimer
induces allosteric reorganization of the architec-
ture of the HTH motifs and thereby modifies
the binding properties of the protein to its DNA
target (23). In agreement with this paradigm, the
EthR2–SMARt-420 cocrystal revealed that the dis-
tance separating the HTHmotifs is far larger than
the ±34 Å required for the binding of the regu-
lator to DNA (27–29), thus providing the mech-
anism of action of SMARt-420 (Fig. 2D).
To quantify the inhibition of EthR2-binding
to its DNA target by SMARt-420, we designed
a synthetic mammalian gene circuit that senses
the EthR2-DNA interaction in human cells and
produces a quantitative reporter gene expres-
sion readout [secreted alkaline phosphatase
(SEAP)] (Fig. 3A) (30). In contrast to its repressor
role in mycobacteria, binding of EthR2 to the
chimeric promoter used in this assay is expected
to activate the expression of the SEAP reporter
gene. In the absence of SMARt-420, we observed
strong SEAP production, confirming the binding
of EthR2 to its DNA promoter in this cellular con-
text. Upon adding SMARt-420, a dose-dependent
inhibition of SEAP production was observed,
confirming that SMARt-420 impairs the DNA-
binding properties of EthR2. In contrast and as
expected, no effect was observed when the cells
were incubated with BDM41906, confirming the
specificity of the SMARt-420–EthR2 interaction
(Fig. 3A). In vitro, SPR experiments showed that
SMARt-420 inhibits in a dose-dependent manner
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Table 1. Impact of BDM41906 and SMARt-420 on the ethionamide susceptibility of a selec-
tion of clinical strains. (Panel A) Antibiotic profile. Threshold concentrations above which bacteria
are considered clinically resistant are indicated.The drug-sensitivity status of each strain is reported;
green indicates “under the threshold concentration,” and red indicates “above the threshold con-
centration.” Specifically, for ETH, MICs have been defined by MGIT960 and are reported (values in
micrograms per milliliter). All selected strains except the reference pan-susceptible laboratory strain
H37Rv (group 1) are multidrug-resistant (INH- and RIF-resistant). Group 2 includes ETH-sensitive strains.
Group 3 contains ETH-resistant strains without mutation in ethA. Group 4 contains ETH-resistant
strains mutated in ethA. (Panel B) MIC of ETH in the presence of 10 mM first-generation booster
BDM41906. (Panel C) MIC of ETH in the presence of 10 mM SMARt-420.
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the binding of EthR2 to its DNA target (Fig. 3B),
thus confirming that no other partner is required.
The expression of ethA2 upon inhibition of
EthR2 by SMARt-420 leads to efficient bioactiva-
tion of ETH in the bacteria. To evaluate the role
of EthA2 in the SMARt-420–controlled bioacti-
vation of ETH, M. tuberculosis H37Rv was engi-
neered to overexpress ethA2 by using the multicopy
plasmid pMV261 (31). Under these conditions,
the minimal inhibitory concentration (MIC) of
ETH decreased from 2 to 0.25 mg/ml, suggesting
that EthA2 takes part in the bioactivation of ETH
when overexpressed, thus reducing the innate
resistance of the bacteria to ETH (Fig. 3C).
SMARt-420 is the most active compound of a
spiroisoxazoline series for which the binding to
EthR2 (thermal shift assay) and the inhibition of the
DNA binding of EthR2 (SEAP assay) were shown to
be correlated to the ETH-boosting effect on sensi-
tive and on ETH-resistantM. tuberculosis (fig. S2).
As indicated by the transcriptomic analyses,
the basal expression level of ethA2 in the absence
of SMARt-420 is low inM. tuberculosis. We mea-
sured the relative abundance of mRNA by means
of high-throughput RNA-sequencing (RNA-seq)
in M. tuberculosis cells grown to mid-log phase.
We found that ethA2 belongs to the 10% least-
expressed genes in M. tuberculosis (rank 3609
out of the 3973 TB genes), whereas ethA is among
the 10% genes with the highest levels of expres-
sion. When compared with each other, ethA2-
mRNAs were about 60 times less abundant than
ethA-mRNAs in M. tuberculosis grown under
standard conditions. Low expression of ethA2 in
the absence of EthR2 inhibitors is of clinical im-
portance, offering an explanation as to why EthA2
has not been previously identified as involved in
ETH activation, and therefore mutations in this
gene have not been observed in clinical isolates
resistant to ETH so far.
Human-adaptedM. tuberculosis complex com-
prises seven main phylogenetically distinct line-
ages (32). We analyzed the genome sequences of
217 geographically diverse clinical strains repre-
senting all seven lineages (33) and confirmed the
presence of the rv0076c–rv0078 locus in all
strains. In addition, the presence of the locus was
confirmed in a collection of ETH-resistant (171)
and ETH-sensitive (253) clinical isolates of
M. tuberculosis (34). Nomutation in this locus was
observed in the ETH-sensitive population. Only
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Fig. 1. SMARt family of molecules reveals alternative ETH bioactiva-
tion pathway. (A) Bidimensional representation of the properties of ETH-
boosting compounds (BDM). The x axis indicates the shift in the melting
temperature (DTm) of EthR in the presence of BDM compounds, which trans-
lates the capacity of the compounds to bind and thermostabilize EthR in vitro
(values are provided in table S1).The y axis indicates the potency [expressed as
the negative logarithm of the median effective concentration (EC50)] of a panel
of compounds to increase ETH antibacterial activity onM. tuberculosis–infected
macrophages. EC50 is the concentration of compound that allows ETH at
0.1 mg/mL (10 times less than the normal MIC) to inhibit 50% ofM. tuberculosis
growth in macrophages. Blue dots and red dots represent compounds of the
oxadiazole-piperidine family (first-generation boosters) and of the spiroisoxazo-
line family (SMARt), respectively. (B) RNA-seq analysis of genes that are
differentially expressed in M. bovis BCG exposed for 24 hours to 25 mM
BDM41906 (2) or SMARt-420 (3) in comparison with dimethyl sulfoxide–
treated bacteria (1). Only genes showing a minimum twofold change (FC) in
transcript abundance in at least one condition are shown. RPKM, reads per
kilobase per million mapped reads. Whereas BDM41906 specifically induce
the expression of ethA and ethR, SMARt-420 massively induces the expres-
sion of bcg_0108c and bcg_0107c. A weak, but statistically significant, induction
of ethA and ethR is also observed. (C) Comparison of the genetic organization
and predicted function of the corresponding M. tuberculosis loci and proteins.
Genes bcg_0107c and bcg_108c correspond to rv0076c and rv0077c, respec-
tively. Rv0078 is predicted as a transcriptional repressor of the TetR family.
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one ETH-resistant isolate shows a point muta-
tion in rv0078, which also contains a Stop mu-
tation in ethA, which is most probably responsible
for the ETH-resistance phenotype (table S3). Then,
a panel of ETH-sensitive and ETH-resistant MDR
M. tuberculosis clinical isolates were tested by
means of respirometry (MGIT 960) (35) for their
sensitivity to ETH in the presence of SMARt-420.
Treatment of ETH-sensitive strains with SMARt-
420 (10 mM) decreased their ETH MIC (Table 1,
panel C). Strains highly resistant to ETH, be-
cause of mutations in ethA, were also sensitive
to ETH in the presence of SMARt-420 (Table 1,
panel C, group 4). The combination SMARt-420
plus ETH was active against all ETH-resistant,
MDR, and XDR isolates tested. Last, we showed
that overexpression of inhA by using a multicopy
plasmid modified the boosting effect of SMARt-
420, suggesting that the new bioactivation path-
way of ETH still targets InhA (fig. S3). We also
verified that SMARt-420 does not affect the ef-
ficacy of other antibiotics (table S4).
Pharmacokinetic experiments performed in
female Swiss mice showed that a single oral
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Fig. 2. SMARt-420 interacts with the transcrip-
tional regulator EthR2. (A) Global affinity of the
interaction between EthR2 and the ethA2-ethR2 in-
tergenic region measured with SPR. Sensorgrams
of 22.7, 11.35, 5.60, 2.83, 1.41, and 0.28 nM EthR2
(Rv0078) injections over a sensor chip functionalized
with 40 RU (resonance unit) of the biotinylated ethA2-
ethR2 intergenic DNA. (B) Comparison of the injec-
tion of EthR and EthR2 (Rv0078) over 2 sensor
chips functionalized with ethA-ethR intergenic DNA
(top) and with ethA2-ethR2 intergenic DNA (bot-
tom), respectively. (C) Binding of SMARt-420 and
BDM41906 on EthR2 measured by determination
of the melting temperature (Tm) of the complex
(thermal-shift assay) (supplementary materials,
materials and methods). (D) Crystal structure of the
EthR2/SMARt-420 complex and illustration of the
steric inability of binding of the repressor to DNA
because the 40.7 Å spacing of the HTH motifs.The
zoom onto the ligand binding pocket of the protein
shows an omit map contoured at 1.2s for one of
the two SMARt-420 molecules embedded in each
monomer of the EthR2 homodimer (statistics are
provided in the supplementary materials, materials
and methods, and table S2).
Fig. 3. SMARt-420 inhibits the DNA binding activ-
ity of EthR2. (A) Syntheticmammalian gene circuit de-
signed to sense EthR2-DNA interactions (ethA2–ethR2
intergenic region) that are required to induce expres-
sion of the reporter geneSEAP.Thealkalinephosphatase
induced by the EthR2-VP16 complex was inhibited in a
dose-dependent manner by SMARt-420, whereas no
effect was observed in the presence of BDM41906
(supplementary materials, materials and methods,
and fig. S1). (B) Inhibition of the binding of EthR2 to
the ethA2–ethR2 intergenic region by SMARt-420
but not by BDM41906, measured with surface plas-
mon resonance. (C) Effect of the overexpressionof ethA2
(pMV261–ethA2) on the MIC of ETH inM. tuberculosis.
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dose of 30 mg/kg of SMARt-420 provides a circu-
lating concentration of SMARt-420 higher than
that required to boost ETH in vitro (table S5).
Restoration of sensitivity to ETH by SMARt-420
was evaluated in C57BL6/J mice infected by aero-
sol with 105 ETH-resistant M. tuberculosis bacilli
mutated in ethA. Seven days after infection, the
mice were treated with ETH alone or with ETH
in combination with SMARt-420. Daily admin-
istration of up to 50 mg/kg of ETH for 3 weeks
was ineffective in significantly reducing the bac-
terial load in the lungs (Fig. 4), confirming the
resistance to ETH of this strain. In contrast, mice
treated with a combination of ETH and SMARt-
420 (both at 50 mg/kg) showed a striking reduc-
tion of the bacterial load (4.6 log) in the lungs (Fig.
4). The absence of an effect observed with SMARt-
420 administered alone, and a dose-response to
ETH combined with SMARt-420, confirms that
the anti-TB activity of the combination is specif-
ically due to the restoration of ETH sensitivity of
this strain.
We show that drug-resistance to the widely
used antituberculosis drug ETH (36) can be cir-
cumvented by spiroisoxazoline SMARt-420, which
activates cryptic drug-bioactivation pathways in
drug-resistant pathogens. Other ETH activation
pathways may exist inM. tuberculosis, including
the recently described VirS-MymA (37), opening
supplementary avenues for reversing ETH-
resistance and boosting its activity.
Innovative treatment protocols could also be
explored, in which noncontinuous but regular
administration of SMARts to TB patients would
periodically toggle the expression of alternative
bioactivation pathways of pro-drugs. This ap-
proach could be used to limit the frequency of
resistance by systematically destroying subpop-
ulations of resistant bacteria that may emerge
during treatment.
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Fig. 4. Reversion of ETH
resistance in tuberculosis-
infected mice. Mice (five mice
per group) infected with ETH-
resistant bacteria were treated
with the control antibiotic
INH (25 mg/kg), ETH alone
(50 mg/kg), SMARt-420 alone
(50 mg/kg), or a combination of
ETH and SMARt-420. Pulmonary
bacillary loads were enumerated
by colony-forming units (CFUs)
after 3 weeks of treatment.
Administration of up to 50mg/kg
of ETH did not reduce the pul-
monary load of ETH-resistant
mycobacteria, whereas coadmin-
istration of ETH and SMARt-420
showed a dose-dependent reduc-
tion, with a maximum of 4.6 log
(control versus ETH50+SMARt-
420). Details and statistics are
available in “Bonferroni’s multiple
comparison test” in table S6.
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Materials and Methods 
Transcriptomic analysis 
Transcriptomic analys of M. bovis BCG treated or untreated with 25 µM 
BDM41906 or BDM41420 (SMARt-420). 
mRNA extraction/purification. 
Mycobacterium bovis BCG Pasteur 1173P2 was grown at 37°C in 60 mL Sauton 
broth (38) supplemented with 0.001 % ZnSO4 and 0.25 % Triton WR1339 (Sigma) to an 
OD600nm of 0.8. The culture was divided in two; BDM41906 and BDM41420 (SMARt-
420) were added to each part (10 mL) to a final concentration of 25 µM. Incubation was
continued for a further 24 h at 37°C. Mycobacteria were harvested by 10 min
centrifugation at 5,000 g at 4°C, resuspended in 1 mL of RNApro™ (FastRNA® Pro
Blue Kit, MP biomedicals) and homogenized in impact-resistant 2 mL tubes containing
0.1 mm silica spheres (Lysing Matrix B, MP biomedicals) using a FastPrep FP120 cell
disrupter (Thermo Fisher Scientific) at 6.0 m/sec for 40 sec. The ribolysed cells were
centrifuged at 12,000 g to remove cellular debris and RNA was purified following the
manufacturer's instructions. Ribosomal RNA(rRNA) depletion was performed using
magnetic beads (Ribo-Zero rRNA Removal kit-Bacteria; Epicentre) according to the
manufacturer’s protocol. Libraries for Illumina sequencing were prepared with the
TruSeq RNA sample preparation kit version 2.0 rev. A (Illumina Inc.) according to the
manufacturer’s protocol. All cDNA libraries were uniquely indexed. cDNA libraries were
sequenced using an Illumina NextSeq 500 system (Illumina Inc.) in high-output mode
according to the manufacturer’s protocols. All samples were multiplexed on one lane of
the flow cell and sequenced in single-read sequencing mode with reads lengths of 150 bp.
Raw RNA-seq reads were processed with Illumina quality control tools using default
settings. Sequences shorter than 50 bp and/or that contained any ‘Ns’ and/or with a mean
quality score lower than 30 were removed using PRINSEQ
(http://prinseq.sourceforge.net/index.html). Next, residual rRNA-specific reads were
filtered out by mapping all the reads on M. tuberculosis rRNAs sequences using Bowtie2
(http://bowtie-bio.sourceforge.net/bowtie2/index.shtml). Analysis of the RNA sequencing
data was conducted using the Rockhopper open source software package with default
parameters (http://cs.wellesley.edu/~btjaden/Rockhopper/). Rockhopper's RNA
sequencing analysis platform is designed specifically for bacterial organisms. Transcript
abundance levels were quantified using the Reads Per Kilobase per Million mapped reads
(RPKM).
In figure 1.B. Only genes showing a minimum 2-fold change (FC) in transcript 
abundance in at least one condition are shown. Upon treatment of the mycobacteria with 
DMSO (control) or with BDM41906, low expression of BCG_0108c and BCG_0107c 
are shown. 
For RNAseq raw data see the associated compressed folder: Additional "Databases 
S1" deposited in DataDRYAD.org under the doi:10.5061/dryad.mb463 
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Surface Plasmon Resonance (SPR) 
A BIAcore3000 apparatus (BIAcore AB, Uppsala, Sweden) was used for real-time 
analysis of molecular interactions between His6-EthR, His6-EthR2 and the ethA2-R2 
promoter region. 
Production of biotinylated double stranded DNA fragments: A 109-bp fragment 
overlapping the ethA2-R2 intergenic region was obtained by PCR using M. tuberculosis 
H37Rv chromosomal DNA as template and the primer pair OpeRvx1/ OpeRvxbiot1 
(OpeRvx1: 5’-CCTGGGTGCGTCTCTTGATTTC-3’ and OpeRvxbiot1: Biotin-5’-
GCACTAATGTCGATCGTCGACATG-3’. The amplified biotinylated fragment was 
purified on a QIAquick PCR purification Kit column (QIAGEN) before immobilization 
on a flow cell of a sensor Chip SA (GE Healthcare) using the standard protocol provided 
by the manufacturer.  
A 106-bp fragment overlapping the ethA-R intergenic region was obtained by PCR 
using M. tuberculosis H37Rv chromosomal DNA as template and the primer pair 
O270/O271 (O270 : 5’-CGGTCATGGATCCACGCTATCAAC-3’ and O271 : Biotin-5’-
CTGACTGGCCGCGGAGGTGGT-3’). The amplified biotinylated DNA was purified on 
a QIAquick column (QIAGEN) before immobilization on a flow cell of a sensor Chip SA 
(GE Healthcare) using the standard protocol provided by the manufacturer.   
A biotinylated double stranded 113-bp long irrelevant DNA fragment (+14 to +127 
fragment of the E. coli bla gene PCR-amplified from pUC18) was obtained by PCR using 
the primer pair O343/O344 (O343:5’-TTTCCGTGTCGCCCTTATTCC-3’ and O344: 
Biotin-5’-CCACTCGTGCACCCAACTGAT-3’). The amplified biotinylated fragment 
was purified on a QIAquick PCR purification Kit column (QIAGEN) before 
immobilization on a flow cell of a sensor Chip SA (GE Healthcare) using the standard 
protocol provided by the manufacturer.  Briefly, the sensor surface was conditioned with 
three consecutive 1-minute injections of 1M NaCl, 50 mM NaOH before DNA 
immobilization. Several injections of biotinylated relevant or irrelevant DNA at 
0.2µg/mL were performed so as to reach a stable level of 40 Resonance Unit (RU). 
Binding of His6-EthR2 and His6-EthR to the DNA was carried out at 25 °C in HBS-EP 
buffer: 10mM HEPES pH 7.4, 150mM NaCl, 3mM EDTA, 0.005% P20. His6-EthR and 
His6-EthR2 were injected for 3 minutes at the desired concentrations at 20µL/min in the 
running buffer. Based on the dissociation profiles recorded for the various combinations, 
the dissociation flow time was fixed to 5 min. The sensor chip was regenerated by a 30s 
injection of 0.03% SDS followed by 5 min buffer injection for basal signal stabilization. 
Final curves were obtained by subtraction of the signal corresponding to a control flow 
cell functionalized with the irrelevant DNA. 
To measure the capacity of SMARt-420 to inhibit EthR2-DNA interaction, 22.7 nM 
of the purified protein (see Production and purification of His6-EthR2) was incubated 
with serial dilutions of SMARt-420 or BDM41906 (in HBS-EP buffer), placed 5 min at 
37 °C, and injected in BIAcore3000 at a flow rate of 20 µL/min for 3 min. RU were 
measured at the end of the injection period and used to calculate the inhibition of protein-
DNA interaction. Dose response curve of SMARt-420 and BDM41906 were determined 
using GraphPad Prism. RU recorded during the binding EthR2 and DNA in absence of 
SMARt-420 was defined as "100% binding". Maximum efficacy of SMARt-420 was 
obtained at 100 µM (defined as 0% binding on the graph of fig.3B). 
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Thermal Shift Assays 
Thermal Shift Assay on EthR2 
The recombinant M. tuberculosis protein EthR2 (Rv0078) was used at a 
concentration of 10 µM. The fluorescent dye SYPRO® Orange (SigmaAldrich) was used 
to monitor EthR2 unfolding. This dye is environmentally sensitive and leads to an 
increase in fluorescence following exposure of hydrophobic regions during protein 
unfolding. The thermal shift assay was conducted in a Lightcycler 480 (Roche). The 
system contained a heating/cooling device for temperature control and a charge-coupled 
device (CCD) detector for real-time imaging of the fluorescence changes in the wells of 
the microplate. The final sample concentration was 10 µM EthR2, 2.5x SYPRO® 
Orange, 1% DMSO, and 20 µM ligand in the EthR2 buffer (20 mM HEPES, pH 7.5, 300 
mM NaCl, 5% glycerol, 100 mM imidazole). The samples were heated from 37 to 85 °C 
with a heating rate of 0.04 °C/s. The fluorescence intensity was measured at Ex/Em = 
465/510 nm. The data were processed using the algorithmic software Wavemetrics Igor 
by applying the following procedure: The fluorescence intensity of each well/sample is 
plotted as a function of the temperature. Then the 1D numerical derivative of these curves 
is calculated. Finally, the maximum data values, corresponding to the inflection points 
(Tm), are extracted. 
Thermal Shift Assay on EthR 
The procedure was performed in a similar manner than the one described for EthR2. 
Subtraction between the value of the respective Tm obtained with and without addition of 
ligand is defined as ΔTm and was used in the X axis of figure 1.A. 
Production and purification of His6-EthR2 
The DNA coding for EthR2 was amplified by PCR using M. tuberculosis H37Rv 
chromosomal DNA as template and oligonucleotides Rv0078up: 5’-
GAAATCAAGAGACGCACCC-3’ and Rv0078lo: 5’-
TAGCCGTTAAGCATCCCGTCG-3’ as primers. The PCR product was digested with 
NdeI and BamHI, and inserted into pET-15b (Novagen), yielding pET-15b-ethR2. The 
ethR2-encoding fragment was sequenced on both strands. This plasmid encodes EthR2 
containing an amino-terminal tag with the following sequence: 
MGSSH6SSGLVPRGSHM and was introduced into E. coli BL21 (DE3). E. coli BL21 
(DE3) (pET-15b-ethR2) was grown in 2L LB broth to an OD600 nm of 0.6-0.8. 
Isopropylthiogalactoside (IPTG) was added to a final concentration of 1 mM, and the 
culture was grown for an additional 3 hours. The cells were harvested by centrifugation at 
12,000 x g at 4 °C. The pellet was frozen in liquid nitrogen and conserved at -20°C. After 
defrosting, the pellet was re-suspended in 40 mL of lysis buffer (20 mM HEPES, pH 7.5, 
500 mM NaCl, 5% glycerol, 10 mM imidazole, Protease inhibitor cocktail (Roche)) and 
lysed by three passages through a French Pressure cell at 6.2 x 106 Pa. After 
centrifugation (15,000 x g, 30 min, 4 °C), the supernatant was recovered and His6-EthR2 
was separated from the whole-cell lysate using a 5 mL HisTrap affinity chromatography 
columns (GE healthcare). After extensive washing with 10, 20 and 40 mM imidazole in 
lysis buffer, His6-EthR2 was eluted from the resin with 300 mM imidazole in lysis buffer 
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and dialysed overnight against "EthR2-buffer " (20 mM HEPES, pH 7.5, 300 mM NaCl, 
5% glycerol, 100 mM imidazole). Approximately 5.9 mg/mL of purified protein was 
obtained as determined by the NanoVueTM spectrophotometer (GE healthcare) using a 
molar extinction coefficient of ε=20910Lmol-1cm-1). Protein purity was determined by 
Coomassie blue staining after SDS-PAGE on a 12 % polyacrylamide gel. The purified 
protein was stored at – 80 °C until further use. 
Crystal structure of EthR2 in complex with SMARt-420 
EthR2 crystals were obtained by the vapour diffusion method at 293°K using a 
protein sample at 10 mg/mL and the following crystallization solution (200 mM NaCl, 
200 mM Na citrate pH 4.2 and 15% polyethylene glycol monomethylether 5000). An 
iodine derivative for phasing was prepared using in-crystal iodination reaction that 
consisted in incubating a droplet containing EthR2 crystals in iodine vapour overnight at 
a temperature of 293°K. The iodinated EthR2 structure was then solved by Iodine-Single 
wavelength Anomalous Dispersion method (I-SAD). The structure of EthR2 was 
obtained in the absence of SMARt-420 (an unliganded form), by molecular replacement 
using the iodinated structure as search model. The structures of iodinated and unliganded 
EthR2 were deposited in the Protein Data Bank under accession codes 5n1c and 5n1i, 
respectively. Crystals of the complex EthR2/SMARt-420 were then prepared by soaking 
EthR2 crystals for ~1 min in the crystallization buffer containing 1 mM of SMARt-420. 
The X-ray diffraction data were collected on a Pilatus 6M detector using synchrotron 
radiation on the ESRF-ID23 beamline. Indexing was performed using the XDS 
program(39).The structure of the complex was solved by molecular replacement with 
MOLREP (40) using the unliganded structure of EthR2 as search model. The structure 
was refined with REFMAC5 (41) at 2.40 Å resolution. Initially SMARt-420 was 
automatically fitted in the electron density using FINDLIGAND tool of the CCP4 
software suite (42) and then manually positioned using Coot (43). Geometrical and 
chemical restraints of SMARt-420 were generated from the SMILES string using 
LIBCHECK. The final R and Rfree values are 21.2% and 26.0%, respectively. Data 
collection and refinement statistics are shown inTable S2. The refined coordinates and 
the structure factors were deposited in the Protein Data Bank under the accession number 
5icj. 
The omit map shown in figure 2D of the manuscript was obtained by removing 
ligand from the structure, then randomly shaking up all coordinates by a small amount 
(between 0 and 0.3 Å) with PDBSET program and finally running 20 cycles of 
refinement with REFMAC5. 
Mammalian SEAP reporter assay 
Vector design. A chimeric mammalian transcriptional regulator was constructed by 
fusing the coding sequence of EthR2 (Rv0078) from Mycobacterium tuberculosis to the 
Herpes simplex derived transactivator protein VP16. The resulting ORF was sequence-
optimized for expression in human/mouse, synthesized (Genscript) and introduced into 
pSEAP2-control (Clontech) using EcoRI/XbaI to generate the expression vector pCK289 
(PSV40-EthR2-VP16-HA-pA).  To enable EthR2-VP16 based transcriptional control, we 
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designed a synthetic DNA by fusing the 61 nucleotide spanning intergenic region of 
ethA2 (Rv0077c) and ethR2 (Rv0078) upstream of a minimal variant of the human 
cytomegalovirus derived promotor (PhCMVmin). This synthetic promoter was cloned into 
pSEAP2-basic (Clontech) by restriction (XhoI/EcoRI) and ligation to generate pCK287 
(OEthR2-PhCMVmin-SEAP-pA), which enables EthR2-VP16 based control of human 
placental secreted alkaline phosphatase (SEAP) expression. 
Cell culture. Baby hamster kidney cells (BHK-21, American Type Culture 
Collection CCL-10) were cultured in Dulbecco’s modified Eagle’s medium (DMEM, 
Gibco, catalog no. 41966) supplemented with 10% (v/v) heat-inactivated fetal bovine 
serum (FBS, Gibco, catalog no. 10500) and 1% (v/v) penicillin/streptomycin (Gibco, 
catalog no. 15140) in a humidified atmosphere with 5% CO2 at 37°C. Prior to 
transfection, cells from a confluent grown culture dish were split 1:2 to a new petri dish 
and grown for 16hours. For transfection, 10µg of total plasmid DNA (5µg pCK287 and 
5µg pCK289, ratio 1:1) were added to 1mL Opti-MEM reduced serum medium (Gibco, 
catalog no. 11058021), mixed with 30µL MegaTran 1.0 transfection reagent (Origene, 
catalog no. TT200003) and incubated for 15min at room temperature. The DNA mix was 
transferred to the cells and incubated for 6h for plasmid uptake. The cells were detached 
from the plate with 0.05% trypsin-EDTA (Gibco, catalog no. 25300), counted and diluted 
to 500.000 cells/mL using fresh culture medium. Hundred microliter of cell suspension 
was dispersed per well of a 96 well culture dish. Compound dilutions were prepared by 
adding 1.2µL compounds (10mM stock solution in DMSO) to 600µL culture medium, 
1:2 dilution rows were prepared, and 100µL of compound dilutions were finally added to 
the cells. After incubation for 48h the SEAP expression was quantified from cell culture 
supernatants using a p-nitrophenyl phosphate based method (44). 
Intracellular Assay 
The detailed procedure is described in Delorme et al. (45). Briefly, Raw264.7 
macrophages (108 cells) were infected with an H37Rv-GFP suspension at a multiplicity 
of infection (MOI) of 1:1 in 300 mL for 2 h at 37 °C with shaking (100 rpm). After two 
washes by centrifugation at 1100 rpm for 5 min, the remaining extracellular bacilli were 
killed by a 1 h amikacin (20 µM, Sigma, A2324-5G) treatment. After a final 
centrifugation step, 40 µL of M. tuberculosis H37Rv-GFP colonized macrophages were 
dispensed with a Wellmate (Matrix) into 384-well Evotec plates pre-plated with 10 µL of 
compound-mixture diluted in cell medium and incubated for 5 days at 37 °C, 5% CO2. 
Macrophages were stained with SYTO 60 (Invitrogen, S11342) for 1 h followed by plate 
sealing. Confocal images were recorded on an automated fluorescent ultra-high-
throughput microscope Opera (PerkinElmer). Images were acquired with a 20x water-
immersion objective (NA = 0.70). A double laser excitation (488 and 635 nm) and 
dedicated dichroic mirrors were used to record green fluorescence of mycobacteria and 
red fluorescence of the macrophages on two independant cameras. A series of four 
pictures at the center of each well were taken, and each image was then processed using 
dedicated image analysis (Acapella Studio, Perkin Elmer). The percentage of infected 
cells and the number of cells are the two parameters extracted from image analysis as 
previously reported (45). Reported data are the average of two replicates.  
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Extracellular potency Assay of Test Compounds on M. tuberculosis (Ethionamide 
Concentration Fixed at 0.1 µg/mL, Serial Dilution of Test-Compounds).  
Ethionamide (Sigma, E6005-5G) was diluted in DMSO at 0.1 mg/mL, and aliquots were 
stored frozen at −20 °C. Test-compounds were resuspended in DMSO at a concentration 
of 10 µM. Ethionamide and test-compounds were transferred to a 384-well low-volume 
polypropylene plate (Corning, no. 3672) and used to prepare essay plates. Briefly, ten 3-
fold serial dilutions of compounds were performed into black Greiner 384-well clear 
bottom polystyrene plates (Greiner, no. 781091) using an Echo 550 liquid Handler 
(Labcyte). DMSO volume was compensated so that the concentration across all wells 
was equal (0.3%).  Two independent replicates were made for each setting. Finally an 
equal volume of ethionamide (final concentration 0.1 µg/ml) was transferred to one of the 
384-well replicates, using Echo. On the day of the experiment, 50 !L of M. tuberculosis-
GFP culture diluted to an OD600 nm of 0.02 was transferred to each assay plate and
incubated at 37ºC for 5 days. Fluorescent signal were acquired on a Victor multilabel
plate reader (PerkinElmer), using exc=485nm/em=535nm.
Synthesis of SMARt-420 (BDM41420) 
Chemical pathway: 
a) Synthesis of tert-butyl 3-phenyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-8-
carboxylate (1). 
 (E)-benzaldehyde oxime (2.77 ml, 25.34 mmol) was solubilized in dichloromethane 
(100 ml) and dimethylformamide (8 ml) was added. N-Chlorosuccinimide (3.72 g, 27.88 
mmol) was added portion-wise over 30 min to the stirred mixture at 0°C. Tert-butyl 4-
methylenepiperidine-1-carboxylate (5 g, 25.34 mmol) was then added to the mixture 
followed by the slow addition of triethylamine  (10.61 ml, 76.03 mmol).  The resulting 
solution was stirred at room temperature for 24 hours. After completion, the mixture was 
quenched with 1N HCl. The organic layer was extracted with DCM (2x100mL) then 
dried over magnesium sulfate, filtered and concentrated in vacuo. The crude residue was 
purified by flash column chromatography using cyclohexane / AcOEt as eluent to afford 
4.3 g (50.8%) of tert-butyl 3-phenyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-8-carboxylate. 
NMR 1H (CD2Cl2, 300 MHz) δ(ppm) 1.48 (s, 9H, CH3 Boc), 1.72-1.93 (m, 4H, 
CH2), 3.13 (s, 2H, CH2 isoxazoline), 3.41-3.72 (m, 4H, CH2), 7.44 (m, 3H, HAr), 7.67 
(m, 2H, HAr). NMR 13C (CD2Cl2, 75 MHz) δ (ppm)  28.2 (CH3 Boc), 35.8, 45.0 (CH2 
pip), 79.3 (Cq Boc), 84.5 (CH2 isoxazoline), 126.4, 126.7, 129.9, 130.1 (CAr), 154.4 
(C=O Boc), 156.2 (C=N). LC-MS : [M-tBu+H]+ 261, purity >99%. 
NBoc
ON
H
N
OH
N
ON
O
CF3
a) b)
1 BDM41420
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b) Synthesis of 4,4,4-trifluoro-1-(3-phenyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-
yl)butan-1-one BDM41420 (SMARt-420). 
Tert-butyl 3-phenyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-8-carboxylate (4.09 g, 
12.92 mmol) was solubilized in dichloromethane (20 ml). Trifluoroacetic acid (20 ml, 
261.35 mmol) was added dropwise. After completion, the mixture was quenched with 
aqueous saturated sodium carbonate solution. The organic layer was extracted with DCM 
(2x25 mL) and concentrated in vacuo. The resultant crude oil was then diluted in DMF. 
HBTU (7.35 g, 19.39 mmol) and  4,4,4-Triflurobutanoic acid (1.84 g, 12.92 mmol) were 
added to the stirred solution followed by a dropwise addition of DIEA (3.35 ml, 19.39 
mmol). The mixture was stirred at room temperature for 24 hours. The resulting crude 
mixture was quenched with 100 ml saturated NH4Cl and 100 ml Methyl tert-butyl ether 
(MTBE). The aqueous layer was then extracted with MTBE (3x100 ml). The organic 
layers were collected and evaporated in vacuo. The resulting oil was recrystallized using 
diethyl ether and isopropanol to yield 3.57 g of 4,4,4-trifluoro-1-(3-phenyl-1-oxa-2,8-
diazaspiro[4.5]dec-2-en-8-yl)butan-1-one. 
NMR 1H (CD2Cl2, 300 MHz): δ(ppm) 1.72-1.83 (m, 2H), 1.90-2.04 (m, 2H), 2.45-
2.61 (m, 4H), 3.16 (s, 2H), 3.42 (m, 1H), 3.56 (m, 2H), 4.18 (m, 1H), 7.47 (m, 3H), 7.70 
(m, 2H). NMR 13C (CD2Cl2, 75 MHz): δ(ppm) 25.8, 29.5 (q, J=29.1Hz), 35.5, 36.2, 39.0, 
42.4, 45.3, 84.0, 126.4, 127.6 (q, J=273.7 Hz), 128.7, 130.0, 156.3, 167.8. [M+H]+ 342, 
purity > 95%. 
M. tuberculosis strain E1
The M. tuberculosis strain E1 used in the animal experiment (see fig.4), in experiment S2 
and in experiment S4 is a derivative of the Beijing strain W4 that carries a Gly343Ala 
mutation in EthA, which causes resistance to ethionamide (MIC > 32µg/mL measured by 
MGIT960). 
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Antibiotic profile and lineage of the M. tuberculosis clinical strains used in this study. 
Threshold concentrations above which bacteria are considered clinically resistant are 
indicated in parenthesis. The drug sensitivity status of each strain is reported, S 
(Sentitive) meaning "under the threshold concentration", and R (Resistant) meaning 
"above the threshold concentration". Specifically, for ETH, Minimal Inhibitory 
Concentrations have been defined by MGIT960 and are reported (values in µg/mL). 
Bacteria are considered sensitive (greenbox) when MIC is bellow 5µg/mL, and resistant 
(red box) when MIC is above this value. 
TB 
strains 
INH 
(0.1 µg/ml) 
RIF 
(1 µg/ml) 
EMB 
(5 µg/ml) 
OFL 
(1 µg/ml) 
AMI 
(1 µg/ml) 
ETH 
(5 µg/ml) 
EthA status 
Strain lineage 
H37Rv S S S S S 2 wt Euro-American 
L4376 R R R 4 wt nd 
LPN30 R R n 2 nd nd 
L1094 R R R 2 wt nd 
P591 R R 
 
2 nd nd 
L0578 R R S 1 wt nd 
B1166 R R R S R 64 wt Beijing 
B1196 R R S S S 32 wt CAS1_DELHI 
B1004 R R R R R 32 wt Beijing 
B1304 R R S S S 32 wt Beijing 
P379 R R 
   
32 wt nd 
B1001 R R R S S 32 wt Beijing 
B0383 R R S S S 16 wt Haarlem2 
B0391 R R R R R 8 wt Beijing 
B0089 R R R S S 8 wt T1 
LPN4 R R 
 
8 wt nd 
P395 R R S 8 wt nd 
P359 R R S 8 wt nd 
P351 R R 
   
8 wt nd 
B1150 R R R R S 256 P230Q Beijing 
B1602 R R R R R 256 R239G LAM9 
B0775 R R R S S 256 Δa110 Beijing 
B0057 R R R S S 64 Δa110 CAS1_DELHI 
L3556 R R 
   
64 Q165P nd 
B0467 R R R S S 64 wt Beijing 
L0728 R R R 64 ins.c357 nd 
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Fig. S1. 
Extended controls on the Mammalian reporter assay 
These additional data compares the SEAP activity in BHK-21 cells transfected with 
pCK287 (containing the DNA intergenic region of ethA2-ethR2), in combination with 
either pCK289 (expressing the EthR2-VP16 complex) or the equivalent empty vector (no 
EthR2-VP16). These two type of cells were treated with either DMSO (white bars), 10 
µM BDM41420 (SMARt-420) (Black bars) or 10 µM BDM41906 (Grey bars). This 
additional control shows that SMARt-420 inhibits SEAP activity almost as completely as 
the one measured in cells that do not contain the transactivating complex EthR2-VP16. 
On the contrary, BDM41906 has no detectable effect, confirming the specificity of 
interaction of SMARt-420 with EthR2. Graphs show the average of two independent 
experiments. 
Sixteen hours prior infection, 20.000 BHK-21 cells were seeded in 200µL medium to a 
96 well plate. For transfection, 10µg of total plasmid DNA (5µg pCK287 were mixed 
with 5µg pCK289 or empty control vector pcDNA3.1, ratio 1:1) were added to 1mL 
Opti-MEM reduced serum medium (Gibco, catalog no. 11058021), mixed with 30µL 
MegaTran 1.0 transfection reagent (Origene, catalog no. TT200003) and incubated for 
15min at room temperature. Twenty microliter of the DNA mixes were transferred to the 
cells and incubated for 6h for plasmid uptake. The medium discarded and replaced by 
fresh medium containing DMSO, 10µM BDM_41420 or BDM_41906, respectively. 
SEAP expression was determined after 48h of expression. 
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Fig. S2 
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Multidimentionnal SAR in the Spiroisoxazoline family. Graphs of correlation between 
thermal shift assay (ΔTm, see fig. 2C), DNA binding assay (pIC50, SEAP reporter assay, 
see fig. 3A), and boosting effect on bacteria (pEC50, as described in Section Material and 
Methods – Extracellular potency assay) for 5 direct analogues of SMARt-420 
(BDM41420).  
Graph A shows that the capacity of these 5 compounds to boost ETH in H37Rv (pEC50) 
correlates with their binding efficacy to EthR2 (ΔTm), whereas no correlation is observed 
for EthR (Graph B). Graph C shows that mutation in EthA (TB strain E1, see description 
in Material and methods) do not modify this correlation. Graph D shows that the 
inhibition of the binding capacity of EthR2 onto its DNA operator (pIC50) by these 5 
compounds is correlated with their ETH-boosting effect. More precisely, introduction of 
a chlorine atom on the ortho-position of the phenyl ring (BDM41931) does not impair 
activity, while substitution of the para-position with a methyl group (BDM41781) leads 
to a decrease of activity.  
These observations are in accordance with the X-ray structure of the EthR2/SMARt-420 
complex. Replacement of the phenyl ring with thiophenyl (BDM41774), or pyridinyl 
(BDM41778) and cyclopropyl (BDM41787) motifs leads to a loss of activity. 
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Fig. S3 
Effect of the overexpression of inhA onto the boosting effect of SMARt-420. The test 
is performed with an H37Rv derivative expressing GFP (H37Rv-GFP). FLU are arbitrary 
Units of Fluorescence measured after 5 days of growth, as described in Delorme et al.  
(45). Dose response curves ("Log cc" is the log of the concentration) of ETH (upper 
graph in black) versus ETH + fix dose (10 µM) of SMARt-420 (lower graph in red) 
measured on M. tuberculosis overexpressing InhA (pMV261-inhA) and on M. 
tuberculosis (empty plasmid pMV261). Black curves show that, as expected, 
overexpressing inhA impacts on the MIC of ETH. Red curves show that SMARt-420 
reduces the MIC of ETH (open red triangles) and that overexpression of inhA impact on 
this MIC (plain red triangles). Altogether, these data strongly suggest that the 
bioactivation of ETH mediated by SMARt-420 keeps targeting InhA.  
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Fig. S4 
Dose response curve (DRC) of SMARt-420 alone (plain squares) or in the presence 
of a fix dose ETH (0.8 µg/mL) (plain triangles). The E1 strain (mutated in EthA) is 
resistant to high doses of ETH ( > 25 µg/mL). This DRC of SMARt-420 was done in the 
presence of a sub-inhibitory dose of ETH (0.8 µg/mL). The dose of SMARt-420 that 
allows ETH at 0.8 µg/mL to inhibit the growth of the E1 strain is defined as the 
"Effective Concentration 50% " (EC50). Under such conditions, the EC50 of SMARt-420 
was determined as 1.7 10-7M. FLU are arbitrary Units of Fluorescence measured after 5 
days of growth 
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Fig. S5 
Dose response curve of SMARt-420 alone (plain circles) or in the presence of a fixed 
dose ETH (0.1 µg/mL) (plain diamonds). Compounds were tested for the antibacterial 
activity against H37Rv-GFP as previously described (45). FLU are arbitrary Units of 
Fluorescence measured after 5 days of growth 
Log Conc. (M)
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U
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Table S1. 
ID_STRUCTURE Tm(EthR) Tm (+ligand) Unit deltaTM EC50 pEC50 
BDM_14801 62.26 68.24 °C 5.98 1.20E-06 5.92E+00 
BDM_31343 62.11 65.67 °C 3.56 4.70E-06 5.33E+00 
BDM_31344 62.11 70.07 °C 7.96 2.00E-07 6.70E+00 
BDM_31368 62.11 67.41 °C 5.3 2.50E-06 5.60E+00 
BDM_31369 61.35 70.48 °C 9.13 1.00E-07 7.00E+00 
BDM_31371 62.81 71.26 °C 8.45 1.00E-07 7.00E+00 
BDM_31372 62.11 68.04 °C 5.93 3.00E-07 6.52E+00 
BDM_31377 62.11 70.62 °C 8.51 4.00E-07 6.40E+00 
BDM_31381 60.67 71.12 °C 10.45 1.00E-07 7.00E+00 
BDM_41154 62.25 67.29 °C 5.04 2.00E-05 4.70E+00 
BDM_41182 62.25 69.4 °C 7.15 1.30E-06 5.89E+00 
BDM_41183 62.25 68.75 °C 6.5 1.30E-06 5.89E+00 
BDM_41231 62.25 69.65 °C 7.4 5.00E-07 6.30E+00 
BDM_41231 62.31 71.28 °C 8.97 5.00E-07 6.30E+00 
BDM_41269 60.67 66.96 °C 6.29 3.20E-06 5.49E+00 
BDM_41272 60.67 69.19 °C 8.52 8.00E-07 6.10E+00 
BDM_41273 60.67 67.27 °C 6.6 1.00E-06 6.00E+00 
BDM_41280 60.67 68.28 °C 7.61 1.00E-06 6.00E+00 
BDM_41281 60.67 70.41 °C 9.74 4.00E-07 6.40E+00 
BDM_41323 60.67 65.44 °C 4.77 1.00E-05 5.00E+00 
BDM_41325 62.81 73.18 °C 10.37 2.00E-07 6.70E+00 
BDM_41329 62.81 67.72 °C 4.91 5.70E-06 5.24E+00 
BDM_41330 60.67 66.45 °C 5.78 6.30E-06 5.20E+00 
BDM_41425 62.31 69.68 °C 7.37 5.00E-07 6.30E+00 
BDM_41437 62.81 70.01 °C 7.2 2.50E-06 5.60E+00 
BDM_41471 62.81 71.06 °C 8.25 2.50E-06 5.60E+00 
BDM_41523 62.81 71.87 °C 9.06 6.30E-06 5.20E+00 
BDM_41701 61.35 67.08 °C 5.73 2.10E-06 5.68E+00 
BDM_41702 61.35 70.51 °C 9.16 1.10E-06 5.96E+00 
BDM_41711 61.35 69.34 °C 7.99 1.00E-06 6.00E+00 
BDM_41715 61.35 69.57 °C 8.22 7.90E-06 5.10E+00 
BDM_41719 61.35 69.52 °C 8.17 1.00E-05 5.00E+00 
BDM_41722 61.35 68.92 °C 7.57 1.00E-05 5.00E+00 
BDM_41726 61.35 69.72 °C 8.37 1.00E-05 5.00E+00 
BDM_41732 61.35 69.76 °C 8.41 1.00E-05 5.00E+00 
BDM_41734 61.35 69.84 °C 8.49 2.20E-06 5.66E+00 
BDM_41736 61.35 68.98 °C 7.63 2.30E-06 5.64E+00 
BDM_41746 61.35 67.44 °C 6.09 4.30E-06 5.37E+00 
BDM_41752 61.35 69.83 °C 8.48 9.30E-06 5.03E+00 
BDM_41773 61.35 66.4 °C 5.05 4.00E-06 5.40E+00 
BDM_41906 62.31 73.5 °C 11.19 6.00E-08 7.22E+00 
BDM_41946 62.31 72.02 °C 9.71 1.00E-05 5.00E+00 
BDM_41948 62.31 72.08 °C 9.77 4.00E-06 5.40E+00 
BDM_41950 62.31 71.6 °C 9.29 8.00E-07 6.10E+00 
BDM_41952 62.31 68 °C 5.69 6.30E-06 5.20E+00 
BDM_41955 62.31 70.69 °C 8.38 7.90E-06 5.10E+00 
BDM_41956 62.84 72.13 °C 9.29 2.90E-07 6.54E+00 
BDM_43125 62.84 71.32 °C 8.48 1.20E-06 5.92E+00 
BDM_43266 66.35 77.86 °C 11.51 8.00E-08 7.10E+00 
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BDM_31827 65.06 75.7 °C 10.64 2.10E-07 6.68E+00 
BDM_32024 62.84 71.83 °C 8.99 3.40E-07 6.47E+00 
BDM_31883 66.35 71.5 °C 5.15 2.20E-06 5.66E+00 
BDM_41774 61.35 63.45 °C 2.1 3.00E-08 7.52E+00 
BDM_41776 61.35 62.74 °C 1.39 4.00E-08 7.40E+00 
BDM_41420 61.35 63.08 °C 1.73 2.00E-08 7.70E+00 
BDM_41781 61.35 62.99 °C 1.64 2.50E-06 5.60E+00 
BDM_41938 62.31 63.59 °C 1.28 2.00E-08 7.70E+00 
BDM_41931 66.29 66.97 °C 0.68 3.00E-08 7.52E+00 
BDM_43100 62.84 64.27 °C 1.43 2.00E-08 7.70E+00 
Thermal shift values and EC50 from Intracellular Assay (described in Materials and 
Methods) presented in Fig. 1A 
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Table S2. 
I-derivative unliganded SMARt-420 
PDB Accession number 
Data Collection(a) 
5n1c 5n1i 5icj 
X-ray generator Rigaku CuKα Soleil-proxima1 ESRF-ID23 
Detector Saturn944+ Pilatus 6M Pilatus 6M 
Crystal-to-detector distance (mm) 70.00 344.6 312.9 
Wavelength (Å) 1.5418 0.98011 0.97934 
Number of images 1080 1000 720 
Oscillation width (°) 1.0 0.2 0.5 
Space group P212121 P212121 P212121 
Unit cell parameters (Å) 59.7; 74.9; 87.5 59.6; 74.1; 89.1 59.8; 74.2; 88.1 
Resolution range (Å) 60.0-2.6 
(2.67-2.60) 
50.0-2.4 
(2.54-2.40) 
60.0-2.4        
(2.54-2.40) 
Completeness (%) 99.6 (98.9) 99.0 (94.7) 99.8 (98.8) 
No. of unique reflections 12520 (901) 16231 (2440) 15892 (2494) 
Redundancy 38.5 (26.2) 7.0 (7.1) 12.8 (13.1) 
Rmeas
(b) 0.234 (1.7) 0.083 (0.83) 0.121 (1.11) 
<I/σ(I)>(c) 19.3 (2.6) 14.5 (2.5) 19.2 (2.8) 
CC1/2
(d) 0.999 (0.70) 0.999 (0.88) 0.999 (0.85) 
Wilson B factor (Å2) 49.3 60.4 52.2 
Refinement data statistics 
     Resolution limits (Å) 57.1-2.6 38.4-2.4 37.9-2.4 
     Number of reflections(e) 11878(626) 15361(809) 15053(793) 
     Number of refined atoms 
protein 2911 2861 2783 
water 6 4 3 
iodine 9 0 0 
ligand 0 0 48 
     Final Rwork
(f)/Rfree
(g) (%) 24.3/30.8 22.2/26.9 21.2/26.0 
RMSD bond lengths (Å) 0.012 0.012 0.013 
RMSD bond angles (°) 1.553 1.515 1.578 
Overall mean B factor (Å2) 
protein 48.8 60.8 50.0 
 ligand - - 61.5 
solvent 31.2 50.0 48.0 
MolProbity statistics 
    Ramachandran favoured (%)(h) 97.4 99.7 100.0 
    Ramachandran outliers (%)(h) 0.0 0.0 0.0 
Clash score all-atom 5.32 (99th) 3.64 (99th) 2.67 (100th) 
MolProbity score 1.80 (99th) 1.15 (100th) 1.32 (100th) 
(a)For data-collection, the numbers in parentheses represent values for the highest resolution shell.
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(b) Rmeas = ∑hkl [N/(N -1)] 
½ ∑i |Ii(hkl) - <I(hkl)>|/∑hkl ∑i Ii(hkl) , is the multiplicity (N) independent Rmerge,
where Ii is the intensity of the ith observation and <I> is the mean intensity of the reflections.
(c) <I/σ(I)> = mean of I/σ(I)of unique reflections.
(d) The mean intensity correlation coefficient of half-datasets.
(e) Numbers in parentheses are the number of reflections in the free set.
Data collection and refinement statistics for X-ray data. "I-derivative" stands for EthR2 
iodinated derivative,  "unliganded" stands for the unliganded form of EthR2, "SMARt-
420" stands for the form of EthR2 liganded with SMARt-420.  
Table S3. 
See separated associated file. 
Locus Rv0077-Rv0078 of ETHr and ETHs clinical isolates. Snip analysis in Casali's 
dataset of ETH sensitive and ETH resistant clinical isolates. See interpretation of the data 
in the main text. Genomes analyzed in this work are from strains described in Casali et al 
(30). 
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Table S4. 
AB + No cpd (1) AB + cpd at 0.3 µM AB + cpd at 2.5 µM 
 MIC90 
(M) 
 MIC90 
(M) 
 MIC90 
(M) 
MOX 6.53E-08 MOX + BDM41906 9.12E-08 MOX + BDM41906 9.37E-08 
MOX + SMARt-420 8.59E-08 MOX + SMARt-420 9.35E-08 
LNZ 4.03E-07 LNZ + BDM41906 3.92E-07 LNZ  + BDM41906 3.88E-07 
LNZ + SMARt-420 3.77E-07 LNZ + SMARt-420 3.98E-07 
TMC207 1.52E-07 TMC207 + BDM41906 5.17E-07 TMC207  + BDM41906 3.75E-07 
TMC207 + SMARt-420 4.09E-07 TMC207 + SMARt-420 4.05E-07 
EMB 3.89E-06 EMB + BDM41906 3.32E-06 EMB  + BDM41906 3.28E-06 
EMB + SMARt-420 3.30E-06 EMB + SMARt-420 3.29E-06 
PA284 2.81E-07 PA284 + BDM41906 1.30E-07 PA284  + BDM41906 1.24E-07 
PA284 + SMARt-420 1.25E-07 PA284 + SMARt-420 1.35E-07 
INH 7.63E-07 INH + BDM41906 3.28E-07 INH  + BDM41906 1.91E-07 
INH + SMARt-420 3.10E-07 INH + SMARt-420 2.70E-07 
Effect of SMARt-420 onto the MIC of anti-TB compounds other than ETH. To 
verify the specificity of action of BDM41906 and SMARt-420, these compounds were 
tested in combination with Moxifloxacin, Linezolid, Bedaquiline, Ethambutol, PA824, 
Isoniazid against H37Rv-GFP, as previously described (45). Neither BDM41906 nor 
SMARt-420 changed significantly the MIC90 of these antibiotics. (1) "AB" stands for 
antibiotics and "cpd" means compound BDM41906 or SMARt-420 
MIC have been determined using MGIT Bactec 960. 
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Table S5. 
  SMARt-420 MW 340.4 g/mol 
Solubility 44 µg/mL 
Human Clint 0.6 µL.min
-1/mg 
Mouse Clint 98 µL.min
-1/mg 
AUC* 2.63 µg.h/mL 
Cmax* 4.9 µg/mL 
t1/2 19 min 
A-B permeability 75.7 10-6 cm/s 
B-A permeability 29.4 10-6 cm/s 
t1/2 human plasma >24h
*PO @ 30 mpk
Pharmacokinetic profile of SMARt-420. The cyclodextrine vehicle-solution was 
prepared by dissolving 4.015 g of HP-β-CD (MW=1481 g.mol-1; Roquette, France) in 8 
mL of milliQ-H2O. The solution was sonicated until complete transparency was reached 
and filtered on PTFE 0.2µm. The preparation of a stock solution of SMARt-420 was 
made as follow: 3.13 mg of SMARt-420 was transferred in 2 mL tubes containing 1 mL 
of the cyclodextrine vehicle-solution. Tubes were sonicated for 4 min and shaken (1000 
rpm) at 50°C for 4h. 200 µL of this solution were given to mice, which correspond to ±30 
mg.kg-1 for 20g mice. 
Seven Groups of Swiss female mice (SPF OF1) (18-21 g) were given 200 µL of SMARt-
420 orally at 30 mg.kg-1. Replicates of three mice were anesthetized with ketamine-
xyalzine and bled at 10, 20, 30, 60,120, 240 and 480 minutes after administration of a 
single dose of SMARt-420. Blood was collected from the brachial vein. Blood samples 
were centrifuged (5000 g, 15 min) for plasma separation, and the serum was subjected to 
LC-MS/MS analysis. The LC-MS/MS system used was a UPLC I Class – Xevo TQD. 
Analytes in incubation mixtures were separated by HPLC using an Acquity BEH C18 
50x2.1mm, 1.7µm column. The mobile phase solvents used were: (A) 0.1% formic acid 
in water; (B) 0.1% formic acid in acetonitrile. The injection volume was 1 µl, and the 
flow rate was 0.6 mL/min. 
The facilities conformed to Directive 86/609/EEC on the Protection of Animals Used for 
Experimental and Other Scientific Purposes and norms published in the European 
Council ETS123 Appendix A. Facilities and procedures complied with the Belgian Law 
of 14th of August 1986 on animal protection and welfare. Training of experimental 
leaders, bio-technicians and animal caretakers was in accordance with Royal decree of 
13/9/2004, which specifies the training of persons working with laboratory animals. All 
animal experimentation and procedures were validated and approved by the Local Ethics 
Committee (IPH – Pasteur – VAR), which answers to the National Deontological 
Committee. The animal facilities and procedures were under the supervision of an expert 
on animal welfare in accordance with the Belgian Ministry of Health.  
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Table S6. 
log of CFU in the 
lungs 
after 3 weeks of 
treatment 
(7d/week) 
Control INH25 420L50 ETH50 ETH25 ETH50+4
20L50 
ETH25+4
20L50 
ETH10+4
20L50 
6.84 2.4 6.51 5.58 7.03 2.3 4.11 4.93 
6.97 2.4 6.61 5.94 6.81 0 (exclu.) 3.18 5.29 
6.9 2.54 6.56 6.07 6.95 2.95 3.96 5.56 
6.85 2.6 6.38 5.61 6.66 2.9 4.18 4.93 
6.62 2.3 6 5.57 6.08 2.9 2.9 5.28 
Control INH25 420L50 ETH50 ETH25 ETH50+4
20L50 
ETH25+4
20L50 
ETH10+4
20L50 
Number of Mice 5 5 5 5 5 4 5 5 
Minimum 6.6 2.3 6 5.6 6.1 2.3 2.9 4.9 
25% Percentile 6.7 2.4 6.2 5.6 6.4 2.5 3 4.9 
Median 6.9 2.4 6.5 5.6 6.8 2.9 4 5.3 
75% Percentile 6.9 2.6 6.6 6 7 2.9 4.1 5.4 
Maximum 7 2.6 6.6 6.1 7 3 4.2 5.6 
Mean 6.8 2.4 6.4 5.8 6.7 2.8 3.7 5.2 
Std. Deviation 0.13 0.12 0.25 0.23 0.38 0.31 0.59 0.27 
Std. Error 0.059 0.054 0.11 0.1 0.17 0.15 0.26 0.12 
Lower 95% CI 6.7 2.3 6.1 5.5 6.2 2.3 2.9 4.9 
Upper 95% CI 7 2.6 6.7 6 7.2 3.3 4.4 5.5 
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Statistical Analysis: One-way analysis of variance 
  P value < 0.0001 
  P value summary **** 
  Are means signif. different? (P < 0.05) Yes 
  Number of groups 8 
  F 151 
  R square 0.97 
ANOVA Table SS df MS 
  Treatment (between columns) 106 7 15 
  Residual (within columns) 3.1 31 0.1 
  Total 109 38 
Bonferroni's Multiple 
Comparison Test 
Mean 
Diff. 
t Significant? 
P < 0.05? 
Summary 95% CI of 
diff 
  Control vs INH25 4.4 22 Yes **** 3.7 to 5.1 
  Control vs 420L50 0.42 2.1 No ns -0.26 to 1.1
  Control vs ETH50 1.1 5.4 Yes *** 0.40 to 1.8 
  Control vs ETH25 0.13 0.65 No ns -0.55 to 0.81
  Control vs ETH50+420L50 4.1 19 Yes **** 3.3 to 4.8 
  Control vs ETH25+420L50 3.2 16 Yes **** 2.5 to 3.9 
  Control vs ETH10+420L50 1.6 8.2 Yes **** 0.95 to 2.3 
  INH25 vs 420L50 -4 20 Yes **** -4.6 to -3.3
  INH25 vs ETH50 -3.3 17 Yes **** -4.0 to -2.6
  INH25 vs ETH25 -4.3 21 Yes **** -4.9 to -3.6
  INH25 vs ETH50+420L50 -0.31 1.5 No ns -1.0 to 0.41
  INH25 vs ETH25+420L50 -1.2 6.1 Yes **** -1.9 to -0.53
  INH25 vs ETH10+420L50 -2.8 14 Yes **** -3.4 to -2.1
  420L50 vs ETH50 0.66 3.3 No ns -0.026 to 1.3
  420L50 vs ETH25 -0.29 1.5 No ns -0.98 to 0.39
  420L50 vs ETH50+420L50 3.6 17 Yes **** 2.9 to 4.4 
  420L50 vs ETH25+420L50 2.7 14 Yes **** 2.1 to 3.4 
  420L50 vs ETH10+420L50 1.2 6.1 Yes **** 0.53 to 1.9 
  ETH50 vs ETH25 -0.95 4.8 Yes ** -1.6 to -0.27
  ETH50 vs ETH50+420L50 3 14 Yes **** 2.3 to 3.7 
  ETH50 vs ETH25+420L50 2.1 10 Yes **** 1.4 to 2.8 
  ETH50 vs ETH10+420L50 0.56 2.8 No ns -0.13 to 1.2
  ETH25 vs ETH50+420L50 3.9 19 Yes **** 3.2 to 4.7 
  ETH25 vs ETH25+420L50 3 15 Yes **** 2.4 to 3.7 
  ETH25 vs ETH10+420L50 1.5 7.5 Yes **** 0.82 to 2.2 
  ETH50+420L50 vs ETH25+420L50 -0.9 4.3 Yes ** -1.6 to -0.18
  ETH50+420L50 vs ETH10+420L50 -2.4 11 Yes **** -3.2 to -1.7
  ETH25+420L50 vs ETH10+420L50 -1.5 7.7 Yes **** -2.2 to -0.85
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Pharmacodynamic of SMARt-420 in combination with ETH on mice infected with 
ETH-resistant M. tuberculosis. One week after infection (with 104 mycobacteria), either 
with strain H37Rv (control) or with strain E1 (see Materials and Methods), the mice 
(BalbC) were treated 7 days per week for 3 weeks with the indicated doses of ETH and 
SMARt-420 (420L) expressed in mg/kg in Table S6. Except for the mice of the first 
untreated group that were sacrificed at day 1 (D1), all the surviving mice were sacrificed 
at the end of the treatment (day 28) and the pulmonary mycobacterial load was 
enumerated by CFU counts. Values in table S6 are log of the mean of the bacterial loads 
as measured by CFU counts in the lungs. All animal experimentation and procedures 
performed at the National Reference Center for Tuberculosis and Mycobacteria, Bacterial 
Diseases Service, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium, 
were validated and approved by the Ethical Committee of the IPH-VAR (Belgium) under 
the file number 120323-01. The animal facilities and procedures were under the 
supervision of an expert on animal welfare in accordance with the Belgian Ministry of 
Health. 
Databases S1 (separate file) 
This compressed file has been deposited in DATADRYAD.org under accession number 
doi:10.5061/dryad.mb463 
Raw data (demultiplexed and trimmed from their adaptors) of the RNAseq 
experiment. The compressed folder (.gz) contains 3 files (.fastq) corresponding to the 
RNAseq obtained upon treatment of the mycobacteria with DMSO (control), 
BDM41906, or SMARt-420, respectively, as described in Fig. 1B and in Material & 
Methods. 
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Antibiotic resistance is a major and global threat for our health care system. The discovery of 
antibiotics enabled to cure previously deadly bacterial infectious diseases and revolutionized 
modern medicine. Indeed, without antibiotics physicians may no longer be able to perform 
immunosuppressing cancer chemotherapies or simple surgeries that rely on antibiotic 
prophylaxis (Teillant et al., 2015). The risk to enter a post-antibiotic era has been mentioned 
due to the emergence of infections caused by the so-called “superbugs” that do not respond to 
most of antibiotics available (Falagas and Bliziotis, 2007; WHO, 2014). The projections 
estimate that by 2050, drug-resistant infections could kill annualy more than 10 million people 
worldwide if no action are taken to tackle this problem (Review on Antimicrobial Resistance, 
2016).  
One way to tackle antibiotic resistance is to rescue the efficacy of approved antibiotic using 
antibiotic adjuvants that block resistances (Wright, 2016). This strategy has been successfully 
employed since years in the case of β-lactam antibiotics associated with β-lactamase inhibitors, 
such as clavulanic acid, which was discovered 40 years ago (Reading and Cole, 1977). 
However, thus far β-lactamase inhibitors are the only example of antibiotic resistance inhibitor 
in clinical use (Wright, 2016). Overall, our work studied the possibilities to extend this adjuvant 
drug approach to other antibiotics, such as tigecycline and colistin for the treatment of 
A. baumannii infections or ethionamide to target M. tuberculosis. 
 Genome editing platform 
The first step of adjuvant drug development is to characterize the resistance mechanisms 
developed by bacteria during patient treatment in order to identify suitable targets to block 
resistances. This implies to study recently isolated MDR clinical strains instead of the old 
laboratory adapted strains routinely used, which are not representative of the population causing 
infection. Typically, the A. baumannii and P. aeruginosa reference strains ATCC-17978 and 
PAO1, respectively, were isolated more than 50 years ago and represent isolated clonal lineages 
that are not anymore present in the ICUs (Diancourt et al., 2010; Wiehlmann et al., 2007). The 
PAO1 strain has been extensively studied to get insight into P. aeruginosa colistin resistance 
mechanisms (Fernández et al., 2010, 2012, Macfarlane et al., 2000, 1999; McPhee et al., 2006). 
However, PAO1 encodes a truncated cprA gene, which is required for TCSs mediated colistin 
resistance, indicating that findings on PAO1 colistin resistance mechanisms may not be relevant 
for P. aeruginosa species (Gutu et al., 2015). To avoid this kind of incident and increase 
representativeness it is necessary to study resistance mechanisms in several clinical strains. In 
addition, antibiotic resistance mechanisms developed during antibiotic exposure in vitro do not 
necessarily represent the resistance development during patient treatment. For instance, 
A. baumannii exposed to colistin in vitro easily loses its LPS leading to colistin 
resistance (Moffatt et al., 2011). However, this resistance mechanism is not observed in colistin 
resistant strains isolated from patients most likely due to the high fitness cost engendered by 
LPS loss (Beceiro et al., 2014; García-Quintanilla et al., 2015). Similarly, E. coli exposed to 
fosfomycin in vitro shows a high resistance rate whereas resistance rate in vivo is very low, 
which can be explained by the high fitness cost of the resistant mutants obtained in vitro (Pan 
et al., 2017). In summary, relevant antibiotic resistance mechanisms must be studied on a panel 
of resistant strains isolated from patients to avoid misjudgement on target potential. 
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The study of antibiotic resistance in clinical strains is impeded by the lack of methods to 
genetically manipulate such strains. Indeed, strains that are resistant to clinically used 
antibiotics are generally resistant to classical antibiotics used for plasmid selection, such as 
ampicillin, kanamycin, tetracycline and chloramphenicol. The genome editing platform that 
was developed during this thesis is based on a two-step recombination method. Importantly, 
this method requires a single resistance cassette contrary to other methods, such as 
CRISPR/Cas9, λ-red system and other recombineering systems that require multiple selection 
markers making them not compatible with drug resistant strains (Jiang et al., 2013; Poteete, 
2001; Tucker et al., 2014). We implemented a non-antibiotic selection cassette to overcome this 
limitation allowing to select for genomic plasmid integration even in drug resistant isolates. 
The expression of the gene tpm confers resistance to tellurite (TeO32-) in A. baumannii as 
demonstrated in the section 2.1.1. of this thesis and it is also functional in P. aeruginosa, K. 
pneumoniae and E. coli. Tellurite is highly toxic for most microorganisms (Chasteen et al., 
2009). Tellurite toxicity is thought to be due to its high oxidizing ability that leads to superoxide 
radicals generation and subsequent bacterial oxidative burst (Prigent-Combaret et al., 2012). 
Most bacteria can reduce tellurite into elementary tellurium (Te), which is less toxic than the 
tellurite oxyanion and accumulates as black deposit in the cells (Chasteen et al., 2009). 
However, tpm encodes a thiopurine S-methyltransferase that methylates tellurium to produce 
volatile dimethyl telluride (CH3TeCH3) resulting in complete detoxification thus conferring 
resistance (Prigent-Combaret et al., 2012). In our method, tellurite was very efficient in 
selecting tpm expressing bacteria on agar plates after conjugation. Nevertheless, we have 
noticed that liquid culture growth of tpm expressing bacteria in the presence of tellurite was 
associated with strong fitness cost, even when the tellurite concentration was reduced to 
10 µg/ml. Therefore, we recommend to use this resistance marker only for agar plate-based 
selection. 
The second step of the genome editing method consists of plasmid removal from the genome 
by homologous recombination. To overcome the low efficiency of the SacB/sucrose counter 
selection system, we implemented a Tdk/AZT system whose expression is inducible by IPTG. 
The thymidine kinase encoded by tdk can phosphorylate the non-functional thymidine analogue 
AZT. AZT has an azido (-N3) group at the 3’ position instead of the thymidine 3’ hydroxyl 
(-OH) group, which is required to form the phosphodiester bond with the next 
nucleotide (Figure 13). Upon phosphorylation by Tdk, AZT is incorporated into DNA and 
replaces endogenous thymide finally leading to the termination of DNA elongation. AZT 
incorporation in DNA is highly toxic and thus allows plasmid removal counter selection. This 
counter selection system is very efficient in selecting plasmid removal in A. baumannii as 
demonstrated in section 2.1.1. We have further shown that this counterselection method is also 
functional in P. aeruginosa. In contrast, Tdk/AZT counter selection system cannot be applied 
in Enterobacteriaceae because these species endogenously encode Tdk and they are therefore 
susceptible to AZT even in absence of Tdk expressing plasmid. Universal counter selection 
system might reside in endonucleases that catalyse targeted double strand breaks, such as Cas9 
and SceI enzymes (Colleaux et al., 1988; Jinek et al., 2012). Double strand break targeted to 
the plasmid sequence would select for plasmid removal from the genome by inducing 
recombination. The major drawback of such counter selection system is the absolute necessity 
for a tight expression regulation of the system in order to avoid mutational inactivation. 
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Figure 13: Schematic structure of thymidine and its non-functional analogue azidothymidine (AZT)  
The backbone of the genome editing platform is based on the Standard European Vector 
Architecture (SEVA) platform (Silva-Rocha et al., 2013). Consequently, the platform has a 
modular architecture that allows the rapid exchange of the individual genetic building blocks 
enabling the customization to target other important Gram-negative pathogens (Figure 14). In 
addition to selection and counter selection marker, the origin of replication can also be replaced 
to extend the applicability of the method to Enterobacteriaceae. The described plasmid 
platform is designed with a ColE1 origin of replication that is not replicative in A. baumannii 
and P. aeruginosa. In contrast, ColE1 origin of replication is functional in Enterobacteriaceae, 
which does not allow genomic plasmid integration in these species. Replacement of the ColE1 
origin of replication with an R6K origin of replication that is functional only in λpir phage 
lysogenised strains, would allow to target Enterobacteriaceae pathogenic species, such as 
E. coli and K. pneumoniae. 
 
Figure 14: Modularity of the genome editing platform. 
The main building blocks of the genome editing platform and their compatibility for the expansion to other 
species are presented.  
In addition to its high modularity, the genome editing platform is very versatile. The method 
can be employed to produce markeless deletions, insertions (knockin) and point mutations in 
only three days (Figure 15). Altogether, we believe that the developed genome editing platform 
is the most powerful method to edit the genome of Gram-negative without distinction between 
laboratory and clinical strains.   
thymidine                            azidothymidine       
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Figure 15: Genome editing platform applications. 
The first and second recombination steps are represented in the case of genomic markerless A) deletion, B) point 
mutation and C) insertion (knockin). 
A) 
B) 
C) 
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 Adjuvant drug targets to overcome antibiotic resistance 
 Acinetobacter baumannii 
TCSs have been suggested as potential drug targets to overcome antibiotic resistance or to 
reduce virulence (Worthington et al., 2013). TCSs are bacterial signal transduction pathways 
that allow to sense environmental changes and rapidly respond to these perturbations in order 
to survive and proliferate. TCSs are not found in higher eukaryotic organisms whereas they are 
ubiquitous in bacteria. Gram-negative pathogens, such as P. aeruginosa and E. coli, encode 
over 30 ordinary TCSs in their genome while the Gram-positive pathogen S. aureus encodes 
16 TCSs (García-Calderón et al., 2007; Gooderham and Hancock, 2009; Xue et al., 2011). Most 
of these TCSs are not essential for survival in classical in vitro conditions. However, TCSs have 
significant impact on bacterial survival to specific stress conditions, such as those encountered 
during infection, making TCSs attractive targets for novel antibacterial therapeutic 
approaches (Stephenson and Hoch, 2002). On another hand, many TCSs have been associated 
with antibiotic resistance regulation in pathogenic bacteria (Worthington et al., 2013). Our work 
focused on two different TCSs, the AdeRS and PmrAB TCSs, that were shown to be involved 
in A. baumannii tigecycline and polymyxin resistance, respectively (Adams et al., 2009; 
Hornsey et al., 2010). 
 Efflux pump systems  
We demonstrated that AdeRS mediated AdeABC efflux pump expression is the major 
tigecycline resistance mechanism in A. baumannii clinical isolates as previously suggested in 
the literature (Hornsey et al., 2010; Peleg et al., 2007; Ruzin et al., 2007; Sun et al., 2010). 
However, we demonstrated that some clinical strains have an alternative resistance mechanism, 
which is independent of AdeRS and AdeABC expression, and confers moderate tigecycline 
resistance. This observation is in accordance with resistance mechanisms to other antibiotics 
where efflux pumps are rarely the unique mechanism. For instance, aminoglycosides are 
substrates of the AdeABC efflux pump and upregulation of AdeABC confers aminoglycoside 
resistance to A. baumannii (Magnet et al., 2001; Yoon et al., 2015). However, a recent study 
showed that 94 % aminoglycoside non-susceptible A. baumannii isolated from clinical settings 
harboured at least one AMEs, suggesting that the major A. baumannii aminoglycoside 
resistance resides in AMEs expression and that efflux pumps expression is 
secondary (Sheikhalizadeh et al., 2017). The same observation was done in P. aeruginosa 
clinical isolate where efflux pump expression interplays with AME expression to confer high 
level aminoglycoside resistance (Morita et al., 2012). A similar phenomenon applies to 
fluoroquinolone resistance. Fluoroquinolones are substrate of the AdeABC efflux pump and 
overexpression of AdeABC has been associated with fluoroquinolone resistance (Magnet et al., 
2001; Yoon et al., 2015). However, all ciprofloxacin resistant A. baumannii clinical strains, 
which were isolated in two independent studies, harboured at least one mutation in DNA gyrase 
or topoisomerase whereas the ciprofloxacin susceptible isolates had wildtype gyrase and 
topoisomerase (Lee et al., 2005; Vila et al., 1997). These data indicate that, although efflux 
pumps might be involved in ciprofloxacin resistance development, it has only a secondary role 
in clinical strains. The secondary role of the AdeABC efflux pump in A. baumannii antibiotic 
resistance disproved our initial hypothesis, which consisted in AdeRS mediated AdeABC 
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expression inhibition to overcome antibiotic resistance. Furthermore, global efflux pump 
inhibition strategies may not be sufficient to overcome antibiotic resistance in A. baumannii. 
 Phosphoethanolamine transferases 
In our second project we applied the developed gene knockout platform to investigate the 
polymyxin resistance in A. baumannii. It has been proposed that the main colistin resistance 
mechanism in A. baumannii is based on the addition of PetN to lipid A, which is catalysed by 
the PetN transferase enzyme PmrC (Adams et al., 2009; Arroyo et al., 2011; Olaitan et al., 
2014). The response regulator PmrA triggers pmrC overexpression when phosphorylated by 
the pmrB sensor kinase (Park et al., 2011b). Therefore, inhibition of PmrA might revert colistin 
resistance in A. baumannii. This hypothesis has been confirmed by the development of PmrAB 
small molecule inhibitors that break colistin resistance in A. baumannii (Harris et al., 2014). 
However, our data revealed that PmrA mediated overexpression of pmrC is an important but 
not the exclusive colistin resistance mechanism in A. baumannii clinical isolates. Indeed, we 
found clinical isolates where colistin resistance was mediated by the overexpression of the 
PmrC homologue EptA due to ISAbaI element insertion. This finding indicates that PmrAB 
small molecule inhibitor would not be efficient on EptA mediated colistin resistant 
A. baumannii strains. Nevertheless, our results suggest PetN transferase enzymes as potential 
targets to restore colistin sensitivity in A. baumannii.  
PetN transferases are associated with colistin resistance in other clinically relevant Gram-
negative pathogens, such as P. aeruginosa and Enterobacteriaceae (Olaitan et al., 2014). 
However, in contrast to A. baumannii, PetN transferase expression is not the exclusive 
resistance mechanism in other Gram-negative pathogens. In addition to PetN lipid A 
modification, P. aeruginosa and Enterobacteriaceae colistin resistance can be mediated by 
aminoarabinose (AraN) addition to lipid A (Needham and Trent, 2013). The AraN lipid A 
decoration is mediated by the AraN transferase ArnT and is independent of PetN transferase, 
which indicates that PetN transferase inhibitors would not be efficient on strains harboring 
AraN modified lipid A. 
Plasmid mediated expression of mcr-1, which codes for another PetN transferase, has been 
recently identified in colistin resistant E. coli clinical strains in China (Liu et al., 2016). Since 
then, plasmid mediated colistin resistant strains have been reported all over the world (Poirel et 
al., 2017). The mcr-1 gene has been identified predominantly in E. coli and in several other 
Enterobacteriaceae, but not in A. baumannii and P. aeruginosa so far. It is interesting to note 
that mcr-1 could be retrospectively identified in animal samples isolated 30 years ago and that 
the mcr-1 outbreak started in 2009 indicating that mcr-1 dissemination might not be as sudden 
as suggested directly after its worldwide identification (Shen et al., 2016b).  
The genomic organisation of the plasmid encoded mcr-1 shares similarities with the 
A. baumannii chromosomally encoded eptA identified in our work. Both genes present an 
upstream IS element, ISApl1 and ISAbaI upstream mcr-1 and eptA, respectively. They most 
likely provide a promoter for PetN transferase expression. In addition, mcr-1 has been identified 
with both upstream and downstream ISApl1 indicating its presence in a transposable 
element (Snesrud et al., 2016). Our work suggests that eptA is also present in a mobile element 
due to its duplication in the genome of a clinical strain. Unfortunately, we could not resolve the 
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sequence downstream the duplicated eptA but whole genome sequencing of this clinical strain 
would allow to verify this hypothesis. Overall, mcr-1 expression in E. coli leads to a 4- to 8-fold 
increase in colistin MIC whereas eptA expression in A. baumannii leads up to a 254-fold 
increase in colistin MIC. Despite the lower ability of mcr-1 expression to increase colistin 
resistance, mcr-1 expression does not require additional mechanisms to confer colistin 
resistance in Enterobacteriaceae. Alarmingly, mcr-1 has been identified in plasmid harbouring 
multiple resistance genes and plasmid mediated mcr-1 colistin resistance has been reported in 
carbapenem resistant Enterobacteriaceae (Du et al., 2016; Falgenhauer et al., 2016; Poirel et 
al., 2016; Yao et al., 2016; Zhong et al., 2017). In summary, the contribution of PmrC in 
P. aeruginosa polymyxin resistance, the emergence of plasmid mediated mcr-1 polymyxin 
resistance in Enterobacteriaceae and the exclusive role of PmrC and EptA in A. baumannii 
polymyxin resistance make PetN transferases attractive targets to rescue the activity of 
polymyxins in Gram-negative pathogens.   
PetN transferases are composed by a transmembrane domain, that anchors the enzyme to the 
cytoplasmic membrane, attached to a soluble catalytic domain located in the 
periplasm (Anandan et al., 2017). The three-dimensional structure of the catalytic domain of 
Campylobacter jejuni (cEptC), Neisseria meningitidis (cLptA) and MCR-1 (cMCR-1) PetN 
transferases have been determined (Figure 16) (Fage et al., 2014; Stojanoski et al., 2016; Wanty 
et al., 2013).  
 
Figure 16: Three-dimensional structure of bacterial PetN transferases (Stojanoski et al., 2016).  
Crystal structure of A) cMCR-1, B) cEptC and C) cLptA. The disulphide bounds are shown as spare-fill spheres 
in the three structures as well as the active site threonine in its phosphorylated state in red. 
Overall, the three catalytic domains present a similar fold. The active site and most of the 
disulphide bonds are conserved among the three proteins. As expected, the three protein 
catalytic domains have conserved primary amino acid sequences. This sequence similarity can 
be expanded to the catalytic domain of the A. baumannii PmrC and EptA PetN transferases, 
which conserve all the active sites residues and the cysteine forming disulphide bounds 
(Figure 17). This analysis suggests that the catalytic domain of all these PetN transferases are 
very similar and may potentially allow the development of broad spectrum PetN transferase 
inhibitor.  
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Figure 17: Amino acid sequence alignment of PetN transferases catalytic domain. 
PetN transferase catalytic domain amino acid sequence of PmrC (PmrC224-533), EptA (EptA221-527), MCR-1 (MCR-
1241-541), EptC (EptC222-512) and LptA (LptA235-544) were aligned using CLC Main Workbench. Active site residues 
(purple) and cysteine forming disulphide bounds (green) are numbered according to the PmrC amino acid 
sequence. 
 
 Mycobacterium tuberculosis 
We have previously shown that antibiotic resistance mechanisms are complex and can be 
mediated by multiple pathways. This observation holds true for M. tuberculosis ethionamide 
resistance, as presented in the introduction section 1.2.3. of this thesis. The two major 
mechanisms reside in alteration of the ethionamide target InhA or loss of function of the 
bioactivation enzyme EthA (Vilchèze and Jacobs, 2014).  
The mutations affecting InhA result in InhA overexpression or a decreased affinity of 
ethionamide for InhA, which in both cases do not abolish ethionamide activity but dilute out 
the drug (Vilchèze et al., 2006). Therefore, increasing drug concentration may overcome this 
type of resistance. Indeed, high dose regiment of isoniazid, which targets InhA, is expected to 
successfully treat low isoniazid resistant M. tuberculosis strains (Schaaf et al., 2007). However, 
ethionamide high dose regiment cannot be applied due to the adverse effects of the 
drug (Holdiness, 1987; Weinstein et al., 1962).  
In constrast, enhanced intracellular active ethionamide concentrations can be achieved by 
boosting the ethionamide bioactivation pathway. Indeed, Willand and colleagues developed 
EthR inhibitors to derepress the expression of ethA and thereby boost the activation of 
ethionamide (Willand et al., 2009). Co-administration of EthR inhibitors with ethionamide in 
M. tuberculosis-infected mice allowed a three-fold decrease in the dosage of ethionamide. The 
EthR inhibitor BDM41906 reverts ethionamide resistance mediated through non EthA 
mutations, but was not efficient in reverting ethionamide resistance mediated by EthA 
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mutations. Therefore, the identification of the alternative ethionamide bioactivation pathway 
EthA2-EthR2 and the development of EthR2 inhibitors allow to revert ethionamide resistance 
in M. tuberculosis, regardless of the resistance mechanism.  
 Synthetic mammalian gene regulation system 
In this project, we designed and developed the EthR2 based synthetic mammalian gene 
regulation system. This system was designed to sense the binding of EthR2 to its DNA operator 
and monitor the compound-mediated inhibition of this protein-DNA interaction. The gene 
regulation system consists in two vectors co-transfected in mammalian host cells. The first 
vector is an expression plasmid, which allows the constitutive expression of EthR2 fused to the 
VP16 transactivation domain of Herpes simplex. The second vector is a reporter plasmid, which 
enables the EthR2-VP16 regulated expression of the serum alkaline phosphatase (SEAP) 
reporter gene. Indeed, the reporter plasmid was constructed in a way that the intergenic region 
between ethA2 and ethR2, which contains the EthR2 operator, is placed upstream of the SEAP 
gene driven by the minimal variant of the human cytomegalovirus derived promotor (PCMVmin). 
Because VP16 activates the PCMVmin promoter, the binding of EthR2-VP16 to its DNA operator 
induces the quantifiable expression of SEAP. This system enables to evaluate the ability of 
compounds to inhibit the binding of EthR2 to its operator, which is expected to translate into 
the ability of compounds to boost ethionamide activation in M. tuberculosis. 
The implementation of the synthetic gene regulation system in mammalian cells enables to keep 
track on target specificity, cytotoxicity and bioavailability of the tested compounds. First, the 
use of a non-Mycobacterium background avoids potential unspecific interaction with the EthR2 
regulation system thereby limiting the possibility of off-target compound effect. Second, the 
use of mammalian cells as host for the EthR2 based regulation system allows to monitor 
compound cytotoxicity and mimics the infectious environment of M. tuberculosis, which is an 
intracellular pathogen. Finally, working with M. tuberculosis or its non-pathogenic related 
species Mycobacterium smegmatis is very cumbersome due to their low growth rate and 
therefore mammalian cells appear as appropriate host to bypass this hurdle.  
A similar mammalian gene regulation system has been developed for EthR based 
regulation (Weber et al., 2008). The assessment of newly synthesised compounds on the two 
EthR- and EthR2-dependent systems enables the distinction between EthR and EthR2 specific 
ethionamide boosting compounds.    
 Bioactivation pathway as drug target 
In contrast to the multiplicity of resistance mechanisms that impedes the development of 
adjuvant drug to overcome resistance, the two independent ethionamide bioactivation pathways 
are a major asset for the development of adjuvant drug to boost ethionamide. Indeed, the EthA2-
EthR2 bioactivation pathway appears to be ubiquitous in M. tuberculosis despite the low 
expression of ethA2. The low expression level of ethA2 may explain the absence of mutations 
in its coding sequence, which makes this bioactivation pathway a perfect switch to boost 
ethionamide efficacy. Nevertheless, M. tuberculosis resistance through EthA2 loss of function 
mutation may arise due to selection pressure during treatment with the combination of 
ethionamide-EthR2 inhibitor. The development of EthR/EthR2 dual-inhibitor may drastically 
reduce the frequency of resistance. Indeed, EthA or EthA2 loss of function mutation alone 
would not be sufficient to confer resistance to the combination ethionamide-dual inhibitor. 
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Therefore, resistance would need to be mediated by at least two independent mutations, in both 
EthA and EthA2. This delayed resistance development is exemplified by two well-known class 
of multitarget antibiotics, the β-lactams that inhibit penicillin-binding proteins and the 
quinolones that inhibit the DNA topoisomerases (East and Silver, 2013). 
Ethionamide is one of the most potent M. tuberculosis second-line drug and it is recommended 
for the treatment of MDR M. tuberculosis strains. However, to limit the adverse effects 
ethionamide is used at concentrations relatively close to its MIC, which impairs treatment 
efficiency and favors the selection of resistance (Zhu et al., 2002). The EthR2 inhibitor 
compound SMARt-420 not only reverts ethionamide resistance but also boost ethionamide 
activity on M. tuberculosis susceptible strains. Decreasing the dose of ethionamide by co-
administration of EthR/EthR2 dual inhibitors, might, on one hand, lower the toxicity of the 
treatment and improve the quality of life of the patients, and, on the other hand, improve the 
treatment efficacy and potentially reduce the treatment time. This would allow clinicians to 
consider placing the combination ethionamide-EthR/EthR2 inhibitors as a first-line drug to treat 
M. tuberculosis infections. 
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Antimicrobial resistance is a serious threat for public health worldwide. The risk to enter a post-
antibiotic era has been raised due to the emergence of pathogens resistant to most of available 
antibiotics. In the last decades, many of the big pharmaceutical companies pulled away from 
antibiotic discovery due to a lower expectation of profits compared to other therapeutic areas. 
The strong reduction in antibacterial research lead to empty pipelines and a lack of innovation 
in the antibiotic field. Without increasing efforts the risk is high to enter a post-antibiotic era 
where simple infections by drug resistant pathogens may be hazardous due to a lack of treatment 
options. Beside research on novel antibiotics, innovative approaches may provide another 
solution to overcome this lack. 
One of the innovative approach resides in adjuvant therapies that have the capability to revert 
antibiotic resistances. Molecules inhibiting antibiotic resistance mechanisms can prolong the 
life time of currently used antibiotics by delaying the onset of resistance or even revive old 
antibiotics that were left aside due to the high frequency of resistant strains in the environment. 
This approach has been successfully applied during decades with β-lactams inhibitors but never 
expanded to other antibiotics.  
The genome engineering method developed during this thesis allowed us to characterize the 
different mechanisms employed by A. baumannii to resist the antibacterial action of tigecycline 
and colistin antibiotics during patient treatment. Overall, we showed that the mechanisms 
employed to resist the action of a specific antibiotic may be diverse due to the treatment history 
of the individual clinical strains. This impairs the development of adjuvant drug to overcome 
tigecycline and colistin resistances in A. baumannii and it implies a careful evaluation of drug 
target relevance before to develop inhibitors that are specific of one resistance pathway. 
Nevertheless, we propose PetN transferases as attractive targets to restore polymyxin 
sensitivity. 
In contrast to the two studied targets in A. baumannii, we successfully demonstrated that an 
adjuvant approach has the potential to overcome resistance and boost the activity of the 
antibiotic ethionamide in M. tuberculosis. By using the synthetic mammalian gene regulation 
system designed during this thesis we developed EthR2-specific inhibitory compounds that 
boost the newly discovered M. tuberculosis ethionamide bioactivation pathway. These 
compounds not only revert ethionamide resistance in MDR M. tuberculosis, but also boost the 
ethionamide efficacy in drug susceptible strains, rendering ethionamide into a more potent 
antibiotic. These adjuvant compounds are very promising chemical entities and they are 
currently in pre-clinical development. 
The research performed in this thesis demonstrated that the development of adjuvant therapeutic 
approaches is not straightforward and that special attention should be paid to drug target 
evaluation. The non-essential nature of these drug targets promotes a higher diversity and 
heterogeneity and careful target validation is required before starting a drug development 
program. However, the successful development of ethionamide boosting compounds that also 
switch off bacterial resistance traits demonstrates the potential of novel therapeutic adjuvant 
approaches.      
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